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Abstract 
 
In the last decades, nanomedicine – the application of nanotechnology to 
medicine – has opened up an entirely new horizon of possibilities and 
applications, in particular for drug delivery and diagnostic. Indeed, a wide 
range of nanocarrier have been designed and realized. However, more 
recently researcher focused on the development of “multifunctional” 
platforms, i.e. nano-vectors able to simultaneously or sequentially perform 
several functionalities – enzymatic catalysis, controlled degradation, 
controlled drug release and sensing.  
In this context polyelectrolyte multilayer (PEM) capsules fabricated via 
the Layer-by-Layer (LbL) technique have emerged as very attractive tool 
for the assembly of multifunctional carrier systems, because of its ideal 
features like simplicity, versatility, and nanoscale control. 
The final aim of this research activity concerns the realization of 
completely biocompatible and biodegradable nanocarriers with diverse 
functionalities and purposes. The greater ambition, in particular, is the 
realization of nanometric sized drug vehicles entirely derived from natural 
materials but holding the features needed for the drug delivery. Starting 
from an inner oil-core carrier – with tunable sizes ranging from 80 to 200 
nm, built up with natural materials like soybean oil and egg lecithin and 
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able to encapsulate hydrophobic drugs or contrasting agents - oil-core 
polyelectrolytes-shells nanocarriers have been realized. As for the liquid 
core, natural materials have been selected for the realization of the shell, 
and, in particular, polysaccharides. More in detail, polysaccharides used as 
coating have been opportunely modified in order to add desired 
functionalities to the final nano-vectors. As matter of the fact, it was 
demonstrated how the thiolation of the nanocapsules’ surfaces, together 
with the appropriate choice of the materials, sizes and formulation, can 
positively effect on the oral delivery of an unstable nutraceutical, i.e. 
curcumin. Moreover, the modification of natural polyelectrolytes with 
thiol and olefin moieties allowed to covalently cross link the layers by 
applying a photo activated reaction, thiol-ene ‘click’ reaction: it was 
demonstrated that such strategy bring out to a final nano-system with 
enhanced biostability. Lastly, an in situ modification of heparin with an 
aminosilane allowed to apply a modified Stöber sol-gel method for the 
realization of a high versatile multilayered nanocarrier system featuring a 
hybrid polymer/silica-shell.  
All the designed and realized nanocapsules did not show any cytotoxic 
effect, so resulting completely biocompatible and, therefore, of interest for 
the nanomedicine fields. 
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1 Chapter 1 
 
State of art 
 
 
 
 
 
 
 
 
 
Ho sempre tenuto in poco conto la cultura intesa come cosa che fa 
crescere agli occhi degli altri e alla loro considerazione. 
La cultura non deve meravigliare che chi l’apprende, e mai gli altri. 
Alda Merini – Poetess 
 
 
For all things I have the strength through the one who gives me power. 
Philippians 4:13 – Apostle Paul 
 
 
For a man may work hard, guided by wisdom and knowledge and skill, 
but he must hand over his portion to a man who did not work for it. 
This too is futility and a great tragedy. 
Ecclesiastes 2:21 – King Solomon 
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1.1 Nanomedicine and drug delivery 
In his famous lecture “There’s plenty of room at the bottom” (Caltech, 
1959), Nobel Prize Richard Feynman outlined the potential that the 
harnessing of nanoscopic materials could yields.1 What make 
nanomaterials ‘special’ is that they have identical composition but exhibit 
properties completely different from their bulk moduli. This peculiarity 
was already exploited several centuries ago. For example, the Lycurgus 
Cup (Figure 1.1) is a late Roman (IV century A.D., British Museum) cut 
glass vessel. This vessel is a clear example of both the extraordinary 
fabrication method and of the exceptional workmanship involved. 
Moreover, this glass shows non unusual optical effects. Indeed, the glass 
is dichroic; in direct light it resembles a jade with an opaque green-yellow 
tone, but when light shine through the glass (transmitted light) it turn to a 
translucent ruby colour. After several investigations, scientists linked the 
dichroism to the presence of minute amounts of gold and silver in the glass. 
However, simply adding traces of gold and silver to glass would not 
produce these unique optical properties. The critical factor is the formation 
of minute submicroscopic crystals or colloids of the metals.2 
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Figure 1.1. The Lycurgus Cup in reflected (left) and transmitted (right) light. Colloidal 
systems can give rise to light scattering phenomena that result in dichroic effects. It was 
suggested that both the gold and silver contributed to the colour, the gold component 
being mainly responsible for the reddish transmission and the silver for the greenish 
reflection. [1958, 1202.1, Department of Prehistory and Europe, The British Museum, 
h:16.5 cm, d:13.2 cm. Images reprint with the permission of The British Museum 
Website] 
Despite this and other ‘ancient’ examples of applied nanomaterials, 
nanotechnology has attracted wide interest as a new field of technology 
only starting from Feynman concepts. Results obtained during the years, 
before unthinkable, are well summarized by the words of Richard E. 
Smalley (Nobel Prize in Chemistry in 1996): ‘we’ve got to learn how to 
build machines, materials, and devices with the ultimate finesse that life 
has always used: atom by atom, on the same nanometer scale as the 
machinery in living cells’.3 [Presentation to the University of Dallas - 
Board of Councilors, December 7, 1995].  
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Nowadays nanotechnologies found applications in several fields as 
medicine, biotechnology, green technology, energy, industry, agriculture, 
food, art.a  Since most of the application are centred on improving human 
health and diagnosing the human status, nanotechnology has given rise to 
a completely new field known as nanomedicine. 
Nanomedicine can be defined as the application of nanotechnology to 
medicine.4 Such field has opened up an entirely new horizon of 
possibilities and applications. For example, nanotechnologies applied to 
the physiological system has provided the possibility to study biological 
processes on a more intimate level and, consequently, to enhance their 
understanding. More importantly, nanomedicine has the aim to overcome 
the limitations related to the conventional medicine, for both diagnostic 
and therapy. In particular, the main limitations concern the poor safety and 
efficacy of the conventional therapies. Many therapeutic agents are not 
successful because of their limited ability to reach selectively the target 
tissue. For example, in cancer chemotherapy, cytostatic drugs damage both 
malignant and normal cells alike. Thus, a drug delivery strategy that 
selectively targets the malignant tumor would be the ideal solution.  
                                                          
a An innovative and promising subsection of nanotechnology derives from Carbon-based 
Nanomaterials. Such materials are finding application in medicine, composite materials, 
microelectronics, solar cells, electronic components, energy, optical, mechanical, etc. 
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Drug Delivery Systems (DDSs) are conceived to improve the 
pharmacological and therapeutic properties of drugs administered in vivo, 
designing carriers that can act as drug reservoirs. Drug carrier system 
should allow for the controlled release of drugs at the desired sites, thus 
positively altering both the pharmacokinetics and biodistribution of the 
drugs.5 More in details, an ideal DDS should be able to reach selectively 
the target tissue, thus reducing the drug toxicity.  
To this aim, DDS should result firstly stable and with a longer blood half-
life to have enough time for the accumulation in the target tissue. 
Biostability is related to the material used, the degradation time and the 
body clearance.  
The clearance is the result of the interaction with serum protein.6 These 
proteins instantaneously bind onto the nanoparticle surface and dictate the 
long-term fate, metabolism, clearance, and immune response7, because 
they are able to “tag” the DDS for removal by the mononuclear phagocyte 
system (MPS) inside the liver and spleen. This process is known as 
opsonisation because a foreign organism or particle is covered with 
opsonins proteins and becomes visible to phagocytic cells. Moreover, it is 
followed by the phagocytosis, which is the engulfing and eventual 
destruction or removal of foreign materials from the bloodstream.8 For this 
reason, an ideal DDS should be able to avoid the attachment of opsonins 
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proteins. The most usual way to keep drug carriers in the blood as long as 
is possible, is to “mask” them by modifying (grafting) their surface with 
water-soluble polymers with a well-solvated and flexible main chain, such 
as polyethylene glycol (PEG). The surface-grafted “protective” polymers 
effectively prevent, i.e. slow down, the opsonization of drugs and drug 
carriers and their clearance.9, 10 Secondly, the DDSs should have an ideal 
size. Dimensions started to be considered important when Matsumura and 
Maeda11 described the mechanism, called Enhanced Permeability and 
Retention (EPR) effect (Figure 1.2), of successful delivery of carriers to 
certain tissues.  
 
Figure 1.2. Schematic representation of passive and active targeting. Passive tissue 
targeting is achieved by extravasation of nanoparticles through increased permeability of 
the tumour vasculature and ineffective lymphatic drainage (EPR effect). Active cellular 
targeting (inset) can be achieved by functionalizing the surface of nanoparticles with 
ligands that promote cell-specific recognition and binding. Reprinted with permission 
from Nat. Nanotechnol.12  
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Their investigations showed that most solid tumors have blood vessels 
with defective architecture and usually produce extensive amounts of 
various vascular permeability factors. Consequently, most solid tumors 
exhibit enhanced vascular permeability, which will ensure a sufficient 
supply of nutrients and oxygen to tumor tissues for rapid growth. The EPR 
effect considers this unique anatomical and physiological nature of tumor 
blood vessels that facilitates transport and accumulation of 
macromolecules into tumor tissues. In contrast, this EPR effect-driven 
drug delivery does not occur in normal tissues.13 As a result, in tumor 
tissues, large molecules and even relatively certain particles below 500 nm 
in size, preferably below 200 nm, can leave the vascular bed and 
accumulate inside the interstitial space.12, 14, b  
Such spontaneous accumulation is called “passive” targeting, because a 
physical property such as the size, is used to help the DDS to reach its 
target, i.e. the tumour tissue. Passive targeting differs from the active one, 
where the DDS is opportunely modified to interact actively with tissues or 
cells to deliver its drug selectively (Figure 1.2, inset). Different 
biomolecules15 (antibodies, aptamers, peptide or small molecules) have 
                                                          
b For this reason, DDSs scaled down to nano-scale are also called DDnSs or NDDSs, 
namely Drug Delivery nano Systems. 
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been used to recognize the tumour and to help nanocarriers to enter the 
cancer cell.16 
Lastly, an ideal DDS should be designed in order to possess peculiar 
characteristics, namely to maximize the therapeutic activity while 
minimizing the toxic side effects of drugs. To this purpose the choice of 
materials and the design of the DDS are crucial. Many properties can be 
tailored for specific applications: solubility, biodistribution, 
biocompatibility, biodegradability, drug release, drug encapsulation and 
shape.17 Below in this chapter it will be discussed about the possibility of 
using natural materials, appropriately chosen and modified, in order to 
design DDSs for specific applications. 
1.2 LbL technique applied to nanomedicine 
Multilayer thin films have garnered intense scientific interest due to their 
potential application in diverse fields such as catalysis, optics, energy, 
membranes, and biomedicine. Layer-by-layer (LbL) assembly is a 
prevalent method for coating substrates with functional thin films.18 Early 
studies on multilayer assembly date back to fifty years ago.19, 20 However, 
it is only in the last two decades that it has witnessed considerable growth. 
In particular, in 1990s Decher’s group developed a “simple approach that 
would yield nanoarchitecture films with good positioning of individual 
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layers, but whose fabrication would be largely independent on the nature, 
size, and topology of the substrate”.21 This process, known as layer-by-
layer, is extremely simple (Figure 1.3).  
 
Figure 1.3. (A) Schematic of the film deposition process using slides and beakers. Steps 
1 and 3 represent the adsorption of a polyanion and polycation, respectively, and steps 2 
and 4 are washing steps. The four steps are the basic build-up sequence for the simplest 
film architecture, (A/B)n. The construction of more complex film architectures requires 
only additional beakers and a different deposition sequence. (B) Simplified molecular 
picture of the first two adsorption steps, depicting film deposition starting with a 
positively charged substrate. Counterions are omitted for clarity. Polyion conformation 
and layer interpenetration are an idealization of the surface charge reversal with each 
adsorption step. [From G. Decher, Science 277 , 1232 (1997). Reprinted with permission 
from AAAS] 
It is a cyclical process in which a charged material is adsorbed onto a 
substrate, and after washing, an oppositely charged material is adsorbed 
on top of the first layer. This constitutes a single bilayer with a thickness 
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generally on the order of nanometers, and the deposition process can then 
be repeated until a multilayer film of desired thickness has been assembled.   
 
Figure 1.4. Versatility of layer-by-layer assembly. Schematic overview of LbL assembly 
[Illustration credit: Alison E. Burke and Cassio Lynm; from Richardson et al., Science, 
348, 6233 (2015). Reprinted with permission from AAAS] 
In addition to the simplicity, the potential of this method consists in the 
possibility of controlling the film thickness at the nanometric scale. 
Moreover, it would be possible to build up infinite coatings on diverse 
substrates (e.g., flat surfaces, porous membranes, particles), simply 
changing the nature of the layers deposited. Indeed, although electrostatic 
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interactions remain widely used in films formation, other molecular 
interactions (e.g., covalent, hydrogen-bonding, host-guest) are now well 
established for LbL assembly with diverse materials (e.g., polymers, 
proteins, lipids, nucleic acids, nanoparticles, suprastructures) used as film 
constituents (Figure 1.4).18, 22 
From first Decher’s works, LbL was largely used thanks to the possibility 
to vary the substrate, the layers’ materials, the LbL assembly technologies 
and methods. The simplicity, versatility, and the control at nanometer 
scale, provided by LbL assembly make it one of the most used 
technologies of coating in a diverse range of fields, including optics, 
energy, catalysis, separations, and nanomedicine (Figure 1.5).  
 
Figure 1.5. Versatility of layer-by-layer assembly. Overview showing that the assembly 
technology influences film and process properties, as well as application areas. 
[Illustration credit: Alison E. Burke and Cassio Lynm; from Richardson et al., Science, 
348, 6233 (2015). Reprinted with permission from AAAS] 
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In particular, LbL technique resulted to be very attractive for the 
realization of DDSs with the ideal features discussed above. Indeed, the 
facile construction on colloidal substrates (template) of multilayer 
architectures with nanometer precision allows to realize devices with 
multiple properties. For example, by varying the size of the template it is 
theoretically possible to obtain capsules with different sizes, ranging from 
micrometer or sub micrometer to nanometer scales.23 Moreover, different 
functionalities can be simultaneously engineered in the same carrier by 
loading several types of components into the lumen or within the shell of 
the carrier. Their external surface can be functionalized to partially control 
their biodistribution (PEGylation24 and active targeting25). Therefore, 
capsules with well-controlled size and shape, finely tuned shell thickness 
and variable shell compositions can be obtained by using LbL technique.  
Despite the potentiality of the LbL technique, some limitations must be 
taken into account. First of all, the process is very time consuming. The 
deposition of a film consisting of dozens of bilayers takes more than 10 h 
using a robotic dipping apparatus.26 The most common technology for 
immersive assembly on particulate substrates is performed by adding 
polymer solution to dispersed dense particulate substrates, pelleting the 
particles with centrifugation, removing the supernatant, washing multiple 
times with a similar pelleting process, and then repeating the steps for 
13 
 
multilayer growth.27, 28 This is generally time-consuming and labour-
intensive due to the centrifugation steps, and particles dense and large 
enough to be pelleted are required. The time-consuming multistep 
assembly procedure, along with the aggregation of particles from repeated 
centrifugation steps and the difficulty to automate the procedures, has 
limited its industrial applications. To overcome these limits different 
approaches have recently been proposed. For example, the use of spray-
assisted LbL-assembly, both for planar films as well as for the construction 
of polymeric particles, has emerged as a possible strategy to reduce the 
deposition times per layer from tens of minutes to a few seconds.23 Another 
promising approach was recently proposed by Caruso et al.29 who 
described the simple one-step assembly of metal–polyphenol (Fe(III)–TA) 
capsules with biologically tunable physicochemical properties.c   
The limitations of LbL here reported can be overcome through the 
development of a facile and versatile strategy for particle engineering. This 
is, in fact, the only way to realize DDSs with desirable features together 
with an economical attraction. 
                                                          
c The method exploits a coordination complex of natural polyphenol tannic acid and 
Fe(III) ions. The assembly process results to be easy, low cost and scalable and the 
capsules obtained are pH responsiveness. 
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1.3 Polysaccharides-based polyelectrolyte 
multilayers 
Polysaccharides are natural polymers that belong to the family of the 
carbohydrates and play fundamental roles in many biological contexts. 
Their structure is made of sugar rings linked by glycosidic bonds and 
various side functions. These highly abundant molecules are from various 
origins including algal origin (e.g. alginate and carrageenan), plant origin 
(e.g. cellulose, pectin and guar gum), microbial origin (e.g. dextran and 
xanthan gum), and animal origin (e.g. chitosan, hyaluronan, chondroitin 
and heparin).30  
Naturally occurring polysaccharides are diverse in their physicochemical 
properties. They possess multiple chemical structures (Figure 1.6) and the 
chemical composition greatly varies, as well as the molecular weight (Mw) 
and ionic nature. This versatility also contributes to a wide range of 
biological activities. From a pharmaceutical standpoint, polysaccharides 
possess many favourable characteristics such as low toxicity, 
biocompatibility, stability, low cost, hydrophilic nature and availability of 
reactive sites for chemical modification.31 
15 
 
 
Figure 1.6. Chemical structure of some natural occurring polysaccharides. 
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Two elements are of utmost importance in the chemistry of 
polysaccharides. Firstly, the glycosidic bonds can be the target of 
glycoside hydrolase enzymes and can thus be biodegraded relatively 
easily. Secondly, the side groups can directly affect the polysaccharide's 
charge density, hydration and chemical reactivity, and can also be 
responsible for the formation of secondary structures. When charges are 
resent, polysaccharides behave like polyelectrolytes. The negative groups  
(COO−) with pKa around 3–5 or sulfate groups (SO3−) with a pKa of 
around 0.5–1.5.32 The positively charged groups are ammonium groups 
(NH3
+) with a pKa of around 7–10.33, 34  
In particular, the presence of negative and positive group make these 
polymer suitable for LbL application.35 Indeed, Polyelectrolyte Multilayer 
(PEM) films give rise to self-assembly via LbL, because of both 
interactions between the negative and positive groups and the entropic gain 
associated with these interactions.  
In addition, the presence of carboxylic and ammonium group makes these 
polymers suitable for chemical modifications. However, certain 
difficulties are encountered when working with polysaccharides. Chemical 
modification can be a real challenge because of the high hydration shell 
and poor solubility in organic solvents. Due to their lower solubility, pH 
and ionic strength I can only be varied to a lower extent than for their 
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synthetic counterparts. The advantages and limitations of using 
polysaccharides are summarized in Table 1.1, as reported by Crouzier et 
al.35 
Table 1.1. Comparison between the advantages and disadvantages of synthetic 
polyelectrolytes and polysaccharides used for the build-up of multilayer films in the 
context of biomedical and biomaterials research (as reported by Crouzier et al.35) 
 Synthetic polyelectrolytes Polysaccharides 
Advantages 
 Large choice of chemistry, 
structures and charge 
densities 
 Flexibility 
 Large working range of pH 
and ionic strength 
 Easy chemical modification 
 Abundant and usually cheap 
 Available with highly 
controlled quality 
 Natural polyelectrolytes 
(biomimetism) 
 Interesting structural 
properties: interaction with 
water, self-assembly, 
hydrogel formation 
 Functional properties: 
specific cell receptor, 
interaction with bioactive 
molecules, present in the 
pericellular coat 
 Biodegradability and 
biocompatibility (for most 
of them) 
Limitations 
 Most often non-
biodegradable 
 Potentially harmful 
degradation products 
 No particular bioactivity 
 Limited availability with 
well-defined properties 
(purity, polydispersity) 
 Chemical modification can 
be particularly difficult due 
to the poor reactivity of the 
group, low charge density 
and poor solubility in 
solvents 
 Limited pH and ionic 
strength working range due 
to solubility issues 
 
These peculiar properties of polysaccharides explain the reason of their 
use as biomaterial. Moreover, they are naturally degraded by different 
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kinds of enzymes present in vivo giving polysaccharides a great advantage 
over synthetic polyelectrolytes.35, 36 These superior advantages for 
biomedical applications as compared to synthetic polyelectrolytes explain 
why they have been increasingly employed as film constituents since the 
early 2000s. 
The properties of two common polysaccharides used in this research 
project (i.e. chitosan and heparin) are detailed below in the next paragraph. 
Chitosan and glycol chitosan 
Chitosan (CT) is a linear polysaccharide composed of β-(1,4)-linked D-
glucosamine and N-acetyl-D-glucosamine (Figure 1.7). Even though the 
discovery of chitosan dates from the 19th century, it has only been over 
the last three decades that this polymer has received attention as a material 
for biomedical and drug delivery applications. The accumulated 
information about the physicochemical and biological properties of 
chitosan led to the recognition of this polymer as a promising material for 
drug delivery and, more specifically, for the delivery of delicate 
macromolecules.37 CT is obtained by deacetylation from chitin, a highly 
abundant polysaccharide, which is the main component of the crustaceans 
and insects exoskeleton, and certain fungi.38 Due to the limited solubility 
of chitin in aqueous solutions, chitosan is more suitable for industrial 
applications.39 Whereas chitin is a polymer of N-acetyl-D-glucosamine 
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units, chitosan is less easily defined in terms of its exact chemical 
composition. It usually refers to a family of polymers that are characterized 
by the number of sugar units per polymer molecule (n+m), which defines 
the molecular weight, and the degree of deacetylation (DD, Figure 1.7).  
 
Figure 1.7. Chemical structure of chitosan. CT is a linear polysaccharide composed of β-
(1,4)-linked D-glucosamine (n) and N-acetyl-D-glucosamine (m). The relative abundance 
of the acetylated or deacetylated forms can be expressed in percentage as Degree of 
Acetylation (DA) or Degree of Deacetylation (DD). The amine group of D-glucosamine 
results to be positively charged in acidic media making chitosan a polycation. 
The degree of deacetylation (DD) affects the pKa34 and, consequently, the 
solubility of chitosan in aqueous solutions, making the polymer soluble in 
acidic solutions and insoluble in neutral or in weak alkaline solutions.40  
The intriguing properties of CT have been known for many years and the 
polymer has been used in the fields of agriculture, industry and 
medicine.38, 41 In particular, the pharmaceutical and biomedical 
applications of CT probably offer the greatest promise.37, 41 CT lacks 
irritant or allergic effects and is biocompatible with both healthy and 
infected human skin.42 When chitosan was administered orally in mice, the 
LD50 was found to be in excess of 16 g/kg, which is higher than that of 
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sucrose.38 CT is approved for dietary applications in several country and it 
has been approved by the FDA for use in wound dressings.43  
Due to its protonable amine groups, CT has a polycationic nature and, 
therefore is able to form PEM films. Actually, the choice of a polycationic 
polysaccharide is very limited. In fact, only chitosan is currently available 
and used in PEM films.35 Thanks to its numerous interesting properties, 
above mentioned, chitosan is probably by far the most widely used 
polysaccharide in LbL film.44 Its positive charge also facilitates adherence 
to mucosal surfaces, which are mostly negatively charged.37 In addition, 
the amine groups can be also used for chemical modifications. As reported 
in Table 1.1, however, the main problems concerning chemical 
modification of the amine group are (i) the difficulty to perform any 
modification with a limited pH working range and (ii) the reduced 
solubility of the modified chitosan in water due to the loss of free amine 
groups. Several attempts were made to improve the water solubility of CT, 
but most of them also reduce the fraction of free amine groups. On the 
other hand, a different modification of chitosan was proposed to obtain a 
polymer with improved water solubility but with no reduction of free 
amine groups. Glycol chitosan (GC) owes its water solubility to the 
incorporation of the hydrophilic glycol group (Figure 1.8), introduced by 
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reacting chitin with ethylene oxide followed by its deacetylation.45, d For 
these reasons, GC could represent a valid alternative to CT for the 
realization of PEM films, in particular when modified polymers are 
required. 
 
Figure 1.8. Chemical structure of glycol chitosan. GC is a modified chitosan with a glycol 
group linked to the hydroxyl in position 6 of the sugar ring. 
Heparin 
Heparin is a sulfated polysaccharide belonging to the family of 
glycosaminoglycans (GAG). Like most of the GAGs, heparin is a linear 
polysaccharide constituted by alternating disaccharide sequences of a 
uronic acid and an aminosugar. The uronic acid residues of heparin are L-
iduronic acid (IdoA) and D-glucuronic acid (GlcA), and its only 
aminosugar is D-glucosamine (GlcN). GlcN is prevalently N-sulfated in 
heparin and N-acetylated in minor sequences. Both the uronic acid 
                                                          
d Knight et al. characterized GC and proposed a different structure with mono- and di-
substitution of amine groups, so resulting partially N-glycolated. 
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(especially IdoA) and the aminosugar bear O-sulfate groups (Figure 
1.9).46  
 
Figure 1.9. Chemical structure of the most abundant disaccharide sequence of heparin 
(IdoASO3 - GlcNSO3).  
Due to high content of sulfate and carboxyl groups, heparin has the highest 
negative charge density of any known biological molecule.47 Thus, in 
contrast with CT and its low density charge and limited pH working range, 
heparin is a strong polyelectrolyte with an higher solubility in a wide pH 
range. This features reflect on the possibility to easier modify the polymer, 
in particular, exploiting its carboxylic groups. The Mw of heparin varies 
between 5 to 40 kDa and it is extracted mainly from mucosal tissues of 
porcine and bovine.46 Clinically, heparin has been used as an anticoagulant 
since the 1930s.46 Beyond its anticoagulant activity, heparin has been 
shown to have antiviral activity, regulate angiogenesis and inhibit 
complement activation.48  
The high negative charge density makes heparin suitable for PEM. Indeed, 
as strong polyelectrolyte, its negative charge is almost independent on the 
pH (in particular, because of the sulfate groups).35 For example, Boddohi 
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et al.49 studied PEM assembly of heparin and chitosan as a function of pH 
and ionic strength, showing how these parameters effect on the interaction 
of the two polyelectrolytes and on the thickness of the resulting PEMs. 
1.4 Oil-core polyelectrolyte nanocarriers 
As previously mentioned, LbL technique has been widely explored to 
realize micro- and nanocapsules with different functions and properties. 
LbL technique is very versatile, in fact different materials can be used for 
the realization of the layer; in addition, different templates with cores of 
different size and nature can be chosen. 18 In the case of a typical PEM 
carriers (with micrometric or sub micrometric size) a solid core is used as 
a “sacrificial” template and a hollow shell is obtained by dissolution. Then 
the hollow shell can be refilled with the desired composition by changing 
pH, salt or temperature, factors that influence shell permeability.23, 50 
Alternatively, loading of active components can be accomplished before 
formation of the cores (e.g. by co-precipitation with core materials) or by 
adsorption onto pre-formed templates (Figure 1.10). Solid organic 
(latexes) or inorganic (e.g. CaCO3) microparticles have mostly been used 
as cores for formation of capsules with active ingredients.51  
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Figure 1.10. Schematic of loading based on smooth and porous particles, using the layer-
by-layer (LbL) technique for capsule shell formation, followed by decomposition of the 
core material. [Reprinted from Parakhonskiy et al.51] 
The principle disadvantages of the method of sacrificial core are (i) some 
traces of the destructed core that might be trapped in the capsules, (ii) the 
disruption of the shell structure in consequence to the core dissolution and 
(iii) a low efficiency of loading of the active substance into the hollow 
shells.52, 53 In addition, it must be taken into account that many therapeutic 
substances are lipophilic and these strategy could result unsuccessful.54  
25 
 
In the past decades a large effort has been devoted to the development of 
functionalized nanoscale oil-core carriers (e.g., micro- and nanoemulsions, 
colloidosome particles, polymeric nanoparticles and nanocapsules) that 
selectively deliver biologically active compounds to diseased sites such as 
malignant cancers (Figure 1.11).55, 56 Indeed, the development of novel 
types of micro- and nanocontainers is constantly one of the main topics in 
the scientific research and in the last few years the major progress in the 
synthesis and application of various methods of template mediated 
synthesis of drug vehicles has been achieved.57, 58  
 
Figure 1.11. Examples of structured emulsions that can be created by structural design 
principles using emulsion droplets as a building block 
The key functions of the these nanocarriers are: 
- successfully encapsulation of hydrophobic drugs in order to target 
cells;  
- to improve drug efficacy and provide for its better intracellular 
penetration; 
- to serve as shields to protect a hydrophobic therapeutic or 
diagnostic cargo (e.g., photosensitizers and other NIR dyes, 
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cytostatics, quantum dots, magnetic nanoparticles, PET or MRI 
contrasts) from degradation and various toxic interactions with the 
biological environment.54, 57, 58 
For all the reasons discussed above, an alternative method of encapsulation 
of hydrophobic active ingredients was proposed, namely the LbL coating 
on emulsion and microemulsion droplets.52, 53, 59, 60 However, the process 
of liquid core enclosure is more challenging since the application of the 
rinsing step between deposition of both polycation and polyanion layer is 
usually not straight forward. Excess of polymer, used for the layer 
formation, may induce polymer depletion flocculation. Moreover, at the 
next adsorption step polyanion/polycation complexes would be formed, 
and it would be difficult to separate them from capsules suspension.18, 54 A 
number of strategies54 have been applied to produce stable multilayer 
systems without droplet aggregation during the rinsing: 
- Centrifugation method. Any excess non-adsorbed polyelectrolyte 
molecules are then removed by centrifuging the suspension, 
collecting the particles, and resuspending them in a rinsing 
solution. The main problem with this method is the possible 
coalescence of emulsion droplets during centrifugation. In 
addition, the centrifugation of micro- and nanoemulsions is 
problematic due to small size and/or low density difference.  
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- Filtration method. The excess of polyelectrolyte molecules in the 
continuous phase is removed by membrane filtration of the 
suspension. A filter is used such that only polyelectrolyte 
molecules pass through it – not the emulsion drops. By applying an 
external pressure, the aqueous phase containing the excess 
polyelectrolyte is forced to pass through the filter. At the same 
time, a rinsing solution is added to the colloidal suspension to keep 
the overall volume of the system constant. After the rinsing step, 
the suspension is mixed with the solution of polyelectrolyte of an 
opposite charge. Filtration of nanoemulsions requires usage of 
ultrafiltration cells with membranes with the cut-off of 50–100 nm; 
therefore, high pressure needs to applied with the substantial risk 
of membrane fouling. As an alternative, dialysis can be used, but 
long time and large amount of rinsing solutions are required. 
- Saturation method. In that method the rinsing step is omitted since 
it is possible to add just enough polyelectrolyte to completely coat 
all of the particles present in the system, so that there is a few 
amount of free polyelectrolyte remaining in the aqueous phase. For 
every system the right amount, namely the “saturation 
concentration”, has to be determined empirically. The saturation 
method can be conveniently used for micro- or nanoemulsions 
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without any limitations. Unfortunately, it leads to a systematic 
dilution of the emulsions at every adsorption step. This method, 
used for the realization of the DDSs presented in this work, is better 
displayed in the following paragraph. 
2.1.1. Saturation method for oil-core polyelectrolyte multilayer 
The main problem with using the LBL technique to prepare multilayer 
emulsions is the tendency for droplet to aggregate during the preparation. 
To minimize or avoid droplet aggregation it is important to carefully 
control solution composition and preparation conditions:61 (i) there should 
be sufficient polyelectrolyte present to saturate all of the droplet surfaces; 
(ii) the polyelectrolyte molecules should adsorb to the droplet surfaces 
more rapidly than when droplet–droplet collisions occur; (iii) there should 
not be too much polyelectrolyte present to promote depletion flocculation; 
(iv) the repulsive interactions between the coated droplets should be strong 
enough to prevent droplet aggregation.   
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Figure 1.12. Schematic diagram of the different events occurring when an electrically 
charged polyelectrolyte is added to a colloidal dispersion containing oppositely charged 
spherical particles. 
Figure 1.12 shows a schematization of the model proposed by Mc 
Clements61 in which is well summarized the different events occurring 
when an electrically charged polyelectrolyte is added to a colloidal 
dispersion containing oppositely charged spherical particles. Particles, in 
fact, are stable to droplet aggregation when their surfaces are completely 
saturated with polyelectrolyte (Csat) and there is no free polyelectrolyte 
present in the continuous phase. On the contrary, when the polyelectrolyte 
concentration is insufficient to completely saturate the particle surfaces, 
bridging flocculation occurs. On the other side, when the concentration of 
free polyelectrolyte exceeds another critical value (CDep) depletion 
flocculation occurs because the attractive depletion forces are strong 
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enough to overcome the various repulsive forces. Finally, when the 
concentration is intermediate between saturation and depletion, i.e.  when 
there is free polyelectrolyte in the continuous phase but it is not enough to 
promote depletion flocculation, the system results to be stable. However, 
it is more desirable that no free polyelectrolyte is present because 
polyanion/polycation complexes would be formed at the next adsorption 
step.  
These considerations highlight the importance of determine the saturation 
concentration Csat for each layer deposited around the particle. To obtain 
empirically this value, the most convenient method contemplates the 
measurements of the change in ζ (zeta) potential along with the change in 
the mean particle diameter when a polyelectrolyte is added to an emulsion 
containing oppositely charged droplets. The optimal addition of 
polyelectrolyte can be determined as corresponding to the point just before 
reaching the plateau of the dependence of zeta potential on the amount of 
polyelectrolyte (Figure 1.13).54, 61  
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Figure 1.13. Change in electrical charge (ζ-potential) as cationic chitosan is added to the 
anionic emulsion. [Reprinted from McClements61] 
More recently, Vecchione et al. proposed alternative methods to determine 
the saturation concentration, based on spectrofluorimetry62 or isothermal 
titration calorimetry (ITC).63 In particular, the ITC-based method allows 
not only to perform a complete physicochemical characterization of the 
system, but also to detect two separate binding events, instead of just one 
saturation event. 
1.5 Aim of research and thesis outline 
LbL technique represents a very attractive tool for the realization of DDSs 
with ideal features like simplicity, versatility, and nanoscale control. The 
final aim of this research activity concerns the realization of completely 
biocompatible and biodegradable nanocarriers with diverse functionalities 
and purposes. The greater ambition, in particular, is the realization of 
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nanometric sized drug vehicles entirely derived from natural materials but 
holding the features needed for the drug delivery. My research group 
started few years ago to realize systems with these facets. Starting from 
natural materials like soybean oil and egg lecithin as surfactant they were 
realized nanoscaled oil-core carriers in which hydrophobic drugs or 
contrasting agents have been successful encapsulated.62 The O/W 
nanoemulsions proposed by Vecchione et al. possess relevant  
characteristics. Thanks to the use of a high pressure homogenizer the O/W 
emulsion obtained has a tunable size ranging from 80 to 200 nm 
(depending on the pressure applied and the surfactant used) with an 
excellent size distribution (PDI below 0.1).62 The so realized 
nanoemulsion has been used as liquid core for the realization of oil-core 
polyelectrolytes-shells nanocarriers. As for the liquid core, natural 
materials have been selected also for the realization of the shell, and, in 
particular, polysaccharides and polyaminoacids.62, 63   
Starting from these conditions this research project has focused on the 
modifications of the polysaccharides used as coating in order to add 
desired functionalities to the final nano-vectors. In Chapter 2 a 
nanoemulsion loaded with curcumin and coated with a modified chitosan 
(with thiol moieties) is presented as an oral delivery nanocarrier (Figure 
1.14, on the left). In vitro tests tried to clarify the routes of the nanosystem 
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and, in particular, how it interacts and passes the intestinal barrier. In vivo 
tests, instead, showed how the size and the amount of thiols on the surface 
effect on the drug assimilation and anti-inflammatory activity.  
 
Figure 1.14. Schematic summary of the nano-systems proposed in the current thesis. 
Starting from an oil in water nanoemulsion, three different systems are proposed. For 
each system modification of biopolymers used (chitosan and heparin) was needed in order 
to add functionalities and obtain versatility. 
In Chapter 3 a multilayer system with modified glycol chitosan and 
heparin is proposed (Figure 1.14, in the center). The glycol chitosan is 
modified with a thiol moiety, whereas heparin is modified with an allylic 
moiety. The polymer modifications allowed to apply a photo activated 
reaction – thiol-ene ‘click’ reaction – to covalently cross link the layers. 
The system submitted to cross-linkage result to be more stable than the 
unmodified one, even if changes in pH and ionic strength occur. It then 
could represent a proof of concept for the realization of LbL nanocapsules 
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with enhanced biostability. In Chapter 4 a multi-shell nanocarrier system 
featuring a hybrid polymer/silica-shell is proposed and realized (Figure 
1.14, on the right). In detail, a bilayer composed of chitosan and heparin 
has been deposited on an oil core and an in situ modification of heparin 
with an aminosilane (APTS) allowed the realization of an outer silica shell, 
using a modified Stöber sol-gel method.64 The final system resulted to be 
highly versatile: the possibility to tune the shell thickness determines its 
mechanical properties; the possibility to load the oil core with lipophilic 
drugs or contrast agents together with the possibility to further 
functionalize the polymeric shell allow for the use of the system for drug 
delivery or diagnostic; the possibility to modify the external surface and to 
coat it with PEG allows to improve the half-life and to add targeting 
functionalities. Final conclusions and future perspectives are synthetically 
presented and discussed in Chapter 5. The reader will appreciate how the 
current thesis have been presented in order of complexity of the final 
system but also how the realization of each system results to be relatively 
simple and, in consequence, potentially scalable for industrial applications. 
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2 Chapter 2 
 
Curcumin bioavailability from oil in water 
nano-emulsions: in vitro and in vivo study 
on the dimensional, compositional and 
interactional dependence1 
 
                                                          
1 This work has been submitted for publication to Journal of Controlled Release: R. 
Vecchione, V. Quagliariello, D. Calabria, V. Calcagno, E. De Luca, R. V. Iaffaioli, P. A. Netti. 
“Curcumin bioavailability from oil in water nano-emulsions: in vitro and in vivo study on 
the dimensional, compositional and interactional dependence”. The Supplementary 
Section is not included in the submitted publication.  
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Abstract. Although nanocarriers can enhance the bioavailability of free 
curcumin in the blood, a systematic study on the parameters that affect 
such enhancement is still missing. In this work we focused the attention on 
a nanocarrier represented by an oil in water nano-emulsion coated with a 
thiol modified chitosan and carried out a comprehensive study on the 
effects that parameters such as size, co-delivery of piperine and degree of 
chitosan modification can exert on curcumin bioavailability and quantified 
their impact. We obtained an unprecedented pharmacokinetic profile of 
curcumin with the best formulation, represented by a combination of a 
small nano-emulsion size (110 nm), co-delivery of curcumin and piperine 
(weight ratio 100:1) and a high degree of chitosan thiolation (around 15%). 
Then, we assessed its anti-inflammatory properties after oral 
administration in rats at low doses (≤ 0.1 times the volume administered 
in the pharmacokinetic study) compatible with a possible transfer to 
humans. Furthermore, the proposed food grade nano-emulsions loaded 
with curcumin did not show any cytotoxic effect on normal fibroblasts, 
while they were able to promote death in colon cancer cells in agreement 
with the common knowledge of the selective action of curcumin. 
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2.1 Introduction 
Curcumin, a bioactive compound isolated from the rhizome of the 
Curcuma longa plant, has a long history of use in traditional Chinese and 
Indian medicine. An interesting example concerns the common use of 
curcumin powder for the treatment of cough and related respiratory 
diseases1 and as an antidysenteric.2 Moreover, in the past, it was also used 
to treat dental diseases, digestive disorders such as dyspepsia and acidity, 
indigestion, flatulence, ulcers and many inflammatory conditions in 
different body regions.3 From a chemical point of view, curcumin is 
diferuloyl methane molecule [1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione)] containing two ferulic acid residues joined by a 
methylene bridge. Curcumin acts as a ROS scavenger, increases 
antioxidant glutathione levels by induction of glutamate cysteine ligase, 
and acts as an anti-inflammatory agent through the inhibition of NF-κB 
signaling.4 It acts through the inhibition of I-κB phosphorylation and thus 
prevents I-κB degradation by the proteosomes. Despite its numerous 
applications, the most relevant issues concerning the pharmacokinetics of 
curcumin are: molecular instability, poor solubility in water, rapid 
conjugation in the liver with biliary excretion and poor enteral absorption.5 
To increase its bioavailability, several approaches have been tried: 
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phospholipid complexes (phytosomes), which increased the area under the 
blood concentration-time curve (AUC) of curcumin after oral 
administration in rats by 5 times;6 association with cyclodextrin, with a 
ten-fold increase in curcumin AUC;7 BCM-95 extract, whose 
bioavailability in rats was 7.8 times higher than unformulated curcumin;8 
mixing of curcumin with an essential oil obtained from standardized 
turmeric where AUC was 7–8 times higher than unformulated curcumin.9 
Another interesting approach to improve the biodistribution of curcumin 
is based on its combination with piperine, the alkaloid responsible for the 
pungency of black pepper and long pepper; it inhibits the glucuronidation 
processes by the enzyme UDP-glucuronosyltransferase (with Ki of 70 µM) 
in the liver and small intestine, as demonstrated by the administration of 
unformulated curcumin and piperine.10, 11 It is also known that oil in water 
nano-emulsions can enhance bioavailability, as well as provide an anti-
inflammatory action as a response to the free curcumin in the blood.12 The 
best performing nano-emulsion produced so far has provided no more than 
a ten-fold increase in the AUC compared to unformulated curcumin in 
mice.13 The best performing systems have been up to now based on the use 
of colloidal curcumin nanoparticles, named 'theracurmin' that showed 
AUC after oral administration 40-fold higher than that of curcumin powder 
in rats.14 Motivated by the very interesting properties of curcumin, in our 
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study we proposed an easily tunable nanocarrier in order not only to find 
out optimal conditions to further enhance curcumin bioavailability, but 
also to better understand the impact of different nanocarrier parameters to 
address the design of more and more performing nanocarriers. In 
particular, we developed and tested biologically, in vitro and in vivo, a new 
nanometric formulation of curcumin combined with the alkaloid piperine, 
both loaded in oil in water nano-emulsions stabilized by a layer of chitosan 
chosen for its resistance to the gastro tract and adhesive properties towards 
the intestinal lumen.15 Due to the enhanced adhesive properties of the 
chitosan derivative possessing thiol moieties,16 we optimized the degree of 
functionalization of chitosan with 2-iminothiolane and tested the system at 
different degrees of functionalization to quantify its impact. Emulsion size 
is another important parameter to investigate; although most of the studies 
report bioavailability improvement with a reduction in nanocarrier size,17, 
18 there is evidence that -in some cases- size plays a minor role.19 In this 
context, we analyzed the effects of size on the bioavailability of free 
curcumin by using a first emulsion with a 110 nm diameter and a second 
almost double in size. In combination with the pharmacokinetic study we 
also carried out a biodistribution analysis and evaluated the cytotoxic 
effect of the curcumin loaded nano-emulsion on normal fibroblasts and on 
colon cancer cells to assess curcumin activity upon encapsulation in our 
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nanocarrier. Finally, to assess the efficacy of the proposed nanotool, as a 
functional test, we tested the anti-inflammatory properties of the best 
formulation on lipopolysaccharide (LPS) treated rats in comparison with a 
traditional lipid formulation based on curcumin phosphatidylcholine 
complexation at different volume doses, including volumes compatible 
with a possible transfer to humans. 
 
2.2 Results and discussions 
Nano-emulsions analysis 
Particle size of curcumin loaded nano-emulsions was characterized by 
DLS. Smaller nano-emulsions coated with pristine chitosan exhibited a 
size of 110 nm in diameter and a PDI of 0.09, as depicted in Figure 
2.1F. However, the use of chitosan 2-iminothiolane conjugate as a coating 
did not significantly affect the final size and PDI even at the highest degree 
of modification (size 110 nm and PDI 0.1). Then, to study the effects of 
size on bioavailability, the formulation with a lower amount of lecithin 
surfactant was also measured by DLS showing a circa double final size 
(size 230 nm and PDI 0.06). In this work pristine chitosan was modified 
with FITC and as an example the smaller nano-emulsion containing 
curcumin was coated with such FITC labeled chitosan to be visualized in 
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fluorescence. In particular, this nano-emulsion was characterized by using 
a STED microscope (high resolution < 100 nm), since the expected size 
was around 110 nm. This size measured by DLS was confirmed by STED 
analysis, as illustrated in Figure 2.1A-E, where confocal and STED 
acquisition are compared. Real size given by the STED image indicates 
that most of the nano-droplets are about 110 nm large, proving the narrow 
distribution feature of our secondary nano-emulsions. Statistical analysis 
confirmed size and monodispersion provided by DLS. In addition, as 
shown in a previous work20, 21  the process utilized to produce such 
chitosan coated nano-emulsions allows stability to last longer than 1 year. 
This characterization demonstrates -as already shown by DLS- the 
capability to dimensionally control our nanocarriers so that all the results 
can be associated to a specific size. The degrees of functionalization 
measured by applying the Ellman’s test were 7.2% for the chitosan 2-
iminothiolane conjugate at the medium degree of modification (CT-IT-m), 
15.1 % for the highest degree of modification (CT-IT-h) in the case of 
deposition on the larger nano-emulsion size and -finally- 13.6% for the 
highest degree of modification in the case of deposition on the smaller 
nano-emulsion. 
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Figure 2.1. Analysis of chitosan coated nano-emulsions loaded with curcumin: (A) 
Confocal and (B) STED imaging; (C) Enlargements of the areas boxed in A and B; (D) 
Gaussian fit of the intensity point measured on the STED image. The white arrows show 
the point where the line profile was measured; (E) Statistical analysis of the FWHM 
obtained with the Gaussian fit of 30 individual emitting spots; (F) DLS measurement. 
Changes in the structure upon functionalization can be evidenced also by 
NMR spectra, presented in Figure 2.2. Compared to the spectrum of 
pristine chitosan (in the bottom of the image), it is possible to observe the 
appearance of new peaks, in particular at 1.76 ppm, 2.30 ppm and 2.42 
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ppm, associated with the methylene groups of the thio-butyl-amidine (at 
the top right corner of the figure). 
 
Figure 2.2. 1D 1H NMR spectra of pristine chitosan (bottom line) and chitosan 2-
iminothiolane conjugate (top line). New signals associated with the methylene groups of 
the thio-butyl-amidine appear after the functionalization, in particular at 1.76 ppm, 2.30 
ppm and 2.42 ppm. 
Cell cytotoxicity  
We tested the biosafety of the nano-emulsions and the capability of our 
nano-emulsion to maintain curcumin activity by carrying out cytotoxicity 
tests on the different formulations loaded and non-loaded with curcumin 
and/or piperine always at 1/100 w/w ratio with curcumin. First of all, cell 
viability results demonstrated, in 3T3 (Figure 2.3A) and HT29 (Figure 
2.3B) cell lines, the non-toxicity of the different formulations alone 
indicating the biosafety of the tested carriers.  
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Figure 2.3. Viability of 3T3 (A) and HT29 (B) cells after 24 h of exposure at 37 °C as a 
function of nano-emulsion (mg oil/ml) without curcumin. *p<0.01; **p<0.05; n.s: not 
significant 
 
As regards formulated curcumin, against fibroblasts, nano-emulsions 
loading curcumin alone and in combination to piperine (weight ratio 
100:1) did not show a significant toxicity up to 100 µg/ml of corresponding 
curcumin concentration for incubation times up to 24 h (Figure 2.4).  
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Figure 2.4. Viability of 3T3 (A) and HT29 (B) cells after 24 h of exposure at 37 °C as a 
function of nano-emulsion (mg oil/ml) and curcumin (µg/ml) concentration. *p<0.01; 
**p<0.05; n.s: not significant. 
Similarly, unformulated piperine and nano-emulsions loaded with piperine 
(Figure 2.5) showed no significant cytotoxicity against both cell lines.  
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Figure 2.5. Viability of 3T3 (A) and HT29 (B) cells after 24 h of exposure at 37°C as a 
function of piperine (µg/ml) concentration. 
In contrast, formulated curcumin showed high toxicity in the colon cancer 
cells (HT29 cell line, Figure 2.6B) after 24 h of contact compared to 
unformulated curcumin (Figure 2.4B). In addition, NE-CT-110-curc 
showed a lower level of toxicity compared to NE-CT-IT-h-110-curc 
(p<0.05).  
51 
 
 
 
Figure 2.6. Viability of 3T3 (A) and HT29 (B) cells after 24 h of exposure at 37 °C as a 
function of nano-emulsion (mg oil/ml) and curcumin (µg/ml) concentration. *p<0.01; 
**p<0.05; n.s: not significant. 
This effect can be explained considering the higher cytoadhesive 
properties of thiolated polymers due to more interactions with the cellular 
membrane.22, 23 According to this concept an IC50 at 65 and at 25 µg/ml, 
respectively, for NE-CT-IT-m-110-curc and NE-CT-IT-h-110-curc, was 
observed, indicating a concentration-dependent interaction between the 
thiol groups on chitosan and the cell membrane. Administration of 
curcumin and piperine in combination led to a higher level of cytotoxicity, 
that is statistically significant only when comparing NE-CT-IT-h-110-curc 
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and NE-CT-IT-h-110-curc-piper(p<0.05), as depicted always in; this 
behavior suggests a possible adjuvant action of piperine in the anti-
proliferative molecular mechanism of curcumin against human colon 
cancer cells (Figure 2.4B and Figure 2.6B). On the basis of these results, 
the best cytotoxic formulation was the NE-CT-IT-h-110-curc-piper, 
exhibiting an IC50 value at 24 h of 15 µg/ml of curcumin, which was 
significantly lower than curcumin concentrations needed to reach IC50 by 
the other formulations (in the case of unformulated curcumin IC50 was not 
reached at all). Interestingly, comparing results on both cell lines, we 
observed selective toxicity of curcumin against human colon cancer cells 
in agreement with recent literature sources reporting selective anticancer 
properties of this molecule alone,24 or in combination with conventional 
anticancer drugs.25-27 These results prove that the selective action property 
of curcumin is maintained when encapsulated in our nano-emulsions.  
Cancer cell imaging and internalization studies 
Following FITC emission, a cell uptake study was carried out. For this 
analysis we used the 110 nm curcumin nano-emulsion coated with FITC-
labelled chitosan, NE-FITC-CT-110-curc at a correspondent curcumin 
volume concentration of 1 µg/ml. The graph presented in Figure 2.7 
corresponds to the amount of internalized nano-emulsions (expressed as 
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µg of chitosan /mg of proteins), plus cell surface-bound nano-emulsions. 
NE-FITC-CT-110-curc were taken up very rapidly by HT29 cell line, with 
a value of 150 µg of corresponding chitosan per mg cell protein reached 
after as early as 4 h of incubation; other literature reports confirm the 
rapidity of cellular uptake due to electrostatic interactions between the 
cellular membrane and the positively charged chitosan 28. 
 
Figure 2.7. Overall cellular uptake quantification of NE-FITC-CT-110-curcat a 
corresponding  curcumin concentration of 1 µg/ml internalized in colon cancer cells 
(HT29 cell line) as a function of time. 
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Figure 2.8. Confocal Laser Scanning Microscope images of colon cancer cells (HT29 
cell line) after 0.5 (A), 2 (B), 4 (C) and 24 h (D) of contact with NE-FITC-CT-110-curc 
at a corresponding curcumin concentration of 1 µg/ml; the green punctuated fluorescence 
corresponds to uptaken nano-emulsion, which clearly moves from a peripheral to a central 
(perinuclear) localization during the incubation time. Green signal: FITC; Red signal: 
Concanavalin A Tetramethylrhodamine Conjugate. Scale bar: 50 µm. 
Confocal images show that NE-FITC-CT-110-curc (green in Figure 2.8) 
was visibly associated to peripheral intracellular compartments at early 
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time points (0.5-4 h, Figure 2.8A-C), whereas a more central localization 
was recorded after 24 h (Figure 2.8D). These results demonstrate the 
nano-emulsion uptake ability and the time dependent internalization in 
human colon cancer cells with a tendency to accumulate in the perinuclear 
regions of the cells after 24 h, which is generally advantageous for drugs 
that intercalate with DNA -such as curcumin. 
Pharmacokinetic studies 
Pharmacokinetic data related to 8 mg/kg doses are reported in Table 2.1 
and Figure 2.9. They include data related to absolute curcumin AUC, 
curcumin Cmax, curcumin AUC ratio with its two main metabolites and 
relative curcumin bioavailability (%). As shown, compared to 
unformulated curcumin, orally administered nano-emulsions loaded with 
curcumin always determined an increase in both maximum concentration 
(Cmax) and AUC of the curcumin and its two metabolites, glucoronidated 
and sulphated; thus, formulated curcumin led to a greater intestinal drug 
adsorption capacity than unformulated curcumin, with a consequent 
increase in its metabolized forms.  
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Table 2.1. Calculated nanomolar plasma peak levels (Cmax), time of peak levels (Tmax), 
AUC expressed as µg min /ml and relative bioavailability (%). 
Formulations 
(8 mg/kg of curcumin) 
Parameters Curcumin 
Curcumin 
glucoronide 
Curcumin 
sulphate 
 Cmax (nM) 0.12 ± 0.04 4.5 ± 0.25 0.21 ± 0.18 
Unformulated curc Tmax (min) 30 30 60 
 AUC (µg min/ml) 0.09 ± 0.03 3.7 ± 0.1 0.34 ± 0.11 
 Relative bioavailability (%) 1   
     
 Cmax (nM) 0.28 ± 0.19 68.7± 5.4 0.48 ± 0.25 
NE curc Tmax (min) 15 30 60 
 AUC (µg min/ml) 0.27 ± 0.07 71.4 ± 8.6 0.38 ± 0.08 
 Relative bioavailability (%) 3 ± 0.1   
     
 Cmax (nM) 0.69 ± 0.47 112.5 ± 2.5 0.84 ± 0.56 
NE-CT-110-curc Tmax (min) 15 30 60 
 AUC (µg min/ml) 0.52 ± 0.13 121.8 ± 7.3 0.93 ± 0.17 
 Relative bioavailability (%) 5.7 ± 0-8   
     
 Cmax (nM) 1.05 ± 0.32 88.7 ± 1.8 0.9 ± 0.33 
NE-CT-110-curc-piper Tmax (min) 15 30 60 
 AUC (µg min/ml) 0.83 ± 0.18 81.1 ± 4.3 0.98 ± 0.12 
 Relative bioavailability (%) 9.2 ± 1.5   
     
 Cmax (nM) 1.69 ± 0.5 201.5 ± 2.4 0.82 ± 0.2 
NE-CT-IT-m-110-curc Tmax (min) 15 30 60 
 AUC (µg min/ml) 1.86 ± 0.21 211.8 ± 13.3 1.21 ± 0.3 
 Relative bioavailability (%) 9.5 ± 1.1   
     
 Cmax (nM) 2.78 ± 0.31 101.8 ± 3.1 0.98 ± 0.83 
NE-CT-IT-m-110-curc-piper Tmax (min) 15 30 60 
 AUC (µg min/ml) 1.98 ± 0.34 118.3 ± 15.6 0.63 ± 0.3 
 Relative bioavailability (%) 22 ± 2.8   
     
 Cmax (nM) 2.07 ± 0.21 341.1 ± 1.7 1.14 ± 0.4 
NE-CT-IT-h-110-curc Tmax (min) 15 30 60 
 AUC (µg min/ml) 2.99 ± 0.55 316.2 ± 18.3 2.09 ± 0.22 
 Relative bioavailability (%) 33.2 ± 2.7   
     
 Cmax (nM) 3.98 ± 0.13 153.4 ± 2.6 1.28 ± 0.61 
NE-CT-IT-h-110-curc-piper Tmax (min) 15 30 60 
 AUC (µg min/ml) 5.73 ± 0.61 156.7 ± 17.2 1.47 ± 0.13 
 Relative bioavailability (%) 64 ± 4.3   
     
 Cmax (nM) 1.07 ± 0.18 172.1 ± 2.3 0.96 ± 0.9 
NE-CT-IT-h-220-curc Tmax (min) 15 30 60 
 AUC (µg min/ml) 1.19 ± 0.15 216.4 ± 11.2  2.09 ± 0.3 
 Relative bioavailability (%) 13.2 ± 1.2   
     
 Cmax (nM) 2.18 ± 0.23 1.07 ± 1.9 0.88 ± 0.31 
NE-CT-IT-h-220-curc-piper Tmax (min) 15 30 60 
 AUC (µg min/ml) 2.11 ± 0.18 102.7 ± 16.2 0.97 ± 0.12 
 Relative bioavailability (%) 23.4 ± 1.9   
     
 Cmax (nM) 0.61 ± 0.21 121.4 ± 5.2 0.93 ± 0.46 
Phosphatidylcholine based 
formulation of curc 
Tmax (min) 15 30 60 
AUC (µg min/ml) 0.85 ± 0.18 163.8 ± 17.3 0.66 ± 0.13 
 Relative bioavailability (%) 9.4 ± 0.5   
     
 Cmax (nM) 1.06 ± 0.42 82.8 ± 4.3 0.91 ± 0.49 
Phosphatidylcholine based 
formulation of curc-piper 
Tmax (min) 15 30 60 
AUC (µg min/ml) 1.44 ± 0.22 89.9 ± 11.8 0.59 ± 0.1 
 Relative bioavailability (%) 16 ± 1.3   
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Figure 2.9. Curcumin AUC (A) AUC ratio between curcumin and curcumin glucuronide 
and sulphate (B, C) and relative bioavailability (%) comparison (D) between 
unformulated curcumin and nano-emulsions at 8 mg/kg orally administered in rats. 
*p<0.01; **p<0.001; ***p<0.05; ns: not significant. 
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For example, the relative bioavailability of NE-CT-IT-h-110-curc-piper-8 
was 64 times higher than that of Unformulated curc-8. In relation to the 
different nano-emulsion parameters, the presence of thiols on chitosan 2-
iminothiolane conjugate demonstrated a central role in increasing 
curcumin AUC after oral administration in rats; the beneficial effects of 
piperine co-delivery, are also evident as well as the role of the size, whose 
scaling was fundamental to strongly gain in curcumin AUC.   
In particular, all the results summarized in Table 2.1 and Figure 2.9 
confirm the essential role of piperine in the pharmacokinetic profile of 
curcumin, in agreement with previous works related to the co-
administration of unformulated curcumin and piperine.11, 29 In fact, as 
reported in Figure 2.9, which describes the ratios of metabolites 
(glucuronide, C and sulphate, E) to parent curcumin AUCs, the presence 
of piperine determined beneficial changes in curcumin metabolism with 
the various treatments.  
In addition, with respect to the effect of chitosan modification, as reported 
in Table 2.1 and Figure 2.9, focusing on the cases of piperine co-delivery, 
oral administration of NE-CT-110-curc-piper-8, NE-CT-IT-m-110-curc-
piper-8 and NE-CT-IT-h-110-curc-piper-8, compared to Unformulated 
curc-8, increased AUC of curcumin 9.2, 22 and 63.6 times, respectively. 
These data indicate the important role of the degree of chitosan 
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modification with 2-iminothiolane in the phenomena of uptake and 
intestinal absorption after oral administration in rats.  
Finally, from Table 2.1 and Figure 2.9 it is also possible to make a 
comparison in terms of size. Specifically, NE-CT-IT-h-220-curc-piper-8 
increased curcumin AUC 23.4 times compared to Unformulated curc-8 
but, very interestingly curcumin AUC value was drastically lower than 
curcumin AUC provided by NE-CT-IT-h-110-curc-piper-8 (2.11 ±0.18 vs. 
5.73 ± 0.61; p<0.001), indicating the essential role of size of the nano-
emulsion in the phenomena of uptake and intestinal absorption after oral 
administration in rats.  
For completeness, we also performed a comparison with a more traditional 
lipid formulation based on a curcumin phosphatidylcholine complexation 
under the same conditions of dilution; our best nano-emulsion showed a 
significant improvement in curcumin bioavailability, as reported in Table 
2.1 and Figure 2.9A. For example, NE-CT-IT-h-110-curc-piper increased 
curcumin AUC 4 times compared to curcumin-piperine 
phosphatidylcholine complexation (5.73 ± 0.61 vs. 1.44 ± 0.22) in a 
statistically significant manner (p<0.001) 
In conclusion, on the basis of these pharmacokinetic data, co-
administering curcumin and piperine in stabilized lipid 110 nm nano-
emulsions and coated with chitosan 2-iminothiolane conjugate at the 
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highest degree of modification, we achieved, compared to other 
pharmacokinetic studies after oral administration in rats, a 6-fold increase 
in curcumin AUC compared to the most recent nano-emulsion systems,13 
and a 1.6-fold increase compared to the best performing system so far 
reported.14 
Very interestingly, from an applicative point of view, even administering 
0.8, 0.4 or 0.2 mg/kg of corresponding curcumin concentration of CT-IT-
h-110-curc-piper, we continued to see detectable amount of curcumin and 
its metabolites as shown in Table 2.2 and Figure 2.10 and the difference 
between concentrations was always statistically significant. 
Table 2.2. Calculated nanomolar plasma peak levels (Cmax), time of peak levels (Tmax) 
and Area Under Curve (AUC) expressed as µg min/ml for NE-CT-IT-h-110-curc-piper 
at 0.8, 0.4 and 0.2 mg/kg of corresponding curcumin concentration. 
Formulations Parameters Curcumin 
Curcumin 
glucoronide 
Curcumin 
sulphate 
 Cmax (nM) 3.98 ± 0.13 153.4 ± 2.6 1.28 ± 0.61 
NE-CT-IT-h-110-curc-piper  
(8 mg/kg of curcumin) 
Tmax (min) 15 30 60 
AUC (µg min/ml) 5.73 ± 0.61 156.7 ± 17.2 1.47 ± 0.13 
     
 Cmax (nM) 0.65 ± 0.09 24.8 ± 1.2 0.21 ± 0.1 
NE-CT-IT-h-110-curc-piper  
(0.8 mg/kg of curcumin) 
Tmax (min) 15 30 60 
AUC (µg min/ml) 0.85 ± 0.12 25,7 ± 2.8 0.26 ± 0.02 
     
 Cmax (nM) 0.36 ± 0.07 13.6 ± 0.9 0.13 ± 0.2 
NE-CT-IT-h-110-curc-piper  
(0.4 mg/kg of curcumin) 
Tmax (min) 15 30 60 
AUC (µg min/ml) 0.51 ± 0.11 14.2 ± 1.5 0.14 ± 0.03 
     
 Cmax (nM) 0.2 ± 0.06 7.2 ± 0.5 0.09 ± 0.05 
NE-CT-IT-h-110-curc-piper  
(0.2 mg/kg of curcumin) 
Tmax (min) 15 30 60 
AUC (µg min/ml) 0.22 ± 0.05 6.8 ± 0.9 0.09 ± 0.01 
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Figure 2.10. Curcumin AUC comparison between unformulated curcumin and nano-
emulsions at 8, 0.8, 0.4, 0.2 mg/kg orally administered in rats. *p<0.01; **p<0.001; 
***p<0.05; ns: not significant. 
 
Biodistribution studies  
We evaluated the biodistribution of different fluorescent nano-emulsions, 
such as NE-FITC, NE-CT-110-FITC and NE-CT-IT-h-110-FITC, from 
the gastrointestinal tract to different organs within 2 h after a single oral 
administration in rats. Accumulation of nano-emulsions in different organs 
expressed as % of the injected dose is shown in Figure 2.11. All tested 
nano-emulsions induced a significant increase in fluorescence in at least 
one of the tested organs, as expected in the case of passage through the 
intestinal wall. In the stomach there was a time dependent decrease in 
fluorescence related to all formulations with a very low percentage of the 
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injected dose 2 h after oral administration; conversely, we observed a time 
dependent increase in fluorescence in the liver and spleen with higher 
levels of accumulation achieved 2 h after oral administration. The general 
high fluorescence intensity in liver can be justified by the presence of the 
reticuloendothelial system (RES); in fact, oral delivery along its path 
unavoidably encounters liver parenchyma where hepatocytes and liver 
macrophages (Kupffer cells) are able to recognize and metabolize 
nanocarriers like liposomes and/or macromolecules; the same happens at 
the spleen level.30 In this context, the co-delivery of piperine was helpful 
since it could inhibit some enzymatic activities of curcumin useful for its 
bioavailability, as demonstrated in the pharmacokinetic study. 
Interestingly, in the small intestine (after 1 h of administration) and liver  
(after 2 h of administration) the percentage of the injected dose of NE-CT-
IT-h-110-FITC was significantly higher than that of the NE-CT-110-FITC 
(p<0.01 for both organs) and NE-FITC (p<0.005, p<0.01 for small 
intestine and liver, respectively).  
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Figure 2.11. Biodistribution study in rats after a single oral administration of NE-FITC (A), NE-
CT-110-FITC (B) and NE-CT-IT-h-110-FITC (C). *p<0.001; **p<0.01 
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Specifically, the percentage of the injected dose of NE-CT-IT-h-110-FITC 
was more than 3 times higher, at 1 h after administration, compared to NE-
FITC and 1.5 times compared to NE-CT-110-FITC (p<0.01) in agreement 
with a supposed improved passage through the intestinal barrier deriving 
from the higher mucoadhesive ability of nano-emulsions determined by 
the presence of chitosan and especially of modified chitosan (Figure 
2.11A-C).  
Conversely, NE-FITC seemed to accumulate more in the large intestine 
compared to the others (p<0.001) indicating, probably, a worse 
mucoadhesive ability in the small intestine. Future experiments are under 
investigation for the use of 14C-labelled curcumin in order to follow more 
closely the destiny of the drug. 
Anti-inflammatory effects in lipopolysaccharide-exposed rats  
Many cytokines and interleukins have been reported to act as anti or pro-
inflammatory factors; it has been recently found that these are produced 
also by cancer cells, or by the tumor microenvironment, in order to develop 
their progression and survival.31, 32 In this study, we focused our attention 
on four molecules, tumor necrosis factor (TNF-α), interleukin (IL)-1β, IL-
8 and IL-6. TNF-α is an extremely potent autocrine and paracrine mediator 
of inflammation and several studies demonstrated its over expression in 
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cancer tissue and carcinoma cell lines.33 Il-1 β is another essential pro 
inflammatory cytokine that plays a regulatory role in the growth of cancer 
cells also by autocrine mechanisms;34 IL-8 a is a pro-inflammatory 
cytokine with a key role in  the initiation and amplification of acute 
inflammatory reactions35 and regulation of tumor cell growth and 
metastasis of thyroid, colon and breast cancer. IL-6 is a cytokine whose 
hypersecretion by tumor microenvironment induces proliferation and a 
more aggressive phenotype, for example, in ER-positive breast cancer 
cells;36 it is also well known that an increased IL-6 expression is related to 
an advanced stage of disease and decreased survival in colorectal cancer 
patients.37 
On the basis of the emerging key role of cytokines in tumor growth and 
survival, a potential modulation of the plasma concentration of these 
cytokines also under pro-inflammatory conditions could be crucial. The 
above mentioned pro-inflammatory cytokines (TNF-α, IL-1β, IL-8 and IL-
6) were produced in this study upon LPS injection in vivo. These cytokines 
were used, both in cellular and animal studies, as mediators of molecules 
present in the outer membranes of Gram-negative bacteria.38, 39 As shown 
in Figure 2.12, interleukin plasma concentration increased exponentially 
by two (IL-1β, IL-8) and three (IL-6) orders over 5 h upon LPS injection 
in rats (point 0) with a mean value of 356.6 ± 11.1, 455.3 ± 19.2 and 853.8 
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± 14.5 pg/ml, respectively. Instead, TNF-α levels showed a sharp 
plasmatic increase by two orders over 2 h upon LPS administration with a 
successive plateau phase with a mean concentration of 788.5 ± 7.3 pg/ml 
after 5 h. The increase in plasma concentration of the analysed interleukins 
is in agreement with literature,40 and is mainly related to the TLR4 receptor 
stimulation by LPS with subsequent induction of cytokines and interleukin 
production.41  
 
Figure 2.12. Effects of Unformulated curc-8, NE-CT-IT-h-110-curc-8 and NE-CT-IT-h-
110-curc-piper-8 on plasma cytokine levels-time profiles in lipopolysaccharide-exposed 
rats. The levels of plasma cytokines were measured before and after 2 and 5 h the LPS 
intraperitoneal injection in rats pre-treated with normal saline solution (Control) and 
Unformulated curc at 0.8 mg/kg; NE-CT-IT-h-110-curc at the same curcumin dose of 0.8 
mg/kg; NE-CT-IT-h-110-curc, at the same curcumin dose of 0.8 mg/kg and piperine 0.01 
mg/kg. * p < 0.001. ** p<0.05. 
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Oral pre-administration of Unformulated curc-0.8 did not show any 
statistically significant changes in cytokine levels in plasma, 
demonstrating no significant anti-inflammatory activity (Figure 2.12). 
Conversely, oral pre-administration of NE-CT-IT-h-110-curc-0.8 reduced 
the magnitude of the increase in plasma IL-1β, IL-8, IL-6 and TNF-α 
levels; specifically, the treatment reduced approximately by 40% (213 ± 9 
vs. 356 ± 11) 25% (588 ± 11 vs. 788 ± 7), 26% (632 ± 22 vs. 853 ± 14) and 
24% (346 ± 25 vs. 455 ± 19) the production of IL-1β, TNF-α, IL-6, IL-8, 
respectively, compared to the control group (p < 0.005), (Figure 2.12). In 
the presence of piperine co-delivery NE-CT-IT-h-110-curc-piper-0.8 
reduced the magnitude of the increase in plasma IL-1β, IL-8, IL-6 and 
TNF-α levels in an even more significant manner indicating the adjuvant 
effect of the alkaloid piperine; specifically, it reduced approximately by 
57% (153 ± 13 vs. 356 ± 11), 48% (406 ± 15 vs. 788 ± 7), 51% (416 ± 18 
vs. 853 ± 14) and 60% (181 ± 15 vs. 455 ± 19) the production of IL-1β, 
TNF-α, IL-6, IL-8, respectively, compared to the control group (P < 0.001) 
(Figure 2.12). These data indicate that even at a 1/10 dose (=0.75 ml/kg), 
the best formulation coming from the pharmacokinetic study, NE-CT-IT-
h-110-curc-piper, has an effective anti-inflammatory action when orally 
administered to LPS treated rats. 
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Moreover, we tested the anti-inflammatory effect of two lower doses, such 
as NE-CT-IT-H-110-curc-piper-0.4 and of NE-CT-IT-H-110-curc-piper-
0.2. As it is possible to see from Figure 2.13, in both cases a relevant 
reduction of IL-1β, TNF-α, IL-6, IL-8, as compared to the control groups 
(P < 0.01) was obtained.  
Specifically, the first dose (0.4 mg/kg) reduced by approximately 37% 
(253 ± 15 vs. 402 ± 22), 30% (582 ± 23 vs. 821 ± 31), 32% (628 ± 33 vs. 
921 ± 28) and 39% (293 ± 23 vs. 478 ± 11) the production of IL-1β, TNF-
α, IL-6, IL-8, respectively, compared to the control group (P < 0.01). The 
second dose (0.2 mg/kg) reduced by approximately 25% (301 ± 14 vs. 402 
± 22), 14% (702 ± 26 vs. 821 ± 31), 19% (745 ± 27 vs. 921 ± 28) and 14% 
(407 ± 17 vs. 478 ± 11) the production of IL-1β, TNF-α, IL-6, IL-8, 
respectively, compared to the control group (P < 0.01). 
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Figure 2.13. Concentration dependent anti-inflammatory effects of NE-CT-IT-h-110-
curc-piper-0.8; NE-CT-IT-h-110-curc-piper-0.4 and NE-CT-IT-h-110-curc-piper-0.2 in 
lipopolysaccharide-exposed rats. The levels of plasma cytokines were measured just 
before and after 2 and 5 h from the LPS intraperitoneal injection. *p<0.05; **p<0.01; 
***p<0.001 
2.3 Conclusions 
The oral route remains the easiest way to effectively deliver natural 
substances, such as nutraceuticals. In this work we used a modular system 
to convey curcumin based on a food grade nano-emulsion; the system is 
capable of controlling the interface properties and therefore the interaction 
with the intestinal barrier by easy deposition of functionalized 
biopolymers. In particular, we studied curcumin bioavailability by using 
chitosan with different degrees of modification with 2-iminothiolane and 
the effects of the nano-emulsion size by comparing 110 nm and 230 nm 
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emulsions and the effects of piperine co-delivery, which has been already 
reported to enhance curcumin bioavailability. We obtained the highest 
degree of bioavailability in the case of the smaller nano-emulsion coated 
with the highest degree of chitosan modification with 2-iminothiolane and 
co-delivery of piperine. Apart from elucidating the roles played by the 
different parameters in a systematic way, we obtained a relative 
bioavailability of NE-CT-IT-h-110-curc-piper which was 64 times higher 
than unformulated curcumin, the highest ever reached. Then, we showed 
very high anti-inflammatory activities based on the reduction of IL-1β, 
TNF-α, IL-6 and IL-8 in LPS treated rats at 0.8 mg of curcumin per kg of 
rat (corresponding to 0.75 ml/kg of rat) and even significant at doses as 
low as 0.2 mg of curcumin per kg of rat (corresponding to 0.19 ml/kg of 
rat). In addition, we propose a modular system which may add complexity 
by exploiting its capability to further deposit layers and create multi-
compartmentality and therefore multifunctionality. Given the anti-
inflammatory and also chemopreventive power of curcumin, we have 
planned clinical trials in the care of the inflammatory bowel disease (IBD) 
and in chemoprevention of the colorectal cancer. In addition, based on the 
selective action of the curcumin against cancer cells as proved in literature, 
we demonstrated that this property is maintained when curcumin is 
encapsulated in our systems. Finally, studies of combinatory treatments of 
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chemotherapy drugs and curcumin, both orally administered, exploiting 
their pharmacological synergism and chemosensitization in different 
cancer types are currently under investigation. 
2.4 Materials and Methods 
Materials 
Oil in water nano-emulsions were obtained by using a formulation based 
on pharma grade products such as soy-bean oil and Lipoid E80 lecithin, 
both purchased from Lipoid and used without further purification. 
Millipore® Milli-Q water was used for the preparation of all emulsions 
and solutions. The emulsions were then coated with chitosan (CT, LMW 
90-150 kDa, DD 84% determined via 1H-NMR) also purchased from 
Sigma-Aldrich and purified before use.42 For the in fluorescence analysis, 
chitosan was chemically labelled with Fluorescein 5(6)-isothiocyanate 
(FITC, m.w.=389.38 g/mol) purchased from Sigma Aldrich. 1,4-
diazabicyclo[2.2.2]octane (dabco) (m.w.=112.17 g/mol), antifade, also 
purchased from Sigma Aldrich, was used to avoid the bleaching 
phenomenon of FITC. Optical dishes FD3510 (Fluorodish Cell Culture 
Dish - 35mm) with a cover glass bottom were used to allow STED 
observation of the samples. Curcumin (from Curcuma longa (Turmeric), 
powder, m.w.=368.38) and piperine (97%, m.w.=285.34) were both 
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purchased from Sigma-Aldrich and used with no further purification. 2-
Iminothiolane hydrochloride (2-IT), DL-Dithiothreitol (DTT), deuterium 
oxide (D2O), trifluoroacetic acid (TFA), 5,5’-dithiobis(2-nitrobenzoic 
acid) (DTNB, also known as Ellman’s reagent) were also purchased from 
Sigma Aldrich while dialysis membranes (12-14 kDa MWCO) from 
Spectrum Laboratories, Inc. and used during the phases of 
functionalization and characterization of the chitosan. For cellular studies 
Dulbecco's Modified Eagle's Medium (DMEM) and McCoy’s 5A medium 
were obtained from Sigma Aldrich, instead Fetal Bovine Serum (FBS), 
Penicillin/Streptomycin (10000 U/ml) and Glutamine were purchased 
from Invitrogen, Life Technologies. For pharmacokinetic and anti-
inflammatory studies, Proteinase k and Lipopolysaccharide (LPS) were 
obtained from Sigma-Aldrich. 
Synthesis of CT-IT  
Chitosan Low Molecular Weight (CT-LMW, 100 mg, 0.50 mmol) was 
dissolved in 10 ml of 0.1 M of acetic acid solution. After complete 
dissolution, pH was adjusted to 6 with NaOH. 2-iminothiolane 
hydrochloride (2-IT, 40 mg, 0.30 mmol in one case and 20 mg, 0.15 mmol 
in the other case) were added and pH was further adjusted to 6.5 with 
NaOH and HCl. The reaction proceeded under magnetic stirring and at 
room temperature overnight. After reaction, DL-Dithiothreitol (DTT, 40 
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mg, 0.25 mmol) was added and left to react for 1 h. Then the pH was 
adjusted to 3.5 with HCl and the sample was dialyzed (dialysis tubing with 
12-14 KDa Cut-Off) and freeze-dried for 48 h. Eight dialysis cycles were 
executed: 4 cycles with NaCl 1% w/v pH 3 water solution, and 4 cycles 
with pH 3 water solution. Samples were characterized with 1H NMR 
spectroscopy and the amount of free thiols was evaluated with the 
Ellman’s test.42, 43 
Synthesis of CT-FITC  
Chitosan Low Molecular Weight (CT-LMW, 100 mg, 0.50 mmol) was 
dissolved in 10 ml of 0.1 M of acetic acid solution. After complete 
dissolution, a solution of FITC (5.0 mg in 500 µl of DMSO) was added 
dropwise. The reaction proceeded overnight at room temperature. Sample 
was then precipitated adjusting the pH to 10 with NaOH and the precipitate 
was collected by centrifuge (9000 rpm, 15 min). Sample was washed with 
water by means of several centrifugations, until negligible fluorescence 
was detected in the supernatant (using Perkin Elmer 2300 Enspire Plate 
Reader, λex = 488 nm, λem = 510 nm). Finally, the purified product was 
freeze-dried for 48 h. 
Sample preparation and characterization  
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The systems proposed in this work are mainly based on nano-emulsions 
coated with chitosan; however, other formulations were also used as a 
control. Two different sizes of nano-emulsions were prepared depending 
on the amount of surfactant, Lipoid E 80, dissolved in soy-bean oil and for 
each size we prepared two different carriers, one with curcumin and one 
with piperine. In particular, 5.8 g of surfactant in 24 ml of oil were used 
for the smaller emulsion and 1.44 g of surfactant in 24 ml of oil were used 
for the larger emulsions. For curcumin loaded nano-emulsions, 100 mg of 
curcumin were added to the 24 ml of oil phase while for piperine loaded 
nano-emulsions 400 mg of piperine were added to the 24 ml of oil phase. 
To promote dissolution, the oil phase containing surfactant and 
biomolecule (curcumin or piperine) was mixed by alternating a high speed 
blender (RZR 2102 control, Heidolph) at 60 °C and 500 r.p.m. to room 
temperature sonication with an immersion sonicator (Ultrasonic Processor 
VCX500 Sonic and Materials), according to a process protocol previously 
reported.20, 44 Then, to obtain the pre-emulsion, the oil phase was added 
dropwise to 90 g of Milli-Q water and mixed using the immersion 
sonicator and controlling temperature in order to avoid overheating. The 
pre-emulsions were finally passed at 2000 bar through the high-pressure 
valve homogenizer (Microfluidics M110PS) according to the same 
previous protocol.20 Primary emulsions were then coated with pristine 
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chitosan or chitosan 2-iminothiolane conjugate, exploiting their positive 
charge for the deposition around the oil droplets stabilized with lecithin, 
which is negative. Chitosan solutions were prepared in 0.1 M acetic acid 
Milli-Q water bringing the pH to 4 with a small addition of NaOH 6 M 
solution. The two phases were mixed 1:1 (v:v) quickly under vigorous 
stirring and kept under stirring for 15 min to allow uniform chitosan 
deposition, thus obtaining secondary emulsions. The final concentration of 
oil was 10% (wt.), whereas chitosan was 0.1% (wt.) to guarantee saturation 
of chitosan around emulsion.20, 44 The emulsions coated with chitosan were 
passed through a high-pressure valve homogenizer at 700 bar for 100 
continuous steps, and re-processed after a few days in the same conditions 
on the same systems (at 700 bar for 100 continuous steps) having found 
benefit in terms of stability by double re-dispersion process, as previously 
reported.20 Emulsions were measured in terms of size and Z-potential 
(Zetasizer zs nano series ZEN 3600, Malvern Instruments Ltd., Malvern, 
U.K.) by diluting them up to a droplet concentration of approximately 
0.025% (wt.) using Milli-Q water in the case of primary emulsions and 
acetic acid solution (pH 4, 20 mM) in the case of secondary emulsions. 
The Z-potential analysis was carried out by setting 50 runs for each 
measurement, whereas default refractive index ratio (1.52) and 5 runs for 
each measurement (1 run lasting 100 s) were used in the calculations of 
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the particle size distribution. Secondary emulsions embedding curcumin 
and coated with FITC-labelled chitosan were also observed with a SP8-
STED fluorescence optical microscope (Leica Microsystems, GmbH, 
Germany) using a 100X oil immersion objective (HCX PL APO 100x/1.40 
OIL). Samples were excited at 488 nm, and the emitted fluorescence was 
collected between 500 and 550 nm. For image acquisitions in STED mode, 
a continuous doughnut-shaped STED laser emitting at 592 nm was used. 
Samples were diluted with a 20 mM acetic acid solution at pH 4 at the final 
oil concentration of 0.02% (wt.) and put in glass bottom FD3510 optical 
dishes. After 30 min of incubation the samples were washed out 3-times 
with a 5% (wt) dabco antifade solution and observed with a microscope. 
Images were acquired with a pixel size of 25 nm. The full width at half 
maximum (FWHM), as represented between arrows in the Figure 2.1, and 
the statistical analysis of the profiles were obtained using Origin 9.1.  
As control systems -apart from pure curcumin and piperine- we also tested 
a phytosome formulation. Curcumin and curcumin-piperine 
phosphatidylcholine complexes were prepared as described in literature.45 
Briefly, the complex was prepared with curcumin and hydrogenated soy 
phosphatidyl choline (HSPC) at a molar ratio of 1:1. Weighed amount of 
curcumin and HSPC were put in a 100 ml round bottom flask and 20 ml 
of dichloromethane was added. The mixture was refluxed at a temperature 
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of maximum 60 °C for 2 h. The obtained solution was evaporated and 10 
ml of n-hexane was added under continuous stirring. The curcumin–
phospholipid complex was precipitated, subsequently filtered and dried 
under vacuum to remove traces of solvents. The same procedure was 
followed for the synthesis of the curcumin-piperine phosphatidylcholine 
complex. 
All the tested samples are summarized with their acronyms in Table 1. To 
represent a particular amount in mg of curcumin per kg of rat, this value 
will be reported at the end of the identifying code, e.g. NE-CT-110-curc-8 
to indicate a formulation based on the 110 nm nano-emulsion coated with 
chitosan and at a dose of 8 mg of curcumin per kg of rat (corresponding to 
7.5 ml of 10 %wt emulsion) will be delivered. Lower doses indicated with 
0.8, 0.4 and 0.2 are obtained by administering lower amounts of emulsion 
(0.75, 0.38 and 0.19 ml/kg, respectively). In the case of piperine co-
delivery, piperine is always intended as 1/100 w/w as compared to 
curcumin amount.  
Cell culture 
Mouse fibroblast (NIH/3T3, ATCC® CRL-1658™) and colon cancer cell 
lines (HT29 ATCC®) were seeded (density 3000 cells/well) in 96-well 
plates, cultured in DMEM and McCoy’s 5A medium, respectively, and 
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both with 2mM glutamine, 10% FBS1% penicillin streptomycin (full 
medium) and incubated for 24 h under standard sterile conditions for cell 
cultures (5% CO2, 37°C). 
Cell cytotoxicity experiments 
The cytotoxicity of the nano-emulsions was assessed on both NIH/3T3 and 
HT29 evaluating their mitochondrial dehydrogenase activity by means of 
a modified MTT [3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] method according to the manufacturer’s instructions (Dojindo 
Molecular Technologies Inc., Rockville, MD). Cells were seeded in 96-
well plates at a density of 10000 cells per well in complete medium at 37 
°C in a humidified 5% CO2 atmosphere. After 24 h of appropriate growth, 
we tested viability of both cell lines incubated one day, under standard 
conditions, with all the systems. Curcumin concentration was tested from 
2 up to 100 µg/ml in all the cases; the weight ratio between curcumin and 
piperine was fixed at 100/1 w/w. At the end of the incubation period, cells 
were washed three times with PBS at pH 7.4 and incubated with 100 μl of 
a MTT solution (0.5 mg/ml in cell culture medium) for 4 h at 37 °C. The 
absorbance measurements were acquired at a wavelength of 450 nm with 
the Tecan Infinite M200 plate-reader using I-control software. The relative 
cell viability (%) was calculated by the formula [A]test/[A]control×100, 
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where “[A]test” is the absorbance of the test sample, and “[A]control” is 
the absorbance of the control cells incubated solely with culture medium. 
After evaluating cell cytotoxicity, the total protein content was measured 
by using the Micro BCA protein assay kit (Pierce). Briefly, cells were 
washed with ice-cold PBS, and incubated for 15 min in 150 μl cell lysis 
buffer (0.5% v/v Triton X-100 in PBS), to which 150 μl of Micro BCA 
protein assay kit reagent (prepared following the instructions of the 
manufacturer) were added. The absorbance at 562 nm was finally 
measured on a plate reader. The cytotoxicity measurements were then 
normalized by the amount of total protein content in each well. 
Cancer cell uptake studies: uptake quantification and cell-imaging by 
Confocal Laser Scanning Microscope 
For uptake quantification studies in colon cancer cells, after culturing 
HT29 cell line as previously described, 5x103 cells/well were seeded in 
24-well plate and allowed to grow for 24 h. The medium was then replaced 
with 500 µl of a solution composed by culture medium and the 110 nm 
nano-emulsion coated with FITC-labelled chitosan (NE-FITC-CT-110-
curc), with an equivalent curcumin molar concentration of 2.71 µM 
(corresponding to 0.24 wt% of O/W emulsion) and incubating them for a 
time comprised between 0.5 and 8 h. Cells were then washed twice with 
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PBS (pH 7.4) and after specified time intervals the experiments were 
terminated by removing the supernatant, washing the cells three times with 
10 mM PBS and lysing them with 0.1 ml of 0.5% Triton X-100 in 0.2 N 
NaOH. The membrane-bound and internalized nano-emulsions were 
quantified by analyzing the fluorescence of the cell lysate (λexc = 492 nm, 
λem = 528 nm), employing a calibration with a solution composed of the 
110 nm nano-emulsion coated with FITC-labelled chitosan with a 
curcumin concentration ranging from 5 µM (corresponding to 0.44 wt% 
of O/W emulsion)  up to 0.1 nM (corresponding to 0.00009 wt% of O/W 
emulsion) dispersed in a cell lysate solution (106 untreated cells dissolved 
in 1 ml of the Triton X-100/0.2 N NaOH solution). 
For cell imaging studies in colon cancer cells, after culturing HT29 cell 
line as previously described and washing the cells with PBS twice (pH 
7.4), the membrane was stained by using concanavalin A 
tetramethylrhodamine conjugate (Invitrogen, Life Technology) at a final 
concentration of 100 μg/ml. Subsequently, cells were thoroughly rinsed 
three times with PBS and fixed with a 2.5% glutaraldehyde in PBS for 20 
min. Then, cells were blocked with 1% BSA in PBS for 20 min and washed 
three times with PBS. Finally, they were observed Using a Confocal 
Microscope (C1 Nikon) equipped with an EZ-C1 Software for data 
acquisition and 60x oil immersion objective. The nanostructures were 
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imaged through excitation/emission of FITC at 492/528 nm while the cell 
membrane with excitation/emission at 555/580 nm. 
 
HPLC assay 
Analysis of samples was performed using an Agilent Infinity 1200. 
Separation was achieved with a C18 column (2.1 mm × 250 mm) kept at 
35°C. The mobile phase consisted of two components: A: 10 mM 
ammonium acetate pH 4.5, B: acetonitrile. Initial conditions were 95% A 
progressing to 55% A at 20 min and 5% A at 33 min. The retention time 
was 4.6 min. The flow rate was 1.5 ml/min. Curcumin and conjugated 
metabolites were detected at 426 nm and reduced curcumin metabolites at 
280 nm using a Varian 325 UV-vis detector. The precision of the 
procedure was determined by a repeatability method. Solutions of 
curcumin, curcumin glucuronide and curcumin sulfate containing 0.5 ng 
and 1000 ng/ml were injected into the system repeatedly five times. The 
percentage RSD (relative standard deviation) of injection repeatability and 
analysis repeatability for curcumin, curcumin glucuronide and curcumin 
sulfate was 0.897% and 0.915%, 0.902% and 0.892%, 0.882% and 
0.903%, respectively. The results obtained confirm good precision of the 
method used for quantification of curcumin and curcumin metabolites in 
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rats. The linearity of the method used for curcumin, curcumin glucuronide 
and curcumin sulfate was checked at six concentration levels over the 
concentration range of 0.5-1000 ng/ml. For all equations obtained, the 
mean correlation coefficient (R2) was 0.997 ± 0.001. Limit of 
quantification for curcumin, curcumin glucuronide and curcumin sulfate 
was 0.13, 0.21 and 0.12 ng/ml for 100 μl injection volume. 
Pharmacokinetic studies  
Forty-five male Wistar albino rats (mean weight: 400 g) were purchased 
from Charles River (Calco, Italy) and kept under a 12 h light/dark cycle on 
standard lab chow. All animals were maintained within conditions 
specified in approved Institutional Animal Care and Use Committee 
protocols. The experiment protocol had been previously approved by the 
local ethics committee. After overnight fasting, animals were randomized 
in 15 groups (n=3) based on oral administration of all the samples 
previously listed in the table. For all the systems, the volume administered 
to the rats was 7.5 ml when using piperine, weight ratio between curcumin 
and piperine was 100/1 w/w, as from literature.46 We chose to work with 
such high doses to allow the reading of free curcumin in the blood in all 
the systems including the less performing that is the unformulated 
curcumin. 
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For each formulation we took, in triplicate, 0.2 ml of blood from rat at each 
time point (15, 30, 60 and 120 min after oral administration) for a final 
volume of blood drawn of 0.8 ml, that is <1% of total blood volume (TBV) 
of a rat weighing 400 g (according to the Veterinary Recommendations for 
Multiple Blood Draws). Blood was collected by withdrawal via the tail 
vein into heparinised tubes, centrifuged at 7,000 g for 15 min and plasma 
was then decanted. Curcumin and curcumin metabolites (glucuronide and 
sulphate) were extracted from plasma by solid phase extraction; 
specifically, 0.2 ml of plasma were loaded onto a 0.2 cc Oasis HLB 
cartridge and washed with 0.2 ml of a solution of methanol: water: glacial 
acetic acid at 25:25:1 v/v ratio and eluted with 0.2 ml of methanol 
containing 2% (v/v) of glacial acetic acid. Eluent was evaporated to 
dryness at 45 °C under nitrogen, and the residue was re-suspended in a 75 
µl of 50% v/v water/ acetonitrile solution. Studies of AUC 0-120 min of 
curcumin and curcumin metabolites were performed only up to 2 h guided 
by similar works in literature.47 The relative oral bioavailability of 
curcumin was calculated according to the equation: Relative BA (%) = 100 
x [(AUC formulation / dose formulation) / (AUC unformulated curcumin / dose unformulated 
curcumin)] as described in literature.  
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Biodistribution studies 
Biodistribution study was performed according to literature;48 briefly, 
thirty-six male Wistar albino rats (average weight: 400 g) also purchased 
from Charles River (Calco, Italy), were housed in temperature and 
humidity-controlled rooms and allowed free access to basal diet and water 
ad lib for 7 d before starting the experiment. Rats were randomly divided 
into 4 groups (n=3/group) depending on the different times of digestion 
after oral administration of fluorescent nano-emulsion (NE-110-FITC), 
fluorescent 110 nm nano-emulsion coated with chitosan (NE-CT-110-
FITC) and fluorescent 110 nm nano-emulsion coated with chitosan 2-
iminothiolane conjugate at a high degree of modification (NE-CT-IT-h-
110-FITC): 0.5 h, 1 h, and 2 h. Loading of FITC in the nano-emulsions 
was obtained by mixing 4 ml of ethanol solution of FITC (0.75 mg/ml) to 
the soybean oil during the emulsion preparation and drying the ethanol 
from the mixture with a mild heating. The final concentration of FITC in 
the emulsion at 10% (w/v) of oil in water is 125 µg/ml. A single dose of 
7.5 ml of FITC loaded nano-emulsions was administered through oral 
gavage. Rats in the control group received the same volume of vehicle 
solution (PBS) only. We selected a rather high dose to increase the 
likelihood of generating detectable amounts of the fluorescent nano-
emulsion in tissues. After proper time of digestion, rats were sacrificed and 
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the harvested tissue samples (small intestine, large intestine, liver, spleen, 
stomach, heart, lung, kidney) were digested using an aqueous enzyme 
solution containing 1 g/l proteinase K (Sigma-Aldrich) in 50 mM 
NH4HCO3 buffer (to maintain a constant pH value of 7.4 during enzymatic 
digestion) and 5 g/l SDS to improve activity of the enzyme.49 Specifically, 
organs were carefully weighed and digested in digestion buffer at a weight 
ratio of 1:5. The samples were thoroughly vortexed and incubated at 37 °C 
under continuous stirring in a magnetic stirrer for 4 h. Fluorescence of the 
samples was measured using a Tecan Infinite M200 plate-reader with I-
control software at excitation/emission wavelengths of 420/528 nm. The 
NE-CT-IT-h-110-FITC concentration was determined based on previously 
prepared standard calibration curves in each organ separately, obtained by 
spiking blank organ lysates (prepared as previously described) with serial 
dilutions of fluorescent nano-emulsions ranging from 0 to 50 mg/ml.50 
Anti-inflammatory effects in lipopolysaccharide-exposed rats 
Forty-two male Wistar albino rats (mean weight: 400 g) purchased from 
Charles River (Calco, Italy) were treated as in the biodistribution study 
before starting the experiment. Rats were randomly divided into 7 groups 
(n=6/group): control (normal saline); Unformulated curc, NE-CT-IT-h-
110-curc-0.8, NE-CT-IT-h-110-curc-piper-0.8. In order to verify the 
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possible concentration dependent effects of the formulations, we 
subsequently tested the anti-inflammatory effects of: control (normal 
saline), NE-CT-IT-h-110-curc-piper-0.4, NE-CT-IT-h-110-curc-piper-0.2 
Solutions were administered daily for 2 weeks by oral gavage and, after 
this period, a single intraperitoneal injection (IP) of LPS at 5 mg/kg was 
performed. Blood samples were taken just before (= time 0), and at two 
different times (2, 5 h) after LPS injection under ether anaesthesia- by 
withdrawal via the tail vein. This timing aimed to obtain the maximum 
production of pro-inflammatory cytokines after IP administration of LPS 
in rats, as observed in literature.39, 51 Blood samples were collected in 
heparinised tubes and immediately centrifuged at 3000 rpm for 10 min at 
4 °C in order to obtain plasma that was collected, frozen, and kept at −80° 
C until use for IL-1β, TNF-α, IL-6 and IL-8 analysis performed by 
enzyme-linked immunosorbent assay (ELISA) method using commercial 
kits (Bio-Rad Laboratories, Inc., Italy). Results are expressed as mean ± 
S.D. Data were statistically analyzed using one-way ANOVA tests p＜ 
0.05 was considered to be significant. 
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2.5 Supplementary Section2 
In this supplementary work an air liquid interface (ALI) of CaCo2 cells in 
Transwell was realized as an in vitro testing platform (Figure 2.14) to 
evaluate the potential of an oral nano-delivery system very similar to the 
system presented in the main work of this chapter – i.e. an oil-in-water 
nanoemulsion coated with a thiolated glycol chitosan (Figure 2.15).  
 
Figure 2.14. Schematic representation of air liquid interface of Caco-2 cells in Transwell 
system (on the left). In the central inset an enlarged view of the cell monolayer grown on 
the microporous membrane. On the left the oral nano-delivery system consisting of O/W 
nanoemulsion coated with a thiolated glycol chitosan. 
Again, curcumin was chosen as model drug because of its lipophilic 
nature, its poor stability and its poor oral administration. The presented 
testing platform allowed a comprehensive understanding on the route of 
the nano-system carrying the curcumin, its interaction with the intestinal 
mucosa and the antioxidant effects on cells. Results demonstrated that the 
                                                          
2 The work here illustrated has been realized with the precious collaboration of Dr. 
Angela Langella and our relative research groups. Result here presented will be part of 
a paper currently under preparation: A. Langella, V. Calcagno, V. de Gregorio, G. 
Imparato, F. Urciuolo, R. Vecchione, P. A. Netti. “Oral nano-delivery system for colon 
targeted drug delivery: in vitro study of curcumin biodistribution” 
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in Transwell model, able to promote the polarization of the intestinal 
epithelium, is suitable to mimic as closely as possible the in vivo 
conditions. 
 
Figure 2.15. Schematic representation of the oral nano-delivery system proposed: an oil 
in water nanoemulsion loaded with the curcumin and coated with GC-NAC (glycol 
chitosan modified with N-acetyl-L-cysteine.  
Results and discussion 
Nanoemulsion analysis. Particle size of the starting nano-emulsion and of 
the nano-emulsion coated with glycol chitosan was characterized by DLS. 
Starting from a nano-emulsion loaded with curcumin (1µg/ml of curcumin 
in 20 % (v/v) of O/W nano-emulsion) with a size of ~100 nm and a PDI of 
~0.07, the coating with glycol chitosan did not significantly affect size and 
particle size distribution – size increases of few nanometer (~105 nm) and 
PDI value remains below ~0.08. It is noteworthy that these values of size 
and PDI where obtained with the simple deposition of the polymer under 
vigorous stirring. In contrast to what was required for nano-emulsion 
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coated with CT-IT, where the final system had a higher oil concentration 
(10% w/w) and larger volume were needed, here it was not necessary to 
perform a double re-dispersion process with the high pressure 
homogenizer – the final oil concentration is 2% (w/w) and only few 
milliliters are required for the tests. In addition to DLS analysis, confocal 
imaging of nano-emulsion coated with rhodamine B labelled chitosan 
(Figure 2.16A) and electron microscopy imaging of nanocapsules stained 
with OsO4 vapors were performed (SEM micrograph in Figure 2.16B and 
TEM micrograph in Figure 2.16C), thus clearly confirming the good size 
distribution and dimensions. 
 
Figure 2.16. Imaging characterization of O/W nanoemulsion coated with GC-NAC: (A) 
confocal image of nanocapsules coated with rhodamine B labelled glycol chitosan; (B) 
SEM image and (C) TEM image of nanocapsules stained with OsO4 vapors. Osmium 
staining strengthened the soft nanocapsules in order to avoid collapse due to the vacuum 
of electron microscopes.  
The biopolymer used for the coating was previously modified with a 
thiolation agent, the N-acetyl-L-cysteine (NAC), through an amidation 
reaction with a water soluble carbodiimide as condensing agent (EDC, 
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ethyl-3-(3-dimethylaminoisopropyl)-carbodiimide) and 1-hydroxy-1,2,3-
benzotriazole (HOBt) as additive.52 Polymer characterization was 
performed with 1H NMR spectroscopy and the degree of functionalization  
was determined using the colorimetric Ellman’s test (for more details 
about the synthetic procedure, the amounts of reactants used and the 
characterizations performed see Chapter 3).42 
 
Cell cytotoxicity. We tested the biosafety of the nano-emulsions by 
carrying out cytotoxicity tests on the system loaded with curcumin. As 
resulted from MTT test, cell viability was demonstrated, thus indicating 
the biosafety of the tested nanocarrier towards Caco-2 cells. 
 
Effect on monolayer dynamic. Transepithelial electrical  resistance  
(TEER),  a  widely  accepted  quantitative  technique  to  measure   the  
integrity  of  tight  junction  dynamics  in  cell  culture  models  epithelial  
monolayers, was used to  evaluate the  transport  of  drugs  or chemicals.53 
The reduction of the electrical resistance observed during the first 4 h of 
contact with the nano-emulsion, compared with the starting value (~400 
ohm · cm2), suggested that the nano-delivery system crossed the epithelial 
barrier. However, the TEER value became again comparable to the starting 
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value once the nano-emulsion had passed and the tight junction returned 
to the starting conformation.  
As further confirmation, tight junctions of Caco-2 cells monolayer were 
stained using a primary antibody (ZO-1).54 Comparing the sample treated 
with the nano-emulsion and the control (Figure 2.17) it is clear that the 
contact with the thiolated chitosan induces an opening of the tight junction, 
thus promoting the crossing of the intestinal barrier.16 
 
Figure 2.17. Confocal images of Caco-2 monolayer: nuclei (blue color) and tight junction 
(green color) have been selectively stained with DRAQ5 and ZO-1, respectively. On the 
left, cells in contact with nanoemulsion coated with labelled chitosan (red color, only half 
of the image, on bottom, includes the matching with the Rhodamine-B). 
  
Transport of nano-emulsion. Confocal analysis allowed to evaluate the 
presence, the localization and the transport of our nano-delivery system. 
Preliminary tests were performed with Dextran-FITC,55 thus 
demonstrating that the epithelial monolayer, as a consequence of the AIL 
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polarization, develops all the morphological and functional features of the 
in vivo intestinal epithelium (tight junctions, microvilli, brush borders, see 
Figure 2.18, right). Indeed, as shown in Figure 2.18, dextran crossed the 
cells monolayer, through a para- and trans-cellular transport. 
 
Figure 2.18.  Left: SEM images of Caco-2 monolayer (top view). Right: confocal images 
of Caco-2 monolayer: cytoskeleton (red), nuclei (blue), dextran (green) and matching 
In order to understand the transport of the nano-emulsion, glycol chitosan 
coating was covalently labelled with Rhodamine B. This labelling, 
together with the specific staining of the biological sample, allowed to 
discriminate between the nano-emulsion (red channel), the nuclei (blue 
channel) and the cytoskeleton (green channel), as shown in Figure 2.19, 
left. Confocal analysis clearly shows that the nanocarrier resulted to be 
fully distributed on the surface of the cell monolayer, thus demonstrating 
that the thiolation at the interface of the nanocapsule results in an increase 
of mucoadhesivity.16, 23 In addition, the Z-view image (Figure 2.19, right) 
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shows that the nano-emulsion is able to cross the monolayer of cells 
through the opening of the tight junctions, as discussed above, but also to 
enter the cell thus, exploiting both the para- and trans- cellular transport.  
 
Figure 2.19. Confocal images of Caco-2 monolayer: Y-view matching on the left and Z-
view matching on the right.   
Quantitative analysis of curcumin content. Preliminary tests were 
performed to understand if the selected Transwell, and in particular the 3.0 
µm polycarbonate membrane, results to be permeable to the passage of the 
nano-emulsion. DLS measurement of the upper and lower solutions 
demonstrate that capsules are stable in the medium and are able to pass the 
membrane (Table 2.3).  
Table 2.3. DLS analysis of coated nanoemulsion at different time of incubation (3 and 
24 h) in Transwell.  
Sample name Time (h) Size (d.nm) PDI 
Coated nanoemulsion  3 106.3 0.100 
Upper  3 115.0 0.070 
Lower  3 138.0 0.300 
Coated nanoemulsion  24 114.0 0.090 
Upper  24 113.6 0.070 
Lower  24 118.9 0.130 
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In addition, HPLC measurements were performed to quantify the amount 
of curcumin that passed through the membrane: after 24 h of incubation 
the curcumin is distributed between the upper compartment (63%) and the 
lower one (37%). HPLC quantification was also performed on the Caco-2 
monolayer in Transwell. Results are summarized in Table 2.4 and show 
that the curcumin content is reduced with the time in the upper solution, 
probably because the nanocapsules pass through the cell monolayer or 
enter the cells. However, the decrease in the curcumin content of the upper 
solution is not followed by complementary increase of the drug content in 
lower solution: essentially the amount of curcumin did not change. This 
suggests that a perceptible amount of curcumin is included within the cell 
as nanocapsules content or as metabolites. Further study– HPLC assays of 
the curcumin amount and its related metabolites found in the cell, and 
antioxidant effect of curcumin – will be performed to obtain a complete 
understanding of the curcumin administration in the intestinal epithelium. 
Table 2.4. HPLC analysis of the curcumin content in the upper and lower solutions. 
Sample Time (h) Curcumin (ng/ml) Percentage 
Coated nanoemulsion  37.97 100 % 
Upper 3 28.40 74.8 % 
Lower 3 0.36 0.95 % 
Not detected 3 9.21 24.2 % 
Upper 24 7.30 19.2 % 
Lower 24 0.43 1.13 % 
Not detected 24 30.24 79.6 % 
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Conclusions 
In this section an in vitro testing platform was presented. Morphological 
analysis demonstrated that the epithelial monolayer realized in Transwell, 
as a consequence of the AIL polarization, develops all the morphological 
and functional features of the in vivo intestinal epithelium (tight junctions, 
microvilli, brush borders). In addition, confocal imaging and related 
investigation allowed to understand the route of the nanosystem here 
studied. The designed oral nano-delivery system, an oil in water nano-
emulsion loaded with curcumin and coated with a thiolated glycol 
chitosan, represents an interesting tool for the oral delivery of lipophilic 
drugs. In particular, by modifying the glycol chitosan with a thiol moiety 
it is possible to increase the adhesion to the intestinal mucosa and to open 
the tight junction, so as to make the nanocapsule more performing. 
Materials and Methods 
Below in this paragraph the materials and methods used for this 
supplementary work are presented: these are in addition or partially 
substitution of the materials and methods used for the main work presented 
above in this chapter. 
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Materials. 1-hydroxybenzotriazole hydrate (HOBt), N-acetyl-L-cysteine 
(NAC), Rhodamine B isothiocyanate (RBITC) were purchased from 
Sigma-Aldrich. 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide 
hydrochloride (EDC) was purchased from Iris Biotech. Glycol chitosan 
(GC) was purchased from Wako Chemicals. Caco-2 cells were obtained 
from American Type Cell Colture (ATCC, Usa). Dulbecco’s Modified 
Eagle’s Medium (DMEM, Gibco, Life Technologies), supplemented with 
10% Fetal Bovine Serum (FBS, Sigma Aldrich), 1% 
Penicillin/Streptomycin and 1% L-Glutamine (Lonza, Milan) and 2% 
nonessential amino-acids NEEA (Euroclone, Milan). Hank’s Balanced 
Salt Solution (HBSS) was purchased from Gibco, Life Technologies). 
Transwell Permeable Supports (12-well plates with polycarbonate 
membrane 3.0 µm and 24-well plates with polyester membrane 0.4 µm) 
were purchased from Corning® Costar. FITC-Dextran was purchased from 
Molecular probes, Life Technologies. 
 
Glycol chitosan modifications. Modification of GC with NAC was 
reported in detail in Chapter 3, Materials and Methods section. In one 
case, GC was previously modified with RBITC, thus obtaining a labelled 
polymer (GC-RBITC), and then modified with NAC. The procedure used 
to obtain GC-RBITC was the same proposed for GC-FITC (glycol 
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chitosan modified with fluorescein isothiocyanate), reported in Chapter 
3, Materials and Methods section.  
 
Realization of nanocapsules. Oil in water nano-emulsion was obtained as 
previously described in Materials and Methods section. The nano-
emulsion was then coated with GC-NAC or GC-RBITC-NAC by adding 
1.5 ml of polymer solution (0.033 % (w/v) in acidified water at pH 4) to 1 
ml of water suspensions of O/W nanoemulsion (5 % (w/w) in acidified 
water at pH 4) under vigorous stirring.  
 
Cell Lines and Culture Conditions. Caco-2 cells, a human colonic 
epithelial cell line, were grown in DMEM at 37°C with 5 % CO2 – 95 % 
air in Transwell 12-well plates, that consisting of two chambers separated 
by a polycarbonate membrane (12 mm diameter, 3 μm pore size). The cells 
were seeded at 1x105 in 1.12 cm2 in either insert and grown on 
polycarbonate membrane for two weeks. During the first week cells grew 
till to completely cover all the membrane surface, thus leading to a 
submerged layer; during the second week the upper medium is removed 
and cells were capable to polarize, thus leading to an Air Liquid Interface 
(ALI). Medium was replaced every 48 h: for two weeks in the basolateral 
chamber and for the first week only in apical chamber.  
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Transepithelial electrical resistance assay. TEER (Ohm) of Caco-2 cells 
cultured in Transwell was measured using the Millicell-ERS (Electrical 
Resistence System, Millipore Corporation). The measured value was 
multiply by the area of the membrane (1.12 cm2) to obtain a TEER value 
expressed in Ohm · cm2 in order to evaluate the cell monolayer integrity 
during permeation experiments.  
 
Apical-to-basal permeability assay. The permeability of Caco-2 cell 
monolayers was performed by measuring in dynamic and static mode the 
trans-epithelial passage of the O/W nano-emulsion coated with GC-
RBITC-NAC, of a blank sample (HBSS/DMEM, 1:1) and of FITC-
Dextran solution (1 mg/ml diluted in HBSS), generally used like positive 
control.55 Cells monolayers were incubated for 24 h at 37°C with 5 % CO2 
– 95 % air; for dynamic mode a rotator at 80 rpm was used. A certain 
volume of HBSS/DMEM was placed in the basolateral chamber in order 
to guarantee the dipping of the lower side of the membrane. The passage 
was determined by confocal imaging (Leica SP5 II Laser Scanning 
Confocal Microscope) and fluorescence emission of rhodamine and 
fluorescein, respectively (Perkin Elmer 2300 Enspire plate reader λex=555 
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nm, λem=565 nm and ). RP-HPLC was used as indirect permeability assay 
by detecting the presence of curcumin when used. 
 
Confocal imaging. The monolayer of Caco-2 cells was washed with PBS 
solution and fixed with paraformaldehyde 4% (v/v) at room temperature 
for 20 minutes. Permeabilization was performed using a 0.01% Triton 
solution in PBS for 5 minutes, washing three times with PBS and 
incubating with specific staining. Actin filaments were stained with 
Phalloidin-Alexa Fluor® 488 conjugate (1:50 in PBS). Nuclei were stained 
with DRAQ5™ (1:10000 in PBS). Cellular morphology of the Caco-2 
cells was observed with a Leica SP5 II laser scanning confocal microscope 
using a 63X oil immersion objective (HCX PL APO CS 63.0x1.40 OIL 
UV). Samples were observed with the following specific fluorescence 
channels: cytoskeleton (Phalloidin-Alexa Fluor® 488) λex=488 nm (Argon 
Laser) and λem=500-530 nm, nanoemulsions coated with GC-RBITC-
NAC (rhodamine B) λex=543 nm (Helium Laser) λem=560-610 nm; nuclei 
(DRAQ5™) λex=633 nm λem=650-750 nm. Z-Stack and Y-Stack image 
series were acquired to study the localization of labeled-drug in the caco-
2 cells. Section thickness was set to 0.7 μm for all the images. Images 
analysis was performed using Fiji (Image J, plugin) and LAS AF (Laica 
Applications System). 
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Confocal analysis of nanoemulsions. Samples containing nano-emulsions 
coated with GC-RBITC-NAC were opportunely diluted with 
HBSS/DMEM buffer and 200 μl were put in a FD3510 dish for 30 min to 
allow it to adhere to the glass surface. Sample in excess was washed twice 
by replacing it with 130 µl of HBSS/DMEM solution every 10 min and, in 
the end, with 130 µl of 5% (w/v) DABCO anti-fade solution (needed to 
avoid the bleaching effect of the Rhodamine B). 
 
Electron microscopy. For imaging analysis of nanocapsules samples were 
first exposed to vapors of OsO4 water solution (1% wt.) as oil core dopant 
for not less than 4 h. After that, a small drop of solution containing silica 
nanocapsules was spread onto the surface of an aluminum stub covered by 
a carbon tape or a glass plate.  
For imaging analysis of cells sample was first fixed with a sodium 
cacodylate 0.1 M in 2.5% wt. glutaraldehyde solution at room temperature 
for 2h. Sample was washed with a solution of 0.1 M sodium cacodylate - 
0.1 M sucrose (3 times in an ice bath for 10 min). Sample was then fixed 
with OsO4 (1% wt. in 0.1 M sodium cacodylate - 0.1 M sucrose) and 
washed again with a solution of 0.1 M sodium cacodylate - 0.1 M sucrose 
(3 times in an ice bath for 10 min). In the end sample was dehydrate by 
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replacing the water solution with a series of ethanol solutions (30%, 50%, 
75%, 95%, 95%, 100%, 100%, 100% (v/v)) and dried with a Critical Point 
Drier (Leica EM CPD300).   
The samples, both nano-emulsions that cells, were then sputter-coated with 
a thin Pt/Pd or Au layer (10 nm) in a Cressington sputter coater 208HR. 
The aluminum stub containing the Pt/Pd or gold -coated sample was then 
placed in a FEG-SEM scanning electron microscope and imaged using 20 
kV accelerating voltage. 
 
Immunofluorescence assay. Tight junctions of the monolayer of Caco-2 
cells were stained using a primary antibody (ZO-1). Cells were washed 
with PBS solution and fixed with paraformaldehyde 4% (v/v) at room 
temperature for 20 minutes. Permeabilization was performed using a 
0.01% Triton solution in PBS for 10 minutes, washing three times with 
PBS and first incubating with a blocking solution (PBS, BSA 5% and 
Triton 0.01%) for 2h in a wet chamber. After washing with PBS, cells were 
incubated with ZO-1 antibody (1:50 in PBS) overnight at + 4°C. Finally, 
cytoskeleton and nuclei are stained with Phalloidin-Alexa Fluor® 488 and 
DRAQ5™ solutions, as previously reported. 
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Cell cytotoxicity experiments. The cytotoxicity of the nano-emulsions was 
assessed on Caco-2 cells using the MTT method according to the 
manufacturer’s instructions (Dojindo Molecular Technologies Inc., 
Rockville, MD). Cells were seeded in 6-well plates at a density of 200000 
cells per well in complete medium at 37 °C in a humidified 5% CO2 
atmosphere. After 24 h of appropriate growth, we started the drug test and 
after 24 h we tested the viability of both cells (Treated and untreated) 
incubated one day, under standard conditions. At the end of the incubation 
period, cells were washed three times with PBS at pH 7.4 and incubated 
with 300 μl of a MTT solution (5 mg/ml in cell culture medium) for 4 h at 
37 °C. In the end 150 μl of DMSO were added and samples were incubated 
for 1 h at 37 °C.  The absorbance measurements were acquired at 570 nm 
(Perkin Elmer 2300 Enspire plate reader, λabs=570 nm).  
 
Histochemical Analysis. The monolayer of CaCo-2 cells on a 
polycarbonate membrane was fixed in formalin and then dehydrated by 
replacing the water solution with a series of ethanol solutions (30%, 50%, 
75%, 95%, 95%, 100%, 100%, 100% (v/v)). After dehydration, sample 
was embedded in paraffin, cut in 5-10 μm thin slides by using an 
ultramicrotome (HM 355S Automatic Microtomes, Thermo Scientific) 
and put on a glass slide. Paraffin was de-waxed in xylene, and finally 
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sample was rehydrated and stained with Alcian Blue and Eosin according 
to the specific staining protocols.  
 
RP-HPLC. Analysis of samples was performed using a Waters 2535 
Quaternary Gradient Module, equipped with a 2489 UV/Visible detector. 
Separation was achieved with a C8 column (6 mm × 250 mm) kept at 25°C. 
The mobile phase was a linear gradient consisting of two components: A: 
0.1% TFA CH3CN, B: 0.1% TFA water. The linear gradient ranges from 
45% to 99% over 30 min. The retention time was 4.6 min. The flow rate 
was 1.0 ml/min. Curcumin and conjugated metabolites were detected at 
426 nm and reduced curcumin metabolites at 280 nm. 
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Biostability Enhancement of Oil Core - 
Polysaccharide Multilayer Shell via 
Photoinitiator Free Thiol-ene 'Click' 
Reaction1 
 
 
 
 
  
                                                          
1 This work has been accepted for publication: V. Calcagno, R. Vecchione, A. Sagliano, A. 
Carella, D. Guarnieri, V. Belli, L. Raiola, A. Roviello and P. A. Netti, Biostability 
enhancement of oil core — polysaccharide multilayer shell via photoinitiator free thiol-
ene ‘click’ reaction. Colloids and Surfaces B: Biointerfaces, 2016, 142, 281-289. The 
Supplementary Section is not included in the publication.  
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Abstract. Layer-by-Layer of polyelectrolytes has emerged as one of the 
easiest and most controlled techniques to deposit ultrathin polymer layers 
mainly driven by electrostatic interactions. However, this kind of 
interaction results to be weak and easily breakable in physiological 
environment. Here we report on the preparation of nanocapsules 
completely made of natural biomaterials: a lipophilic core (soybean oil and 
egg lecithin as surfactant) as nanometric template and a polysaccharide-
based multilayer shell (glycol chitosan and heparin) covalently cross-
linked. We first modified glycol chitosan with a thiol moiety and heparin 
with an alkene moiety, respectively, and then we built a polymer 
multilayer film with a covalent cross-linkage among layers, exploiting the 
light initiated thiol-ene reaction, known as click chemistry. We showed the 
possibility to perform the covalent cross-linkage without any 
photoinitiator or metal catalyst, thus avoiding cytotoxic effects and further 
purification steps. The so realized nanocapsules resulted to be stable and 
completely biocompatible and, therefore, of interest for the biotechnology 
fields, mainly for drug delivery. 
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3.1 Introduction 
Layer-by-layer (LbL) assembly is a versatile and robust technique for 
fabricating customized thin films of diverse composition.1-4 It provides a 
high level of control on properties such as thickness, composition and 
nanostructure.2-6 The method has predominantly been used to assemble 
films using electrostatic,1-4  hydrogen-bonding7-9 interactions or 
electrochemical deposition10, 11 and, recently, to fabricate polyelectrolyte 
multilayer capsules.12 The latter ones have attracted widespread interest in 
the field of drug delivery due to their control in the preparation procedure 
and their multifunctional features.13-16 In addition, polyelectrolytes are also 
emerging as bio-functional interfaces in tissue engineering.17  
However, the main forces stabilizing LbL assembled systems are based 
on electrostatic interactions, making such systems very sensitive to 
environmental conditions, such as variations in the ionic strength or 
temperature of the medium, and thus susceptible to disassembly,18, 19 
which represents an important limitation for some biomedical applications.  
Recent approaches have developed LbL polymer capsules whose synthesis 
combines electrostatic forces via LbL assembly and covalent cross-linking 
via click chemistry.20 Click reactions are performed under mild conditions, 
are highly quantitative and inert to other chemical moieties,21 allowing the 
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elegant design of diverse materials with varied functionality. Systems with 
layers linked covalently via click chemistry demonstrated increased 
stability to disassembly under varying conditions thanks to the formation 
of a cross-linked network structure.22-24 The main issue concerning click 
chemistry is that most reactions applied in LbL assembly of capsules are 
catalyzed by copper, thus leading to cytotoxic effects.25 Recently, a metal 
catalyst-free approach to covalently link the multilayer of microcapsules 
made of poly(methacrylic acid) using a particular click reaction, named 
thiol-ene click reaction, has been proposed.26 This chemistry is versatile 
and has been used for a range of applications.27-34  
Despite natural polymers, in particular polysaccharides35 are largely used 
as biomaterials in LbL applications,36 a free catalyst ‘click’ strategy 
applied to such polymers has never been proposed to the best of our 
knowledge. Although polysaccharides display a perfect biocompatibility 
and biodegradability, which are the basic characteristics for polymers used 
as biomaterials, and have several characteristics not found in other natural 
polymers,37 the chemical modification can be a real challenge in 
comparison with synthetic polymers.36 
In this paper, we report the fabrication of a completely biocompatible 
nanocarrier with enhanced biostability. In particular, an oil-in-water 
(O/W) nanoemulsion composed of natural material, i.e. soybean oil and 
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egg lecithin as surfactant, was used as lipophilic nano-carrier and coated 
with a polymeric multilayer film composed of polysaccharides, i.e. glycol 
chitosan and heparin. Alternating layers of glycol chitosan and heparin 
respectively modified with thiol and allylic moieties were covalently 
bonded with an UV irradiation by virtue of the thiol-ene reaction, leading 
to the formation of stable thioether cross-links between the successive 
layers. The reaction was previously characterized on polystyrene 
nanoparticles (PS NPs), a rigid template that can be centrifuged in order to 
be investigated by a properly modified Ellman’s test and because the 
rigidity is necessary to carry out Magic Angle Spinning (MAS) NMR 
spectroscopy.  
O/W nano-emulsions represent an ideal nano-carrier to conveying and 
releasing powerful poorly water-soluble drugs.38-40 The covalently bound 
multilayer resulted to have an increased biostability, for both PS NPs and, 
more interestingly, O/W nano-emulsions templates.  Moreover, the 
possibility to perform the cross-linkage without any photoinitiator, as 
demonstrated through cytotoxicity assays, and the choice of natural and 
biodegradable components make this approach highly biocompatible and 
efficient in the field of bio-applications. 
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3.2 Results and discussions 
Polymer functionalization  
Preliminary tests were performed to obtain the highest degrees of 
functionalization of the two polymers: glycol chitosan (GC) and heparin. 
Polymer functionalization was obtained through amidation of N-acetyl-L-
cysteine (NAC) for GC and allylamine for heparin, in both cases with a 
water soluble carbodiimide (EDC, ethyl-3-(3-dimethylaminoisopropyl)-
carbodiimide) and 1-hydroxy-1,2,3-benzotriazole (HOBt) as additive.41 
This chemistry is very common, but the application to polysaccharides can 
result in low degrees of functionalization like in the case of chitosan due 
to poor reactivity of the functional groups and poor solubility of the 
polymer, which may justify the lack of a free catalyst cross-linkage applied 
to such natural polymers. 
The first attempts of chitosan functionalization were conducted on 
chitosan and depolymerized chitosan, but the low water solubility limited 
the degree of functionalization (see Table 3.1).42 Indeed, the best results 
were obtained using glycol chitosan, a modified chitosan that results to be 
soluble in water even at neutral pH due to the ethylene glycol moiety.43 
Such increase of solubility resulted in a very high content of free thiols (up 
to 650 µmol/g).  
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Table 3.1. Free and total thiol groups for thiolated CT determined by Ellman’s test 
Synthetized   
CT-NAC 
HOBt:CTa:NAC: 
EDC (molar 
ratio) 
Free Thiols 
groups 
(µmol/g) 
Total Thiol 
groups 
(µmol/g) 
Oxidized 
thiols (%) 
CT 1 1:1:0.5:6 37.6 38.2 1.6% 
CT 2 2:1:0.5:6 21.8 36 39.4% 
CT 3 5:1:0.5:6 9.7 35.8 73% 
CT 4 1:1:1:6 75,6 78 3.1% 
CT 5 2:1:1:6 50.4 69 27% 
CT 6 5:1:1:6 24.1 73.5 67.2% 
CT 7 1:1:4:8 136.0 138.2 1.5% 
CT 8 1:1:4:16 294.0 328.5 10.5% 
CT-B 1 1:1:4:16 319.0   
CT-B 2b 1:1:4:16 347.0   
GC-1 1:1:4:16 515.6   
GC-2b 1:1:4:16 581.2   
GC-3b 1:1:4:16c 651.3   
a for chitosan, the moles of its repeating units are considered in the molar ratio with the other 
components of the reaction solution 
b pH was adjusted at a value of 6.8  
c EDC was added gradually (half amount was added at t=0; a quarter was added at t=2 h and the 
final amount was added at t=4 h) 
Heparin was chosen as the polyanionic component to establish the cross-
linkage among layers (Figure 3.1). Thanks to its high solubility in water 
(the negative charge is maintained also in acid conditions due to the 
presence of sulfate groups),44 till 80 % of carboxylic group could be 
functionalized (as determined with 1H-NMR analysis).  
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Figure 3.1. Thiol-ene reaction between allylated heparin and thiolated glycol chitosan. 
Reaction was triggered throughout UV irradiation. 
More in detail, as shown in Figure 3.2, the signal at 5.72 ppm related to 
CH proton of terminal olefin is not overlapped with heparin signals. By 
the integration of the area of this peak and the area between 2.9 and 4.4 
ppm, related to 10 protons of iduronic and glucosamine units, it is possible 
to determine the degree of functionalization, that results being 80.0 %. 
 
Figure 3.2. 1H NMR spectrum of heparin (below) and modified heparin (on top). 
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Investigation of thiol-ene like reaction on modified polymers and on 
polymer multilayer shells  
Modification of polymers was needed to perform a covalent cross linkage 
among successive layers, exploiting the thiol-ene reaction (Figure 3.1). 
This reaction can be photo-initiated (at 365 nm or 254 nm), can be 
performed at room temperature in the presence of oxygen45 and does not 
require potentially toxic metal catalysts. In order to determine the best 
reaction conditions, the modified glycol chitosan (GC-3, see Table 3.1) 
was first made to react with allylamine in solution and the experimental 
conditions (light source, wavelength, time irradiation, presence of oxygen 
and photoinitiator) were investigated. Once added allylamine Ellman’s test 
was performed before and after irradiation and the relative reduction of 
free thiol groups was determined. 
The results (Table 3.2) confirm that the reaction is not sensitive to the 
ambient light and to the presence of oxygen.45 This means that it is possible 
to store and process the functionalized multilayer without any precautions 
in terms of light shielding and inert atmosphere. Moreover, comparing the 
two wavelengths used, it is evident that the irradiation at 254 nm is 
preferable as it is possible to perform effectively the reaction with low 
power irradiation (TLC lamp), without temperature control of the solution 
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and photoinitiators, even though the presence of the photoinitiator 
determines higher yields.  
Table 3.2. Degree of reduction of thiol group by irradiation of thiolated glycol chitosan 
(with 13% of free thiols content) in presence of allylamine 
Test Irradiation 
source (nm) 
Time 
exposure 
Experimental 
condition 
Photoinitiatior reduction 
free thiols 
1 Sunlight 2h N2 No 1.4 % 
2 365 (Hg lamp) 2h N2 Yes 49.4% 
3 365 (TLC lamp) 2h N2, pH 4 Yes 34.7% 
4 365 (Hg lamp) 2h In N2 No 17.2 % 
5 365 (TLC lamp) 2h N2, pH 4 No < 1% 
6 365 (Hg lamp) 2h 25 °C, pH4 No 12.1% 
7 254 (TLC lamp) 2h N2, pH 4 No 39.8 % 
8 254 (TLC lamp) 2h pH 4 No 35.3% 
9 254 (TLC lamp) 2h pH 4 Yes 76.8% 
10 254 (TLC lamp) 2h N2, pH 4 Yes (1/2) 45.5% 
11 254 (TLC lamp) 1h N2, pH 4 Yes 45.3% 
 
To prove that the thiol-ene reaction can be effectively performed not only 
in solution but also on particulate substrates, a bilayer composed of glycol 
chitosan and heparin was deposited on PS NPs by LbL technique, as 
previously described. The amount of polymers needed to coat the 
nanoparticles was determined using the saturation method.46 PS NPs were 
used instead of O/W nano-emulsion because the rigidity of the former 
template is required to characterize cross-linkage among layers, as it will 
be discussed below.  
The bilayer on PS NPs was irradiated using the best conditions previously 
found (254 nm, 2 h) in an open container. A modified Ellman’s test (see 
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Figure 3.3) was used to determine the decrease of free thiol groups that 
corresponds to the amount of thioether bonds formed.  
 
Figure 3.3. Schematic representation of the modified Ellman’s test. The relative 
reduction of free thiols indicates the amount of thioether bond formed 
In particular, the test was performed both on irradiated (2 h at 254 nm) and 
non-irradiated bilayer films. The test was opportunely modified in order to 
be applied to a system containing a particle suspension. Indeed, the 
Ellman’s reagent was added to both suspensions, letting them to react for 
2 h, and then the two samples were centrifuged collecting the supernatant 
for the spectrophotometric measurement. It was possible to obtain a 
solution containing only TNB2- useful for UV measurement. As expected, 
the degree of cross-linkage was higher when using the photoinitiator (54.6 
± 2.0 % against 25.4 ± 0.9 %). We verified that the amount of 
photoinitiator was not above the saturation limit ensuring to not affect 
forcedly following cytotoxicity tests (Figure 3.4).  
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Figure 3.4. Free thiol reduction after cross-linkage (UV irradiation at 256 nm for 2h) of 
bilayer coating on PS NPs varying the photoinitiator content. Error bars indicate the 
standard deviation. 
However, a sufficient reduction of free thiol occurs in absence of 
photoinitiator, demonstrating cross-linkage also in absence of 
photoinitiator. The possibility to trigger the reaction without the use of a 
photoinitiator is a remarkable advantage for bio-applications in which the 
presented systems is subsequently employed.  
The formation of the thiol-ether bond was further proved using Magic-
Angle Spinning 1H-NMR (MAS NMR) Spectroscopy. This technique is a 
powerful tool to study the polymers structure on the surface of rigid 
nanoparticles.47 The reduction of allyl group signals in the spectrum 
confirms the cross-linkage between the allylated heparin and the thiolated 
glycol chitosan adsorbed on the PS nanoparticles surface. In Figure 3.5 
the superimposition of the spectra obtained before and after the UV 
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irradiation is shown. Allyl proton signal at 5.87 ppm is significantly 
decreased, suggesting again that the photoreaction occurs. 
 
Figure 3.5. 1D 1H MAS NMR spectra of PS nanoparticles suspension coated with 
polymer bilayer before (red line) and after (blu line) irradiation with UV light. Allyl 
proton signal at 5.87 ppm is decreased after irradiation. 
Cytotoxicity results  
The cytotoxicity of the above bilayer coated PS NPs was investigated in 
order to verify the effect of the cross-linking process and, in particular, the 
effect of a hypothetical residual presence of the photoinitiator on cell 
viability (photoinitiator is removed dialyzing samples against water over-
night, as previously reported). To this aim, mouse brain endothelial bEnd.3 
cells were exposed to bilayer coated PS NPs for 24 h.  
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Figure 3.6. Viability of bEnd.3 cells 24 h after exposure to suspensions of bilayer-coated 
nanoparticles with a photoinitiator (BL + PI) and the same suspensions without a 
photoinitiator (BL) evaluated by the Alamar Blue assay. Viability of nanoparticle-treated 
cells is normalized to untreated control cells. Error bars indicate the standard deviation. 
As shown in Figure 3.6, no significant cytotoxicity was observed for 
bilayer systems cross-linked without photoinitiator. Conversely, samples 
prepared in presence of a photoinitiator and after purification by dialysis 
provided a decrease of about 35-40% in cell viability. Moreover, confocal 
microscopy images demonstrated the capability of the bilayer coated PS 
NPs to enter cells after 24 h incubation as shown by the intracellular green 
spots mainly localized around the nucleus (Figure 3.7). 
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Figure 3.7. Confocal images of bEnd.3 cells incubated with suspensions of bilayer-coated 
nanoparticles with a photoinitiator (b) and the same suspensions without a photoinitiator 
(c) for 24 h at 37 °C. 
Taken altogether, these preliminary results suggest that this strategy is 
promising in order to obtain stable and biocompatible nanosystems valid 
for bio-applications. 
Biostability tests on multilayer  
To highlight the enhanced stability of the cross-linkage on polymeric 
coating prepared via LbL, we compared two systems made respectively 
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with functionalized and not functionalized polymers on PS NP as template. 
Since chitosan is more sensitive of the heparin to physiological conditions, 
we used chitosan as last layer thus preparing a trilayer coating. Both 
systems were irradiated at 256 nm without the photoinitiator. The trilayer 
was based on a first layer of glycol chitosan, a second layer of heparin and 
again a layer of glycol chitosan. The values of size, PDI and ζ-Potential 
for the starting template and the layers sequentially deposited are shown 
in Table 3.3.  
Table 3.3. DLS analysis of trilayer coating on PS NPs of modified polymers (entries 2-
4) and non-modified polymers (entries 5-7). 
  
Size 
(d.nm) 
PDI 
ζ-Potential 
(mV) 
ζ-Deviation 
(mV) 
1 Template 120.0 0.026 - 35.4 ± 10.8 
2 Monolayer 126.7 0.067 + 39.8 ± 8.39 
3 Bilayer 133.5 0.087 - 30.4 ± 13.3 
4 Trilayer 139.9 0.064 +29.8 ± 8.13 
5 Monolayer 129.6 0.064 + 44.8 ± 8.35 
6 Bilayer 141.3 0.073 - 35.0 ± 7.47 
7 Trilayer 165.8 0.111 +30.3 ± 6.87 
 
It is noteworthy that chitosan is a weak polycation, and the increase of pH 
leads to the loss of positive charges and to the consequent destabilization 
of the entire system.48 For this reason, stability was monitored checking 
the size of the sample over time in media with different pH and ionic 
strength.  
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Figure 3.8. Comparison of size measurement between sample cross-linked (blue bars) 
and non (red bar) in different media: a) sample dispersed in water at pH 4; b) sample 
dispersed in 10 mM phosphate buffer solution at pH 7.3. Error bars indicate the standard 
deviation. 
From Figure 3.8 a it is evident how stability is similar for both systems if 
samples are stored in water at pH 4, where there is no significant ionic 
strength and the pH is ideal to maintain the first and the outer layer 
positively charged. The same comparison was performed in phosphate 
buffer solution at neutral pH to simulate a physiological environment 
where pH and ionic strength increase. In Figure 3.8 b it is shown that the 
not cross-linked sample is sensibly unstable in such conditions: size 
increases dramatically disclosing a fast destabilization. Conversely, the 
sample previously cross-linked resulted to be stable over several days. The 
notable difference between the samples is also macroscopically evident 
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(Figure 3.9), proving that the cross-linkage positively affects the stability 
of the LbL multilayer. 
 
Multilayer nanocapsule on O/W nano-emulsion  
In the end we realized the same trilayer coating an O/W nano-emulsion, a 
liquid template already developed in our lab,49, 50 to show the utility and 
the promising application of the above results. O/W nano-emulsions were 
prepared by using a high-pressure homogenizer and a formulation based 
on natural materials, i.e. soy-bean oil and lecithin as surfactant. Depending 
on the relative amount of oil and surfactant, it was possible to realize nano-
emulsions, ranging from 100 to 200 nm. The liquid template represents a 
promising platform for imaging and drug delivery since it was already 
demonstrated its capability to encapsulate lipophilic drugs (e.g. 
curcumine), dyes (e.g. nile red, fluorescein) or contrasting agents (e.g. 
SPION, QDs; see Figure 3.10).49, 51  
Figure 3.9. Macroscopic comparison between 
samples dispersed in phosphate solution: the sample 
cross-linked (on the left) is not subject to aggregation 
phenomena and the suspension remains clear. 
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Figure 3.10. Confocal and STED image of Oil-in-Water nanoemulsion loaded with: a) 
Nile Red (confocal); b) CdSe QDs (STED); c) FITC (STED). Scale bar 2.5 micron. 
Consequently, several advantages are related to the use of this template: i) 
the core removal is not required; ii) the deposition of few layers is 
sufficient to obtain a stable carrier;52 iii) particle large enough to be 
centrifuged and pelleted are not needed; iv) a post-production step of 
encapsulation is avoided. These advantages result in an approach 
significantly less time-consuming and less labor-intense to obtain nano-
sized capsules.53  
Table 3.4. DLS analysis of multilayer deposition of modified polymers (entries 2-4) on 
O/W nano-emulsion template (entry 1) and of trilayer after irradiation and dispersion in 
PBS (entries 5 and 6). 
  
Size 
(d.nm) 
PDI 
Z-Potential 
(mV) 
Z-Deviation 
(mV) 
1 
O/W nano-
emulsion 
132.0 0.048 - 38.7 ± 6.15 
2 Monolayer 137.7 0.072 + 26.0 ± 6.87 
3 Bilayer 141.8 0.116 - 30.8 ± 3.04 
4 Trilayer 166.4 0.138 + 38.1 ± 4.76 
5 
Trilayer 
cross-linked 
170.9 0.144 + 31.6 ± 4.52 
6 
Trilayer in 
PBS 
169.8 0.126   
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Table 3.4, summarizes the particle size and Z-potential measurement for 
the starting template and for the resulting trilayer built up with 
functionalized glycol chitosan and heparin. The trilayer was irradiated and 
dispersed in PBS to confirm, also in this case, the enhanced stability due 
to covalent cross-linkage among layers (see entry 6 in Table 3.4). Also for 
this sample, after 24 hours of contact with cells, no cytotoxicity was 
observed (% viability = 95.6 %; SD = 13.0%). Further biological tests are 
presently under investigation in order to use this system in specific 
biomedical applications, in particular in drug delivery applications.  
In addition to size measurements, the glycol chitosan of the last layer was 
labelled with fluorescein. In Figure 3.11 it is shown a confocal image of 
cross-linked trilayer coating O/W nanoemulsions dispersed in PBS that 
clearly demonstrate persistence of the outer layer even after disappearance 
of the electrostatic stabilization. DLS of the above nanocapsules is also 
reported in Figure 3.11 to show monomodality and narrow distribution 
(average size in Table 3.4, entry 6). 
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Figure 3.11. Confocal and DLS analysis of a trilayer coatings on O/W nano-emulsion 
after cross-linkage and dispersion in PBS. The outer layer, labelled with fluorescein, 
remains attached to the nanocapsules also if ionic forces are weak in this conditions. 
It is noteworthy that for the first time we propose the use of natural based 
materials, like polysaccharides, stabilized by a thiol-ene click reaction. At 
the same time, we demonstrate that this reaction can be applied to oil core 
based capsules made of completely biodegradable polymers which is an 
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highly wished requisite in drug delivery54 together with the size 
requirement below 200 nm.55 Very interestingly, the degree of cross-
linkage reached in this work was enough for the final aim to stabilize the 
nanocapsules in physiological medium even with no photoinitiator due to 
the high degree of functionalization of the starting polymers and with a 
limited number of polymer layers. Moreover, the oil based nanocarrier 
here proposed is very useful for drug delivery, due to the possibility of 
conveying and releasing bioactive hydrophobic substances. 
3.3 Conclusions 
In this work we showed how the stability of biopolymer multilayers 
obtained via layer by layer can be enhanced introducing covalent bonds 
among layers by means of a metal catalyst-free, light initiated 'click' 
reaction, namely the thiol-ene reaction. In particular, a thiol moiety on 
chitosan and an allylic moiety on heparin were introduced analyzing the 
related degree of functionalization. High degrees of thiolation (up to 650 
µmol/g) could be reached using glycol chitosan. NMR analysis and 
colorimetric tests were performed to demonstrate the occurring of the 
thiol-ene reaction among modified polymers. Interestingly, the reaction 
resulted effective even without a photoinitiator, mainly due to the high 
degree of modification of the biopolymers, providing a completely non-
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cytotoxic final product, as demonstrated through in vitro tests. Cross-
linked multilayers resulted in more stable systems than those stabilized 
with just electrostatic forces, even when they experienced perceptible 
variations in pH and ionic strength. Therefore, we provide an efficient and 
biocompatible approach to fabricate very stable polymer multilayer 
capsules made via LbL technique. In addition, the application of this 
approach to biopolymers surrounding an O/W nano-emulsion 
demonstrates that thiol-ene cross-linkage can be nicely exploited in the 
field of completely biocompatible and biodegradable nanocarriers. Other 
bio-applications where LbL multilayers have to be stabilized may also 
benefit from the proposed approach. 
3.4 Materials and Methods 
Materials 
Chitosan low molecular weight (CT-LMW, 90-150 kDa,), heparin sodium 
salt (from porcine intestinal mucosa), 1-hydroxybenzotriazole hydrate 
(HOBt), acetic acid, sodium acetate, sodium chloride, N-acetyl-L-cysteine 
(NAC), allylamine, sodium nitrite, methanol, ammonium hydroxide 
solution, sodium borohydride, hydrochloric acid, sodium hydroxide, 
deuterium oxide (D2O), trifluoroacetic acid (TFA), 5,5’-dithiobis(2-
nitrobenzoic acid) (DTNB, also known as Ellman’s reagent) and 
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Fluorescein 5(6)-isothiocyanate (FITC) were purchased from Sigma-
Aldrich. Soy-bean oil (density at 20 °C of 0.922 g ml/1) and Lipoid E80 
lecithin (egg lecithin powder 80–85% enriched with phosphatidyl choline 
and 7–9.5% content in phosphatidyl ethanolamine) were purchased from 
Lipoid. Glycol chitosan (GC) was purchased from Wako Chemicals. 1-(3-
dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (EDC) was 
purchased from Iris Biotech. Carboxyl latex beads (4% (w/v), 0.1 µm) and  
FluoSpheres® (Carboxylate-Modified Microspheres, 0.1 µm, yellow-
green fluorescent (505/515), 2% solids) were purchased from Invitrogen. 
Irgacure® 2959 was purchased by Ciba Specialty Chemicals. Dialysis 
membranes were purchased from Spectrum Laboratories Inc. 
Oil-in-Water nanoemulsion  
The O/W nano-emulsion was prepared as previously described.49 Briefly, 
the oil phase was prepared by adding an exact amount of Lipoid E 80 to 
the soy-bean oil at 60 °C and then sonicated with an immersion sonicator 
(Ultrasonic Processor VCX500 Sonic and Materials). To obtain the pre-
emulsion, the oil phase was added dropwise to a weighted amount of 
aqueous phase (Milli-Q water) and mixed using the immersion sonicator. 
The pre-emulsion was finally passed at 2000 bar through the high-pressure 
valve homogenizer (Microfluidics M110PS) to obtain the final nano-
emulsion. 
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Modification of glycol chitosan with N-Acetylcysteine  
Thiolation was performed on different chitosan substrates in order to 
identify the best degree of functionalization: chitosan low molecular 
weight (CT-LMW, Mv = 126.0 kDa), depolymerized chitosan (dCT, Mv = 
17.5 kDa, depolymerization was performed using nitrous acid)56, 57 and 
glycol chitosan (GC, chitosan conjugated with ethylene glycol). In the 
typical procedure, 0.5 mmol of the chitosan substrate were dissolved in 10 
ml of Milli-Q water. Different amounts of HOBt (see Table 3.1) were 
added and pH was at first adjusted to a value of 4 with HCl 1 M to allow 
complete dissolution. Then, different amounts of NAC and EDC (see 
Table 3.1) were added to the solution. The pH was adjusted and 
maintained to a value of 6.8 (pH was kept at pH 5 for CT-LMW to prevent 
the precipitation) throughout the reaction time (3 h). The reactions 
proceeded at room temperature. The product was then purified by dialysis 
four times against water containing 1% (w/v) NaCl and acidified with HCl 
at pH = 3, four times against water acidified at pH = 3. Finally, the purified 
product was freeze-dried for 48 h (Freeze Dryer CHRIST Alpha 1-4 LSC).  
Total and free thiols were determined using a colorimetric assay, the 
Ellman's test.58-60 In particular, after reaction of thiolated chitosan with a 
DTNB solution at 25 °C for 2 h, absorbance was registered at 412 nm using 
a Varian Cary Scan 100 Spectrophotometer. For total thiols evaluation, 
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reduction of disulphide bond with NaBH4 was needed before adding 
DTNB solution. 
Modification of heparin with allylamine  
Heparin (100 mg, 0.150 mmol of –COOH groups) was dissolved in 10 ml 
of Milli-Q water. After the rapid dissolution of the polymer, allylamine 
(112.5 µL, 1.5 mmol) was added to the solution and pH adjusted to 6.8 
value. Then, HOBt (81.22 mg, 0.6 mmol) and EDC (115.2 mg, 0.6 mmol) 
were added. The pH was adjusted again to 6.8 and maintained at this value 
throughout the reaction time (6 h, RT). Sample was then dialyzed (dialysis 
tubing of 6-8 kDa) against water and freeze-dried for 48 h. The degree of 
functionalization was determined with 1H-NMR spectra (Figure 3.2). 
Modification of glycol chitosan with fluorescein isothiocyanate  
Glycol chitosan (GC, 100 mg, 0.20 mmol) was dissolved in 10 ml of 0.1 
M of acetic acid solution. After complete dissolution, a solution of FITC 
(5.0 mg in 500 µl of DMSO) was added dropwise. The reaction proceeded 
over night at room temperature. Sample was then dialyzed (dialysis tubing 
of 6-8 kDa) against water till no dye was detected (using Perkin Elmer 
2300 Enspire Plate Reader, λex = 488 nm, λem = 510 nm). Finally, the 
purified product was freeze-dried for 48 h. 
Solution Nuclear Magnetic Resonance spectroscopy  
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1D 1H-NMR experiments were performed using an Agilent 600 MHz 
spectrometer equipped with a DD2 console and an OneNMR HX probe. 
Samples containing CT or GC were prepared at 10 mg/ml in D2O, 
containing 1 % (v/v) of TFA. Samples containing heparin were prepared 
at 10 mg/ml in deuterium oxide. NMR spectra were recorded with a total 
of 64 transients and a PRESAT sequence was used to saturate the water 
residual peak. Spectra analysis was performed using VNMRJ 4.0 software.  
LbL deposition of functionalized polymers on polystyrene carboxylated 
nanoparticles 
Monolayer deposition. 1 ml of a water suspension (pH 4) of carboxyl latex 
beads (PS NPs, 0.5 % w/v) were added, under vigorous stirring for 15 min 
to 2 ml of a solution of GC (0.04 % w/v) in water at pH = 4.  
Bilayer deposition. 2.5 mL of a water solution of heparin (0.128 % w/v) at 
pH = 4 were added to 2.5 ml of monolayer-coated nanoparticles 
suspension (0.16 % w/v PS NPs; 0.0256 % w/v GC) under vigorous 
stirring for 15 min. 
Trilayer deposition. 2.5 ml of a water solution of GC (0.064 % w/v) at pH 
= 4 were added to 2.5 ml of bilayer-coated nanoparticles suspension (0.08 
% w/v PS NPs; 0.0128 % w/v GC; 0.064 % w/v Hep) under vigorous 
stirring for 15 min. 
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LbL deposition of functionalized polymers on O/W nano-emulsion  
Monolayer, bilayer and trilayer were obtained with the same procedure 
explained above, with the following final concentration: 0.25 % (w/v) 
O/W nano-emulsion, 0.0025 % (w/v) GC, 0.005 % (w/v) Hep, 0.01 % 
(w/v) GC-FITC. 
ζ -potential measurements  
The ζ-potential was determined using a particle electrophoresis instrument 
(Zetasizer zs nano series ZEN 3600, Malvern Instruments Ltd., Malvern, 
U.K.). Samples were diluted up to a concentration of approximately 0.025 
% (w/v) using the proper buffer solution. The ζ-potential analysis was 
carried out by setting 50 runs for each measurement. 
Particle size measurements  
Suspensions were characterized using a laser dynamic light scattering 
(DLS) instrument (λ = 632.8 nm). A detecting angle of 173° was used. All 
the samples were diluted up to a droplet concentration of approximately 
0.025 w/v % by using Milli-Q water acidified at pH 4. A default refractive 
index ratio (1.5900) and 5 runs for each measurement (1 run lasting 100 s) 
were used in the calculations of the particle size distribution. 
Photoreaction of the multilayer  
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The suspensions of PS NPs coated with polymer multilayer were irradiated 
with UV light for 2 h. Two different UV light sources were used: a UV 
Hand Lamp Spectroline® E-Series UV lamp (output 6 W, wavelength 254 
and 365 nm), or a High Intensity Lamp Blak-Ray® UV (Ultraviolet Lamp 
with Spot Bulb, output 100 W, wavelength 365 nm). For the UV Hand 
lamp, the light source was at 3 cm distance. For the High Intensity Lamp 
the distance was increased to 10 cm and a water bath was used to avoid 
overheating of the solution. Photoreaction was conducted both with a final 
concentration of photoinitiator of 0.3 mg/ml and without a photoinitiator. 
Samples for cytotoxic assays were dialyzed against water overnight. 
Ellman’s test. To determine the reduction of free thiols after irradiation 
(corresponding to the degree of cross-linkage), 50 ml of PS NPs coated 
with a bilayer were concentrated to 2 ml by centrifuge (13000 rpm, 10 min, 
4 °C), and sonicated (10 min, 40 MHz, 50 % of power, 4 °C). Half volume 
was stored at room temperature for 2 h in presence of natural light and 
atmospheric oxygen, while half volume was irradiated. Then, 0.5 ml of 
each sample were added to a solution containing the Ellman’s reagent. 
After 2 h, each sample was centrifuged (13000 rpm, 15 min) and 
supernatant was collected for UV measurement. (Figure 3.3) 
MAS NMR Analysis. To confirm the reduction of allyl groups after 
irradiation an NMR analysis was performed. A suspension of PS NPs 
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coated with polymer bilayer was centrifuged, resuspended in 100 µl of 
D2O and then sonicated. The same procedure was used for sample 
irradiated with the UV light. 1D 1H-NMR experiments were performed 
using an Agilent 600 MHz spectrometer equipped with a DD2 console and 
a gHX Nanoprobe. The MAS spin rate was set at 2.7 kHz and the number 
of transients used for spectra acquisition was 4096. A DPFGSE61 sequence 
was used to saturate the water residual peak. Spectra were transformed, 
superimposed and analyzed using the software VNMJ 4.0. 
Stability tests on normal and cross-linked trilayer  
The stability over time of the system was determined dispersing PS NPs 
coated with the trilayer in different media, i.e. water at pH = 4, PBS 10 
mM pH = 7.3. Stability was determined monitoring by DLS particle size 
variations over time. 
Cytotoxicity test  
The Alamar Blue assay was used to test the cytotoxicity of the PS NPs 
coated with a bilayer in presence or not of the residual photoinitiator. 
Immortalized mouse cerebral endothelial cells, bEnd.3 cells (American 
Type Culture Collection, Manassas, VA), grown in DMEM with 4.5 g/l 
glucose, 10 % w/v Fetal Bovine Serum (FBS), 3.7 g/l sodium bicarbonate, 
and 4 mM glutamine, 1 % w/v non-essential amino acids, 100 U/ml 
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penicillin and 0.1 mg/ml streptomycin in 100 mm diameter cell culture 
dish, in a humidified atmosphere at 37 °C and 5 % v/v CO2, were chosen 
as a model of endothelium. Briefly, cells were seeded in 96-well 
microplates (Costar) at a density of 8 × 103 cells/well at a final volume of 
100 µl and incubated for 24 h at 37 °C. Cells were then treated with PS 
NPs coated with two polymer layers (GC-Hep) at a concentration of 0.002 
% w/v in a final volume of 150 µl for each well. The metabolic activity of 
all cell cultures was determined after 24 hours of exposure by using 
standard Alamar Blue assay (Invitrogen) as described elsewhere.62 The 
Alamar Blue reagent reduction of the sample solutions was analysed with 
a spectrophotometer (Perkin Elmer 2300 Enspire Plate Reader, λex = 570 
nm, λem = 600 nm). Data were reported as a percentage of cell viability 
normalized to untreated control cells. Statistical analyses of significance 
were performed using ANOVA test. p values equal or lower than 0.05 were 
considered statistically significant. Experiments were repeated three times 
in triplicates. 
For the observation of multilayer cellular uptake, bEnd.3 cells were 
incubated with the same bilayer on PS NPs at a final concentration of 0.002 
% w/v for 24 h at 37 °C. After each time, samples were washed two times 
with PBS and fixed with 4 % v/v paraformaldehyde for 20 min. Then, cell 
nuclei were stained with DAPI (Sigma-Aldrich) and cytoskeleton 
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microfilaments with red fluorescent phalloidin (Sigma-Aldrich). Samples 
were observed by confocal and multiphoton microscope system (Leica 
TCS SP5 MP) equipped with an oil-immersion 40× objective. Images were 
acquired with a resolution of 1024×1024 pixels.  
Confocal analysis  
Trilayer on O/W nano-emulsion was diluted 1:25 to a final oil 
concentration of 0.01 % w/v in an Eppendorf with PBS 10 mM at pH 7.2 
and 200 µl were put in a FD3510 dish for 30 min to allow it to adhere to 
the surface of the dish. After that, several washes were performed 
replacing the sample twice with 120 µl of water and in the end with 120 µl 
of 5 % w/v DABCO antifade solution, taking care to let always wet the 
central part of the dish. DABCO antifade was needed to avoid the 
bleaching effect of the fluorescein. Samples were imaged with a Leica TCS 
STEDCW microscope (Leica-Microsystems, Mannheim, Germany) 
equipped with an oil immersion 100× objective. Images were acquired 
with a field of view of 25.6 × 25.6 µm for a pixel size of 25 × 25 nm. The 
analysis of the images was carried out using LAS AF software. 
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3.5 Supplementary Section2 
In this section a parallel work performed using chitosan instead of glycol 
chitosan is reported. The limit illustrated for chitosan thiolation with N-
acetyl-L-cysteine are here overcame using a different synthetic approach.   
Chitosan functionalization with 2-iminothiolane 
Chitosan functionalization was obtained using the Traut’s reagent, namely 
2-iminothiolane (2-IT), a heterocyclic thioimidate compound (Figure 
3.12).  
 
Figure 3.12. Schematic representation of the coupling reaction between chitosan and 2-
iminothiolane to obtain chitosan-4-thio-butyl-amidine conjugate (CT-TBA) 
Due to its structure, 2-IT shows angle, torsional and steric strain and, 
therefore, it results to have high reactivity towards amine. In addition, 
reaction with primary amine - in this case, with chitosan - leads to a 
chitosan-4-thio-butyl-amidine conjugate (CT-TBA) which still possesses 
a positive charge.42, 63 This feature represents an advantage for LbL 
                                                          
2 The work here illustrated has been realized with the precious help of Dr. Giusi 
Liberatore Ilardi and Dr. Luigi Angellillo, with whom I had the pleasure to collaborate 
during their respective Master Degree Thesis. 
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application, in that the charge density positively effects on the polymer 
deposition. In addition, the reaction does not require any condensing agent 
or catalyst, the yield strictly depends on the relative amount of 2-IT added 
and thus result to be very high (up to 17.7 % of functionalization). 
However, as reported,64, 65 the major limits related to the formation of 
chitosan-TBA conjugate are the formation of disulfide bonds – resulting 
in the formation of covalent cross-linked gel – and a side reaction that 
involves a cyclization of TBA with the loss of ammonia and the formation 
of N-substituted 2-iminothiolane – the loss of ammonia makes the side 
reaction irreversible and the side product results to be without the positive 
charge and the thiol moiety (Figure 3.13).  
 
Figure 3.13. Schematic representation of the side reaction occurring with CT-TBA. At 
higher pH value (< 3-4) the loss of an ammonia molecules brings to the formation of a 
stable and thiol-free specie, the N-substituted 2-iminothiolane. 
The synthetic procedure has been planned in order to minimize as much as 
possible these problems. In particular, reactions were conducted in inert 
atmosphere by using nitrogen, a mild reducing agent (DTT, dithiothreitol) 
was added to the solutions to remove disulphide bonds and pH was 
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lowered to 3.5 just prior to the purification step to reduce re-oxidation of 
thiols to disulphide and the irreversible loss of ammonia. The so modified 
polymer has been characterized both with 1H-NMR spectroscopy and with 
the colorimetric Ellman’s test.  
Further information about the materials and methods used for the 
synthesis, the characterizations and the degrees of functionalization 
obtained are more fully reported in the previous chapter.  
Biostability test on multilayer with CT-TBA 
As for thiolated glycol chitosan, also CT-TBA was employed to realize 
multilayer coating on colloidal nanoparticles via LbL and the effectiveness 
of the thiol-ene reaction to enhance the stability of the final system as a 
result of the cross-linkage has been evaluated.   
Firstly, a trilayer systems made with functionalized polymers on PS NP as 
template was realized. The trilayer was based on a first layer of chitosan-
TBA, a second layer of allylated heparin and again a layer of chitosan-
TBA. The values of size, PDI and ζ-Potential for the starting template and 
the layers sequentially deposited are shown in Table 3.5. The sample was 
splint in two aliquots, one of which was irradiated at 256 nm without any 
photoinitiator.  
 143 
 
Table 3.5. DLS analysis of trilayer coating on PS NPs with modified polymers 
  
Size 
(d.nm) 
PDI 
ζ-Potential 
(mV) 
1 Template 120.5 0.042 - 35.1 
2 Monolayer 162.5 0.057 + 25.4 
3 Bilayer 148.6 0.060 - 44.9 
4 Trilayer 196.8 0.057 +23.2 
 
Finally, both the samples were dispersed in medium with varied pH and 
ionic strength, namely PBS (10 mM, pH 7.2) and DMEM, to detect any 
difference in the stability of the system before and after the cross-linkage. 
As shown in Table 3.6, system submitted to irradiation shows a higher 
stability, in that size results to be unchanged – or even slightly reduced – 
compared to the system dispersed in the starting acidic medium. On the 
other side, system not irradiated shows an increase in size and/or PDI. Thus 
comparison suggests that cross-linkage effects on the stability of the 
system, even if the differences are not so striking as in the case of the 
thiolated glycol chitosan. 
Table 3.6. DLS analysis of trilayer coating on PS NPs submitted or not to UV irradiation. 
The comparison of the size and PDI measured illustrates that cross-linkage stabilize the 
system. 
 Sample Medium 
Size 
(d.nm) 
PDI 
ζ-Potential 
(mV) 
1 Irradiated PBS 187.6 0.071 + 22.7 
2 Not irradiated PBS 274.5 0.071 + 23.5 
3 Irradiated DMEM 185.5 0.102 + 23.6 
4 Not irradiated DMEM 225.9 0.211 +24.7 
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Subsequently, the same trilayer coating was realized on an O/W 
nanoemulsion. In Table 3.7 are reported the values of size, PDI and ζ-
Potential for the starting oil-core, the layers sequentially deposited and the 
final system dispersed in DMEM and PBS. Results shows that the cross-
linkage does not sufficiently strengthen the system, in that size and PDI 
increase dramatically.  
Table 3.7. DLS analysis of cross-linked trilayer coating on O/W nanoemulsion. 
  
Size 
(d.nm) 
PDI 
ζ-Potential 
(mV) 
1 O/W nanoemulsion 126.5 0.049 - 32.1 
2 Monolayer 142.1 0.092 + 27.6 
3 Bilayer 174.6 0.125 - 32.6 
4 Trilayer 186.7 0.092 + 28.2 
5 Trilayer in DMEM 423.8 1.000  
6 Trilayer in PBS 546.9 1.000  
 
In order to further enhance the stability of the system two possible strategy 
have been hypnotized, both aimed to increase the amount of cross-linkage: 
to increase the number of the layers or to increase the thickness of each 
layer. We oriented to realize the latter hypothesis because it results to be 
easier achievable – by increasing the ionic strength during the realization 
of the layer46 – and without the complications related to the increase of the 
number of layers. In detail, layers’ deposition is performed in an Acetic 
Acid buffer solution (20 mM, pH 4) containing a precise amount of NaCl 
(5 mM). In Table 3.8 are reported the values of size, PDI and ζ-Potential 
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for the starting oil-core, the layers sequentially deposited in this new 
conditions. Results clearly show the increase of size compared to the 
previous system (~ 35 nm for the final trilayer, see Table 3.7 for a 
comparison). Entries 5 e 6 in Table 3.8 also show that the greater thickness 
of the layer positively effects on the stability of the system. Indeed, the 
trilayer maintain the values of size and PDI after dispersion in DMEM e 
PBS.  
Table 3.8. DLS analysis of cross-linked trilayer coating on O/W nanoemulsion obtained 
by increasing the ionic strength of the medium during the LbL deposition. Sizes result to 
be increased up to 35 nm in these conditions (compared with results in Table 3.7). 
  
Size 
(d.nm) 
PDI 
ζ-Potential 
(mV) 
1 O/W nanoemulsion 126.5 0.049 - 32.1 
2 Monolayer 158.4 0.133 + 21.9 
3 Bilayer 176.0 0.108 - 43.4 
4 Trilayer 212.6 0.106 + 18.6 
5 Trilayer in DMEM 211.8 0.118  
6 Trilayer in PBS 226.0 0.127  
 
Conclusions 
In this Section we briefly showed an alternative approach to prepare 
biocompatible nanocapsules with enhanced stability. As discussed above, 
modification of chitosan with N-acetyl-L-cysteine can be very challenging 
and degrees of functionalization result to be very low. The use of 2-
iminothiolane as coupling agent allowed to reach higher percentage of 
thiolation, even if some problems have been encountered. In particular, 
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compared with GC-NAC, CT-TBA resulted to be less stable over time and, 
therefore, difficult to store. Nevertheless, results obtained with this 
different biopolymer further confirm the efficacy of the thiol-ene cross-
linkage to realize very stable polymer multilayer capsules made via LbL 
technique. 
 
  
 147 
 
3.6 References 
1. G. Decher and J.-D. Hong, Makromolekulare Chemie. 
Macromolecular Symposia, 1991, 46, 321-327. 
2. G. Decher, Science, 1997, 277, 1232-1237. 
3. P. Bertrand, A. Jonas, A. Laschewsky and R. Legras, 
Macromolecular Rapid Communications, 2000, 21, 319-348. 
4. G. Decher and J. B. Schlenoff, Multilayer thin films: sequential 
assembly of nanocomposite materials, John Wiley & Sons, 2006. 
5. C. S. Peyratout and L. Dähne, Angewandte Chemie International 
Edition, 2004, 43, 3762-3783. 
6. G. Decher and J. D. Hong, Berichte der Bunsengesellschaft für 
physikalische Chemie, 1991, 95, 1430-1434. 
7. W. B. Stockton and M. F. Rubner, Macromolecules, 1997, 30, 
2717-2725. 
8. L. Wang, Z. Wang, X. Zhang, J. Shen, L. Chi and H. Fuchs, 
Macromolecular rapid communications, 1997, 18, 509-514. 
9. E. Kharlampieva and S. A. Sukhishvili, Journal of 
Macromolecular Science, Part C: Polymer Reviews, 2006, 46, 
377-395. 
10. M. B. Zakaria, V. Malgras, T. Takei, C. Li and Y. Yamauchi, 
Chemical Communications, 2015, 51, 16409-16412. 
11. H. Wang, S. Ishihara, K. Ariga and Y. Yamauchi, Journal of the 
American Chemical Society, 2012, 134, 10819-10821. 
12. G. B. Sukhorukov, A. L. Rogach, M. Garstka, S. Springer, W. J. 
Parak, A. Muñoz‐Javier, O. Kreft, A. G. Skirtach, A. S. Susha and 
Y. Ramaye, Small, 2007, 3, 944-955. 
13. S. De Koker, R. Hoogenboom and B. G. De Geest, Chemical 
Society Reviews, 2012, 41, 2867-2884. 
14. P. R. Gil, L. Loretta, A. Muñoz_Javier and W. J. Parak, Nano 
Today, 2008, 3, 12-21. 
15. A. P. Johnston, C. Cortez, A. S. Angelatos and F. Caruso, Current 
Opinion in Colloid & Interface Science, 2006, 11, 203-209. 
16. Y. Yan, G. K. Such, A. P. Johnston, H. Lomas and F. Caruso, ACS 
Nano, 2011, 5, 4252-4257. 
17. Z. Tang, Y. Wang, P. Podsiadlo and N. A. Kotov, Advanced 
Materials, 2006, 18, 3203. 
18. L. Loretta, P. Rivera-Gil, A. Z. Abbasi, M. Ochs, C. Ganas, I. Zins, 
C. Sönnichsen and W. J. Parak, Nanoscale, 2010, 2, 458-467. 
Chapter 3 
 
148 
 
19. J. F. Quinn, A. P. Johnston, G. K. Such, A. N. Zelikin and F. 
Caruso, Chemical Society Reviews, 2007, 36, 707-718. 
20. B. G. De Geest, W. Van Camp, F. E. Du Prez, S. C. De Smedt, J. 
Demeester and W. E. Hennink, Chemical Communications, 2008, 
190-192. 
21. V. D. Bock, H. Hiemstra and J. H. Van Maarseveen, European 
Journal of Organic Chemistry, 2006, 2006, 51-68. 
22. P. Kohli and G. Blanchard, Langmuir, 2000, 16, 4655-4661. 
23. P. Kohli and G. Blanchard, Langmuir, 2000, 16, 8518-8524. 
24. T. Serizawa, K. Nanameki, K. Yamamoto and M. Akashi, 
Macromolecules, 2002, 35, 2184-2189. 
25. C. J. Ochs, G. K. Such, B. Städler and F. Caruso, 
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4 Chapter 4 
 
Multilayered silica-biopolymer 
nanocapsules with hydrophobic core and 
hydrophilic tunable shell thickness1 
 
 
 
 
 
  
                                                          
1 This work has been accepted on Nanoscale: R. Vecchione, G. Luciani, V. Calcagno, A. 
Jakhmola, B. Silvestri, D. Guarnieri, V. Belli, A. Costantini, P. A. Netti. “Multilayered silica-
biopolymer nanocapsules with hydrophobic core and hydrophilic tunable shell 
thickness”. The Supplementary Sections are not included in the submitted publication.  
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Abstract. Stable, biocompatible, multifunctional and multicompartment 
nanocapsules are highly wished in the nanomedicine field. Here, we report 
a simple, novel, strategy to design an engineered nanocarrier system 
featuring an oil-core/hybrid polymer/silica-shell. Silica shells with tunable 
thickness are grown in situ, directly around a highly mono-disperse and 
stable oil-in-water emulsion system, stabilized by a double bio-functional 
polyelectrolyte heparin/chitosan layer. Such silica has shown a complete 
degradation in a physiological medium (SBF) in a time frame of three 
days. Moreover, the outer silica shell has been coated with 
polyethylenglycol (PEG), in order to confer antifouling properties to the 
final nanocarrier. The outer silica layer, combines its properties of being-
an optimal bio-interface for bio-conjugations and for the embedding of 
hydrophilic drugs in the porous structure- with the capability to stabilize 
the oil core for confining high payloads of lipophilic tracers (e.g. CdSe 
quantum dots, Nile Red) and drugs. In addition, polymer layers – beside 
conferring stability to the emulsion while building the silica shell - can be 
independently exploited if properly functionalized, as demonstrated by 
conjugating chitosan with fluorescein isothiocyanate. Such features into a 
single nanocarrier system make it very intriguing as a multifunctional 
platform for smart diagnosis and therapy. 
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4.1 Introduction 
A great deal of effort has being spent in searching new materials for the 
development of smart nanocarriers1-3 with high stability, 
biocompatibility,4, 5 biodegradability,5 together with high payloads of 
contrast agents and/or drugs,4-6 selective cell targeting7, 8 and release of 
active compounds at the molecular level.2, 9-13 In this race, inorganic 
systems based on silica have been highlighted as one of the most 
interesting bio-interfaces since they couple interesting properties with a 
reduced toxicity.13, 14 Silica is one of the few inorganic materials 
recognized as ‘safe' by the US FDA. In addition, the endogenous nature of 
silica,15 its functional versatility16 - makes it as one of the most intensively 
investigated among inorganic materials in the field of biotechnology, 
health and medicine both for imaging and delivery.16-19 Indeed, silica shells 
can be porous if synthesized on polymer templates, thus allowing the 
embedding of hydrophilic drugs or tracers.20, 21 Moreover, silica 
permeability can be tuned by tailoring synthesis conditions22 and post 
etching treatment.23 Furthermore, it is biocompatible and easy to 
functionalize to guarantee active targeting, as well as long circulation 
times.13, 24 
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It is widely recognized that, due to molecular complexity of many diseases 
(in particular, cancer, cardiovascular diseases, neurological disorders, 
malaria, and AIDS), smart combination of drugs can better modulate cell-
signaling network and maximize therapeutic effect, reducing drug 
resistance as well as side effects.25 Therefore, developing novel systems 
that could jointly encapsulate two different types (hydrophilic and/or 
hydrophobic) of drugs into a single vehicle is still a major challenge for 
smart drug delivery.26 To this end, a capsule-like configuration with 
different compartments to encapsulate both hydrophilic and hydrophobic 
agents is highly desirable. Furthermore, the presence of a silica gel outside 
layer could act as hydrophilic biocompatible compartment for hydrophilic 
drugs.  
In recent papers in situ synthesis of silica nanocapsules has been described 
using liposome templates.27, 28 Although liposome templates can allow 
good monodispersion and nanometric size distribution, their fragile nature 
makes the coating process very delicate and time consuming. 
Alternatively, emulsion droplets have also been reported as templates for 
the synthesis of oil-core silica capsules.29-33 Nano-emulsions are now 
emerging as intriguing carrier systems for theranostic tests as they give an 
opportunity to embed high payloads of lipophilic compounds in the oil 
phase. However, some major concerns are typically associated to this 
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method such as polydispersion and low stability coming from the use of 
emulsions as templates,34 or the use of toxic materials and high 
temperatures during the synthesis process.29 At the same time, among the 
available procedures to produce multifunctional nanocapsules, layer-by-
layer (LbL) method is one of the most controlled.35 By using LbL 
technique capsules with well-controlled size and shape, finely tuned shell 
thickness and variable shell compositions can be obtained. Furthermore, 
the multilayer structure of the capsules allows achieving 
multifunctionality, through the combination of different properties in one 
system. However, as a major issue, LbL assembly, as a multistep 
procedure, is generally time-consuming which limits its industrial 
applications.36  
Here, we propose a synthetic strategy to obtain oil core- multilayered shell 
nanocapsules. In situ deposition of tunable silica shells was carried out 
directly around a mono-disperse oil in water nano-emulsion system,37-39  
stabilized by polymer layers via LbL, but limiting the deposition to only 
two layers, chitosan and heparin respectively, as shown in Figure 4.1 and 
depositing them in saturation conditions to avoid any purification steps. 
Each step was optimized through physical-chemical characterization of 
reacting mixture, thus allowing to carry out an in-situ procedure. The silica 
shell was prepared by an in situ  short (2-4 h) synthesis process, using a 
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modified Stöber sol-gel method19, 40 which employs 3-Aminopropyl 
triethoxysilane (APTS) as a coupling agent41 to ensure covalent grafting to 
heparin.42 Obtained silica nanocapsules were coated by PEG in order to 
improve their half-life.43  
 
Figure 4.1. Schematic synthesis protocol of silica based nanocarrier system with 
core/shell type morphology. Red dots denote hydrophobic materials which can be safely 
encapsulated inside nanocapsules. 
The synthetic strategy was optimized to easily tune the thickness of the 
shell which represents a hydrophilic compartment for polar compounds as 
demonstrated by embedding sulforhodamine B. On the other side, we 
assessed the embedding of hydrophobic fluorescent compounds such as 
CdSe quantum dots as nanoparticles as well as Nile Red as molecules in 
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the oil core while preserving size and PDI of the final nanocapsules. Silica 
nanostructures were characterized by a variety of analytical and 
spectroscopic techniques like Raman Spectroscopy, Dynamic Light 
Scattering (DLS), Electron microscopy (SEM, TEM), and fluorescence 
microscopy (Confocal and STED). Furthermore, in vitro degradation of 
silica shell was also assessed. Then, they were biologically characterized 
to prove their capability to be internalized and to have no cytotoxicity on 
three different cell lines. 
4.2 Results and discussions 
As shown in Figure 4.1 monodisperse O/W emulsion was chosen as the 
morphology-deciding template to obtain silica nanocapsules. Highly 
monodisperse O/W nano-emulsions with droplet size of around 170 ÷ 190 
nm with polydispersity index (PDI) < 0.1 and ζ-potential ~ -35 ± 8 mV as 
measured by DLS were used. Our main goal was to control the size of the 
silica nanocapsules which should be small enough to pass through the 
human capillaries without any hindrance, coagulation and clogging. In 
fact, the fate of nano-materials for in vivo experiments is closely related to 
their morphology as well as size, which determines different sequestering 
efficiencies.44 
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Starting nano-emulsions respect the requirements of size and 
monodispersion, but emulsions are quite delicate systems when used as 
templates and can readily destabilize during the formulation process itself. 
However, before silica shell deposition emulsions were protected and 
stabilized with polyelectrolyte layers. In particular, a layer of chitosan was 
deposited as a first layer and heparin as a second layer (Figure 4.1). This 
was a sensitive process and required optimization beforehand as any 
excess could result in free chitosan molecules in solution resulting in 
precipitation or aggregation in the following steps. When chitosan and 
heparin are added to O/W emulsion, the deposition takes place very 
quickly (within 15 min); this is mainly due to the strong electrostatic 
interaction between surfactant layer and chitosan, and that between 
heparin and chitosan. The amount of heparin was also carefully optimized 
to prevent any excess of polymer in solution as this could either act as free 
sites of silica nuclei formation and subsequent growth of solid silica 
nanoparticles or could also result in agglomeration during the next 
activation process. The hydrodynamic diameter of the emulsion before and 
after deposition of the bilayer, in one example, was 175 nm (PDI=0.055) 
and 211 nm (PDI=0.083) respectively; these results give a rough idea 
about the thickness of polyelectrolytes layers (below 20 nm) and 
monodispersion feature of the template. The ζ-potential measurements 
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confirmed that the charge of the chitosan and heparin layers were > +30 
mV and < – 40 mV, respectively. Then, heparin was coupled to APTS, so 
that silanol (Si-OH) groups from its hydrolysis act as preferential sites 
for condensation of TEOS,45, 46 thus driving the selective growth of silica 
onto the bilayer, as schematized in Figure 4.1.  
The activation of carboxylates for reaction with amines is commonly 
achieved with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC hydrochloride) and N-hydroxy succinimide (NHS) as 
catalysts in the amidation reaction.47 The O-acylisourea group generated 
via activation by the carbodiimide is converted into the NHS-activated 
carboxylic acid group, which is less susceptible to hydrolysis than the O-
acylisourea and improves conversion. The use of this strategy for the 
modification of heparin has therefore been widely employed.43, 47 Reaction 
conditions (time, temperature) were accurately designed with the support 
of literature48 as well as NMR and UV-Vis analysis. Temperature was kept 
low to avoid undesirable side reactions.  
Furthermore, 1H-NMR spectra of the reacting mixture Figure 4.2a 
showed the presence of ethanol as well as a marked change of the signals 
of hydrogen within ethoxy chains, suggesting that hydrolytic processes of 
APTS are quantitative within 20 min. Moreover, a closer look to NMR 
spectra (Figure 4.2b) evidenced a marked decrease of the characteristic 
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signals of heparin, in the range 3.5-4.5 ppm, that are no longer appreciated 
after 1 h. Since any denaturation/degradation process involving heparin 
can be excluded in the operating conditions for reaction, this disappearance 
must be due to some precipitation phenomena of heparin.  
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Figure 4.2. (a) 1H-NMR spectra of heparin (black line) and of the reacting mixture 
(heparin, EDC, NHS and APTS) at 3 different times. (b) Expanded 1H-NMR spectra 
showing the characteristic heparin signals. Mixture was kept at 4° C. 
As a support to this hypothesis, the reacting mixture containing heparin, 
EDC, APTS and NHS lost transparency after 1 h, as proven by pictures of 
reaction batch (inset in  Figure 4.3) and UV-Vis spectra (Figure 4.3), 
showing a broad absorption increase in the visible region, due to scattering 
phenomena. Therefore, the reaction time was set at 15 min in order to limit 
collateral side reactions involving heparin.  
 
Figure 4.3. UV-Vis spectra of reaction mixture containing heparin, EDC, NHS and APTS 
at different times (blue and red line are overlapped). In the inset, the reaction batch just 
mixed and after 1 hour are compared, thus showing the appearance of opalescence in the 
solution. 
In order to confirm the key role played by APTS in the nucleation of silica 
shell, systems where the heparin layer was not conjugated to APTS before 
Chapter 4 
 
162 
 
silica synthesis were also produced as a control experiment. Confocal 
micrographs of these samples show only large irregular fluorescence 
patches (Figure 4.4 a). The images also display non fluorescent nanosized 
objects in the bright field STED camera (Figure 4.4 b), which can be 
simple silica nanoparticles without any oil core as evidenced by the no 
matching between the two images (Figure 4.4 c).  
 
Figure 4.4. Confocal analysis of nanocapsules stained with Nile Red in the oil core: in 
fluorescence analysis (a), in bright field (b); matching of the two images. 
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Figure 4.5. Size dependence as a function of seeded growth time. Inset: ζ-potential 
measurements during the synthesis steps. 
Therefore, these control experiments further proved that the coupling 
reaction between heparin and APTS is strictly required to have silica shell 
grown on the template. The size of silica nanocapsules obtained from the 
seeded growth was measured through DLS and reported as a function of 
seeded growth time in Figure 4.5.  
Table 4.1. DLS data of silica nanocapsules collected at different reaction time intervals. 
Time 
(min) 
Size 1 
(nm) 
PDI 
Size 2 
(nm) 
PDI 
Size 3 
(nm) 
PDI 
7,5 153,3 0,042 152,3 0,036 153,9 0,031 
15 165,1 0,028 161,2 0,015 161,9 0,057 
30 175,4 0,019 172,2 0,017 173,0 0,045 
45 182,3 0,044 181,0 0,018 176,9 0,042 
60 187,8 0,043 186,9 0,037 185,5 0,035 
90 198,7 0,036 199,1 0,022 195,9 0,055 
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120 198,4 0,060 203,6 0,050 203,9 0,030 
150 203,8 0,054 209,4 0,036 204,5 0,054 
180 205,7 0,045 209,8 0,044 209,8 0,057 
 
The results (Table 4.1) displayed a peculiar trend, a sharp increase in the 
hydrodynamic diameter was noticed for the first 60 min; thereafter, the 
process slowed down and after 3 h of reaction no further changes were 
noticed. The PDI was found to be  0.06 in all the cases. Samples collected 
at 1 and 3 h of seeded growth were submitted to Electron microscopy 
(FESEM, TEM) for morphological analysis. Samples collected at shorter 
times (1 h of seeded growth) had very thin silica shell and therefore not 
enough mechanical strength to sustain the low pressure inside the scanning 
electron microscope; as a matter of fact, they rapidly collapsed due to 
vacuum inside the microscopes Errore. L'origine riferimento non è 
stata trovata. a.  
 
Figure 4.6. SEM micrographs (a) of silica nanocapsules after 1 h of seeded growth; TEM 
tomography of a single silica nanocapsule after 1h (scale bar 500 nm) (b) and 3h (scale 
bar 200 nm) (c) of seeded growth 
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On the contrary, as shown in SEM micrograph of silica nanocapsules after 
3 h of seeded growth (Errore. L'origine riferimento non è stata trovata. 
b), a continuous shell formed around the bilayer. Narrow size distribution 
can also be appreciated from the SEM micrograph in agreement with DLS 
results (Table 4.1). Energy dispersive X-Ray (EDX) spectra of 
nanocapsules (Errore. L'origine riferimento non è stata trovata. c) 
show presence of elements like carbon, oxygen of oil and bilayer together 
with silicon, thus confirming the formation of a silica shell. The presence 
of small amounts of nitrogen and sulfur in the EDX measurements further 
confirms the presence inside the nanocapsule of chitosan and heparin 
polyelectrolyte layer. Figure 4.7 shows TEM images on samples with 
different shell thickness collected after 1 h (Figure 4.7 a) and 3 h (Figure 
4.7 b) of seeded growth.  
 
Figure 4.7. TEM micrographs of silica nanocapsules after 1 h (a) and 3 h (b) of seeded 
growth time. 
Chapter 4 
 
166 
 
As seen, samples with just 1 h of reaction (a) had thin and continuous 
shells with a thickness of around 20 nm; particles after 3 h of reaction (b) 
possessed a thicker continuous shell of about 45 nm, which sustained 
spherical morphology and did not collapse even under high vacuum or 
high voltage of the electron beam indicating enhanced mechanical 
strength. Evaluation of silicon amount, obtained deriving the amount of 
silica gel from the shell thickness after 1 h and 3 h of seeded growth and 
comparing the values with the starting TEOS amount, allowed to estimate 
a yield around 36 and 82 %, respectively. 
To further confirm the spherical structure and core-shell morphology of 
silica nanocapsules, experiments were also performed using TEM 
tomography, which is a reconstruction from a series of tilted two-
dimensional TEM images. For this experiment a single isolated particle 
was chosen in the grid and tomography was carefully carried out to obtain 
a detailed 3D structure of the silica nanocapsules with thick stable shells 
able to withstand low pressure inside TEM.  
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Figure 4.8. TEM tomography of a single silica nanocapsule after 1h (scale bar 500 nm) 
(a) and 3h (scale bar 200 nm) (b) of seeded growth. (Click on the black strip to play the 
videos). 
 
Tomography analysis provided important results regarding the mechanical 
strength of shell. After 1 h seeded growth the shell was around 20 nm and 
its mechanical strength was not strong enough to hold the spherical size at 
low pressure environment inside the microscope. Particles therefore 
appeared as flattened discs when rotated between ±50° (Figure 4.8 a). The 
shell of the samples after 3 h of seeded growth was thicker and was strong 
enough to hold its spherical shape (Figure 4.8 b). The relatively smooth 
surface texture of the silica shell, as observed with SEM and TEM, 
provides valuable insight of the formation mechanism of the silica shell, 
and it strongly suggests that the silica growth is initiated by an in situ direct 
deposition mechanism effectively coating organic scaffolds with an 
inorganic layer. The SEM images also ruled out any grown seed in solution 
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deposited on the template afterwards, as seen in the case of silica 
colloidosomes.49 
In order to confirm nano-confinement of solid hydrophobic materials in 
the oil core, we performed characterization with fluorescence microscopy. 
For this analysis, two different sets of experiments were designed. The first 
was carried out with hydrophobic CdSe quantum dots (~3.5 nm, 
Hexyldecylamine used as capping agent) chosen in view of their high 
fluorescence; they were easily tracked by super resolution fluorescence 
microscopy to demonstrate the effective nano-confinement combined with 
no change in dimensional features. Figure 4.9a shows a STED image 
where the green pseudo color corresponds to the nanocapsules with 
entrapped CdSe quantum dots in the core. This experiment proved the 
nano-confinement capability of these capsules, where in place of CdSe 
also other types or nanoparticles, such as gold or iron oxide  (which can 
make these capsules suitable for X-ray or MRI imaging, depending on the 
applications) may be used. 
In the second experiment we used two different dyes; one, Nile Red, to tag 
the oil and FITC to tag the chitosan layer, as detailed in the experimental 
section. Fluorescent nanocapsules were irradiated with two different lasers 
to excite the dyes separately. Figure 4.9b displays emission of FITC dye 
(500 – 600 nm) excited with laser of frequency 488 nm while Errore. 
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L'origine riferimento non è stata trovata. c corresponds to emission of Nile 
Red (530 – 718 nm) excited with laser of frequency 543 nm always in 
confocal modality. Figure 4.9d corresponds to the overlay of two images. 
As can be seen there is a good match between the two colors, indicating 
the co-localization of the two chromophores therefore the core shell 
structure.  
 
 
Figure 4.9. STED image of nanocarriers with oil confining QDs (a); nanocarriers stained 
with FITC labeling the first polymer layer (b); Nile Red nanoconfined in the oil phase (c) 
and matching of the two colors (d). Scale bar is 2 µm. 
These results suggest effective Nile Red nano-confinement and no 
variation of nanoparticle size. Both these experiments confirmed that these 
nanocapsules can act as efficient nanocarriers for various foreign 
materials, such as contrasting agents of nanometric size or lipophilic drugs. 
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The size calculated with STED micrograph in the case of nanocapsules 
containing CdSe quantum dots was nearly identical to the one seen in SEM 
or TEM.  
In order to assess biodegradation of the silica nanocapsules, the 1 h and 3 
h samples were exposed to SBF at constant temperature of 37 °C and 
stirring rate of 200 rpm. Free silicic acid was monitored by colorimetric 
assay as described in Materials and Methods section to follow the 
biodegradation; at the same way the complete dissolution was evaluated 
by adding to the samples a solution of NaOH 5M. In Figure 4.10 the 
absorbance measured from the colorimetric assay for the two samples was 
plotted over time. Complete degradation, indicated by the straight lines 
reported in the graph, happened in both cases within three days even 
though 3 h sample shows a higher plateau, due to higher silica content, as 
expected by the thicker shell. Evaluation of silicon amount, obtained 
deriving the amount of silica gel from the shell thickness after 1h and 3h 
of seeded growth and comparing the values with the starting TEOS 
amount, allowed to estimate a yield around 36 % and 82, respectively.  
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Figure 4.10. Degradation trend of silica shell by colorimetric assay for 1 h and 3 h 
samples. 
Despite the different thickness a similar degradation rate was observed, 
thus suggesting the porous structure of the silica. Indeed, solution can enter 
the whole silica shell promoting in this way its complete degradation in 
the same time frame. Therefore, nanocarrier has enough time to 
accumulate in the target tissue before complete degradation of silica which 
in the meanwhile exerts a protection action of the inner nano-emulsion and 
its cargo. At the same time silica shell can also act as a biodegradable 
hydrophilic compartment. As an example of hydrophilic encapsulation 
sulforhodamine was loaded into the silica shell, as described in the 
Materials and Methods section. To demonstrate the effective encapsulation 
of the silica shell, chitosan was labelled with FITC so a co-localization test 
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by confocal microscopy between the two colors (FITC and rhodamine) 
was performed and a perfect match was found, Figure 4.11.  
 
Figure 4.11. Confocal image of silica nanocapsules by exciting sulforhodamine B in the 
shell (a) and FITC on the chitosan (b) and the overlapped image of a and b (c). Scale bar 
2.5 µm.  
A further proof of the porous structure of the silica shell was provided by 
carrying out an external sink release experiment where capsules of 
different thickness were put in contact under stirring with an organic 
solvent (hexane). The thinner the shell the higher the release of the 
hydrophobic oil core over time as shown in the Figure 4.12. 
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Figure 4.12. UV absorbance of soybean oil released from nanocapsules at different silica 
shell thickness (corresponding to 30, 60 and 180 min of seeded growth time) over stirring 
time in the mixture with hexane. 
PEGylation of silica nanoparticles 
Although the negative surface charge, due to deprotonated silanol groups 
at neutral pH, provides extra colloidal stability to the nanocapsules, it also 
limits their efficacy due to increased interaction with blood proteins which 
can result in rapid capture and removal by reticuloendothelial system.13, 44 
The negative charge can also result in aggregation in highly ionic 
biological media. To potentially reduce these obstacles, we coated the 
surface of nanocapsules with PEG (MW 5000) (experimental section). 
PEG concentration within solution was set at a value (0.220 M) that, 
according to previous studies,43 allowed long term stability of silica sols, 
without any aggregation phenomena due to interlocking of polymeric 
chains.43 
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The non-PEGylated samples could be easily precipitated at 6000 RPM in 
centrifuge, while the PEGylated ones were stable and it was not possible 
to precipitate them even at 14000 RPM.  
In order to confirm PEGylation - as well as composition of the 
nanocapsules - Raman analysis was carried out on bare and PEGylated 
silica nanocapsules after dialysis. The spectra were normalized locally and 
reported, together with Raman spectra of pure PEG in Figure 4.13 for ease 
of comparison.  
 
Figure 4.13. Raman spectra of nanocarriers with PEG, with no PEG and of pure PEG. 
The presence of all the typical Raman bands observed for silica can be 
noticed.50 In fact, stretching peaks centered at 800 cm-1, 1060 cm-1 and 
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1200 cm-1 are attributed to amorphous silica. PEG was also modified with 
FA (adsorption and emission spectra are reported in Figure 4.15) and 
deposited according to the same procedure on the silica shell. Its 
permanence on the shell after dialysis was then confirmed by 
spectrofluorimetry (Figure 4.16) and confocal analysis (Figure 4.14). 
 
 
Figure 4.15. Excitation (black curve) and emission (blue curve) spectrum for FA 
modified PEG5000-COOH. 
Figure 4.14. Confocal image of silica nanocapsules by exciting Nile Red in the oil core (a) 
and PEG-FA on the shell (b) and the overlapped image of a and b (c). Scale bar 2.5 µm. 
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Figure 4.16. Emission spectra of silica nanocapsules coated with FA-labeled PEG5000-
COOH after dialysis. 
 
Cytotoxicity and cellular uptake 
We performed preliminary biological tests on three different cell lines, 
namely bEnd.3, HeLa and U87-MG cells, as models of endothelium and 
tumor tissues, in order to evaluate the biocompatibility of the 
nanocapsules. In particular, uptake and cytotoxicity of the PEGylated and 
non-PEGylated nanocapsules were investigated. As shown in Figure 4.17, 
Figure 4.18 and Figure 4.19, both PEG and no-PEG nanocapsules entered 
cells after 2, 4 and 24 h exposure.  
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Figure 4.17. Confocal images of bEnd.3 (a and b), HeLa (c and d) and U87 (e and f) cells 
incubated with FITC-doped nanocapsules and PEGylated nanocapsules at the final 
concentration of 14.2 µg/ml for 2 hours at 37 °C. 
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Figure 4.18. Confocal images of bEnd.3 (a and b), HeLa (c and d) and U87 (e and f) cells 
incubated with FITC-doped nanocapsules and PEGylated nanocapsules at the final 
concentration of 14.2 µg/ml for 4 hours at 37 °C. 
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Figure 4.19. Confocal images of bEnd.3 (a and b), HeLa (c and d) and U87 (e and f) cells 
incubated with FITC-doped nanocapsules and PEGylated nanocapsules at the final 
concentration of 14.2 µg/ml for 24 hours at 37 °C. 
In all cases, the intracellular distribution of the nanocapsules appeared as 
small aggregates mainly localized in the perinuclear region. As previously 
demonstrated, silica nanoparticles enter cells mainly through 
endocytosis.51 In our case, the spot-like intracellular distribution might 
suggest an endocytic mechanism of internalization and the confinement of 
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the nanocapsules within vesicular structures. Further investigations are 
necessary to better elucidate this issue. In addition, Alamar Blue assay was 
performed in order to verify the effect of NCs on cell metabolism and 
viability. Results, shown in Figure 4.20, indicate no cytotoxic effect for 
PEGylated and non-PEGylated nanocapsules after 24 and 48 h incubation 
for all cell lines at any used concentration. Only a very slight reduction of 
cell viability was observed for U87-MG cells at the higher concentration 
(14.2 µg/ml) of PEGylated nanocapsules.  
 
Figure 4.20. Cell viability of bEnd.3 (a), HeLa (b) and U87 (c) cells at 24 hours after the 
exposure to increasing doses of both PEGylated and non-PEGylated nanocapsules 
evaluated by the Alamar Blue assay. Viability of nanocapsule-treated cells is normalized 
to non-treated control cells. Error bars indicate the standard deviation. 
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Taken altogether, these data demonstrate the capability of these 
nanocapsules to enter the cells and not to affect cell viability. These 
findings were in agreement with others reported in literature indicating no 
significant effects on cell viability of silica nanoparticles with a diameter 
smaller than 200 nm on primary human endothelial cells.52 Although 
preliminary, these promising results suggest that these nanocapsules could 
be used as safe nanosystems for biomedical applications. 
4.3 Conclusions 
One intriguing route for in vivo imaging, as well as drug delivery, is the 
use of core shell type structures that effectively allow confinement or 
protection of both tracers and/or drugs in the inner core. In the present 
work, oil core silica shell nanocapsules with narrow size distribution have 
been successfully prepared at room temperature. The synthetic strategy is 
based on a multistep process involving encapsulation of oil nanodroplets 
within a bilayer of chitosan and heparin followed by in situ synthesis of 
silica by using TEOS as a precursor. APTS has been chemically coupled 
to heparin, allowing condensation reaction of TEOS and therefore 
formation of silica just around oil droplets. Silica nanocapsules keep a 
narrow size distribution and average size of about 200 nm. We 
demonstrated the capability to effectively pre-load lipophilic molecules 
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(Nile Red) as a model drug, as well as inorganic nanoparticles (e.g., CdSe), 
as a contrasting agent model, with no variation in the expected size. At the 
same time, hydrophilic molecules could also be loaded in the silica shell. 
These nanocapsules can be completely degraded in SBF at 37 C under 
stirring in a time frame (3 days) compatible with drug delivery 
applications. Moreover, conjugation of chitosan to optical active 
molecules (FITC) proves the multifunctional behavior of nanocapsules. In 
addition, they were effectively conjugated with PEG for possible in vivo 
applications; cytotoxicity tests validated possible use of these systems both 
in the PEGylated and non-PEGylated form. Therefore, this is an 
innovative, low cost, effective and green way to produce new nanocarriers 
to be used in nanomedicine. 
4.4 Materials and Methods 
Materials 
Soy-bean oil (density at 20 °C of 0.922 g/ml), and Lipoid E80 Lecithin 
(egg lecithin powder 80-85% enriched with Phosphatidyl choline (PC) and 
7-9.5% content in phosphatidyl ethanolamine (PE) as per the 
manufacturer’s specifications), were both purchased from Lipoid and used 
without further purification. Chitosan (CT, LMW 90-150 kDa, DDA 84% 
determined via 1H-NMR, pKa6.7)53 was purchased by Sigma Aldrich. 
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Heparin (Heparin sodium salt from porcine intestinal mucosa, 17-19 
KDa),54 poly(ethylene glycol) methyl ether (PEG, average Mn=5,000), 
methoxypolyethylene glycol 5,000 acetic acid (PEG5000-COOH, average 
Mn=5,000), N-(3-dimethylaminopropyl)-N’-ethyl-carbodiimide 
hydrochloride, (EDC, protein seq. grade), N-hydroxy succinimide (NHS, 
98 %), 3-(aminopropyl)triethoxysilane (APTS), tetra ethyl orthosilicate 
metal basis (TEOS, 99.999 %), ammonium hydroxide (NH3, Lsg acs reagt 
28-30 %), acetic acid ( 99.7 %), 2-propanol, Lumidot™ CdSe 560 core-
type quantum dots, (5 mg/ml in toluene), Nile Red (MW=318.37), 
sulforhodamine B sodium salt (MW=580.65), fluorescein isothiocyanate 
(FITC, MW=389.38) and Fluoresceinamine (FA, MW=347.32) were also 
purchased from Sigma Aldrich and used as such without any further 
purification. Dialysis tubing (RC, 25 kDa and 3.5 kDa MWCO) were 
purchased from Spectrum Laboratories Inc and used after being washed 
with water. For the colorimetric test to analyze silica degradation, 
ammonium molybdate tetrahydrate, oxalix acid, 4-(methylamino)phenol 
hemisulfate salt, sodium sulphite hydrochloric acid 37%, sulforic acid 
were purchased from Sigma Aldrich. 
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Nanocarrier Synthesis 
Nano-emulsions were prepared through a three-step process; this was 
necessary to maintain stability and size distribution of oil droplets as 
narrow as possible. The initial step involved the preparation of 
homogenous oil phase by simply adding a certain amount of surfactant 
(Lipoid E 80, Lecithin (1.2g)) to a predetermined volume of soy-bean oil 
(20 ml) at 60 °C followed by sonication for a few min to homogenize and 
mix. In the second step, a pre-emulsion was prepared by a step-by-step 
addition of the as-prepared oil phase to a weighted amount of aqueous 
phase (Milli-Q water) so as to obtain a final concentration of 10 wt% in 
the oil phase. The mixture was thoroughly mixed through the immersion 
sonicator for a few minutes in a beaker. A low temperature was maintained 
throughout the process by keeping this assembly inside a larger beaker 
containing ice in form of a continuous ice jacket. Finally, in the third step, 
the pre-emulsions were passed at 1000 bar through a high-pressure 
homogenizer (Microfluidics M110PS) with a combination of individual 
cycles and continuous steps until a minimum size and PDI was reached.  
After emulsion preparation, chitosan monolayer was deposited at a final 
concentration of 0.01% wt (at pH=4) whereas oil concentration was 1% 
wt. Bilayer emulsion was prepared by mixing 4 ml of monolayer to 2.5 ml 
of heparin solution (0.044% wt) in water. After the formation of the 
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bilayer, heparin carboxyl (–COOH) groups, were coupled to amino groups 
of APTS molecules, through EDS/NHS chemistry.42 In detail, first 50 µl 
of EDC (6.42 mM) and NHS (74.8 m M) solution in water and then 50 µl 
of APTS solution (15.0 mM) in 2-propanol were added to 1 ml of bilayer 
emulsion under continuous stirring. Reaction was allowed to proceed 
under stirring for 15 min at 4 °C in an ice bath.   
Then, reaction mixture was removed from ice bath and silica shell 
synthesis was initiated at room temperature using a modified Stober 
method. In summary, we deposited silica via a two-step process. In the 
first step, the pH of dispersion was adjusted to 10.0 by adding 2.31 ml of 
NH3 solution in 2-propanol (0.119 M in NH3) followed by slow drop-wise 
addition of 2.31 ml of TEOS solution (in 2-propanol (0.0268 M). Synthesis 
parameters were defined so as to have a 10 nm thick shell, in the former 
step. Moreover,  alkoxide TEOS/APTS molar ratio was kept at 82.5 so as 
to avoid any aggregation phenomena.55 Stirring was continued for another 
1 h at room temperature after which seeded growth was carried out (second 
step). To this purpose, the dispersion was mixed with equal volumes of 
Milli-Q water and subjected to further stirring for variable timings, ranging 
from 5 min to 3 h. The second step was necessary for tuning shell thickness 
and making it suitable for specific applications. To carry out PEGylation 
of the nanocapsules, equal volumes of an aqueous PEG solution 0.220 M, 
Chapter 4 
 
186 
 
were added to the nanocapsule dispersion during the second step (1:2 
dilution), thus obtaining a PEG grafting by means of a transesterification 
reaction.43 Aliquots collected at different times were then dialyzed 
overnight against Milli-Q water to remove any unreacted reactants and 
solvents or physically adsorbed species (PEG). To exclude any presence 
of i-propanol residue we heated the aqueous colloidal sample in rotavapor 
at 50 °C for half an hour and then corrected the reduced volume by addition 
of fresh Milli-Q water. Thanks to the narrow size distribution of the silica 
nanocapsules prepared with this method, there was no need to filter it to 
remove aggregates. These particles had a shelf life of at least 2 months. As 
a control experiment, synthesis of silica was also carried according to the 
procedure detailed before, but leaving out the conjugation step of heparin 
to APTS.  
Oil was also stained both with Nile Red, a lipophilic molecule (0.06 mg/ml 
of oil) used as a model drug, and with hydrophobic CdSe quantum dots 
(0.2 mg/ml of oil) used as a contrasting agent. In the former case emulsion 
was also coated with chitosan conjugated with fluorescein isothiocyanate 
(FITC), in order to show multifunctional behavior such as loading of core 
and shell for a possible theranostic approach. Silica shell preparation was 
completed by using the usual procedure as already described. 
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To obtain FITC modified chitosan, 500 mg of purified and dried chitosan 
were dissolved in 50 ml of aqueous acetic acid solution (0.10 M). After 
complete dissolution, 50 ml of methanol were added. Then 25 mL of a 1 
mg/ml solution of FITC (fluorescein isothiocyanate) in anhydrous 
methanol was prepared. This solution was slowly added to chitosan 
solution and the reaction was allowed to proceed in the dark under 
magnetic stirring for 18 h at room temperature. Finally, chitosan was 
precipitated with a solution of NaOH and the precipitate was collected by 
centrifugation (9000 rpm; 4 °C; 15 min). The obtained FITC-chitosan was 
dispersed in Milli-Q water, washed and centrifuged 6 times until pH had a 
neutral value and no traces of FITC were visible in the waste washing 
solutions.  
In one case, 3 h silica nanocapsules containing FITC modified chitosan 
were exposed to sulforhodamine B at a final concentration of 0.001 % w/v 
of such molecule (10 mg/l, 17.2 µmol/L) and 0,055 % w/v of 
nanocapsules. Then the sample was dialyzed with distilled water. 
External sink release method 
Silica nanocapsules (2 ml) were collected during silica deposition process 
(30, 60, 180 min of seeded growth time) to get different shell diameters 
and placed in vials. In each of the vials 2 ml hexane was added and the 
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samples were stirred vigorously at 1500 rpm. After predetermined times 
hexane layer was collected and analyzed by UV-vis spectroscopy for the 
absorbance of soybean oil between 200-300 nm and then replaced back. 
With the growth of silica shell the release of soybean oil diminished and 
in case of thick silica shell (after 180 min of seeded growth time) only a 
slight increase in absorbance was observed with time even after 8 h of 
rigorous stirring. 
Spectrofluorimetry Analysis and Confocal imaging of PEGylated 
nanocapsules 
To confirm that shell PEGylation occur an experiment was performed 
using PEG modified with FA. Briefly, PEG5000-COOH 
(Methoxypolyethylene glycol 5000 acetic acid, 90.0 mg) and NHS (12.0 
mg) were dissolved in 2.50 ml of MilliQ water. After 10 minutes EDC 
(10.0 mg) was added. In the meantime, 7.0 mg of 6-Aminofluorescein 
were dissolved in 100 µl of DMSO. After 30 minutes the fluorescein 
solution was added dropwise to the PEG5000-COOH solution. pH was 
corrected to 6.7 adding NaOH 1 M. After 24 h the solution was dialyzed 
(dialysis tubing RCE, 3.5 kDa MWCO) against Milli Q water to remove 
solvent and unreacted reactants and freeze dried. An absorbance spectrum 
was recorded in order to select the correct excitation wavelength (480 nm) 
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and, then, the emission spectrum was recorded between 500 and 600 nm 
using an excitation wavelength of 480 nm and a flashes number of 1000 
(Figure 4.15).  
The so obtained PEG-FA was used instead of PEG to mark the sample, 
using the same procedure proposed. The marked sample was dialyzed 
(Dialysis tubing, RC, 25 kDa MWCO) against water to remove the excess 
of PEG-FA and dialysis was monitored recording the fluorescent emission 
of fluorescein in the washing water (EnSpire Multimode Plate Reader 
2300-0000, Perkin Elmer). 10 µl of NaOH solution 1 M were added to 300 
µl of water and loaded in a multi-well (3 replicates for each sample were 
prepared) and irradiated with a light source at 480 nm. Dialysis is kept 
until no significant emission is recorded in the water, also after sonication 
of the sample. Moreover, to show that PEG-FA is still present on the 
sample and, in particular on the shell, an emission spectrum of sample was 
recorded (10 µl of sample were added to 10 µl of NaOH solution 1 M and 
dilute to 300 µl, Figure 4.16) together with a confocal images of silica 
nanocapsules with Nile Red in the core and PEG-FA on the shell surface 
(Figure 4.14). 
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DLS and ζ-Potential characterization 
Size distribution and ζ-potential were measured by Zetasizer (Nanoseries, 
Malvern) using laser dynamic scattering (λ = 632.8 nm) and particle 
electrophoresis techniques, respectively. All the samples were diluted up 
to a droplet concentration of approximately 0.025% wt, by using acetic 
acid Milli-Q water solution (pH 4, 0.2M) in the case of chitosan coated 
emulsions and bare Milli-Q water in the case of primary emulsions, bilayer 
and oil core silica shell nanocapsules. A detecting angle of 173°, a default 
refractive index ratio of 1.52 and 5 runs for each measurement (1 run 
lasting 100 s) were used in the calculations of the particle size distribution. 
In the case of ζ-potential, analyses were carried out by setting 50 runs for 
each measurement. 
Electron Microscopy 
For TEM analysis about 10 µl of the sample was spread on a copper grid 
(200 mesh with carbon membrane). After removing carefully the excess of 
solution grids were left to dry overnight. Contrast for transmission electron 
microscopy (TEM) was also achieved by exposing the samples to vapors 
of OsO4 water solution (1% wt) as oil core dopant for not less than 4 h. 
TEM images were obtained using a TECNAI 20 G2: FEI COMPANY 
(CRYO-TEM-TOMOGRAPHY, Eindhoven) with a camera Eagle 2HS. 
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The images were acquired at 200 KV; camera exposure time: 1 s; size 2048 
x 2048. For SEM and EDX measurements a small drop of solution 
containing silica nanocapsules was spread onto the surface of an aluminum 
stub covered by a carbon tape or a glass plate. The sample was then sputter-
coated with a thin Pt/Pd or gold layer (10 nm) in a Cressington sputter 
coater 208HR. The aluminum stub containing the Pt/Pd or gold -coated 
sample was then placed in a FEG-SEM scanning electron microscope and 
imaged using 20 kV accelerating voltage. 
Confocal and STED Analysis 
A FC3510 dish was first washed with ethanol and dried. Then a water 
solution of poly-L-lysine (0.1 % wt) was added in order to have the dish 
surface positively charged. After 10 min the dish was washed twice with 
water and 150 μl of sample (diluted 1:20 with water) were poured onto it. 
The solution was washed out with water after 30 min and the dish was left 
full of water during sample observation. Laser sources of 488 and 543 nm 
were used to excite samples with CdSe QDs and chitosan-FITC from one 
side and Nile Red and sulforhodamine B from the other side. Samples were 
imaged with Leica TCS STED-CW microscope (Leica-Microsystems, 
Mannheim, Germany). Thanks to the use of QDs and FITC, it was possible 
to work in STED modality with super-resolution down to 100 nm in order 
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to resolve the real size of the samples. For each sample, the images were 
acquired with a field of view of 25.6 x 25.6 μm for a pixel size of 25 x 25 
nm with line average between 8 and 16. The STED-CW beam power was 
430 mW, measured at objective back focal plane. The analysis of the 
images was carried out by LAS AF software. 
Colorimetric test for silica degradation analysis 
The degradation experiments in vitro were carried out by soaking a dialysis 
membrane containing a fixed volume (3 ml) of each sample into 30 ml of 
SBF at constant temperature of 37 °C and stirring rate of 200 rpm. Exactly 
300 µl of SBF were collected each time and replaced by an equal volume 
of fresh SBF. Sample solutions were monitored for free silicic acid, 
Si(OH)4, using the blue silicomolybdic acid (SMA) spectrophotometric 
method.56 Briefly, 150 µl of solution A (2% w/v ammonium molybdate 
tetrahydrate, 6% v/v of concentrated hydrochloric acid) are added to 300 
µl of the unknown concentration of silicic acid solution. After 10 min, 750 
µl of solution B (2% w/v oxalic acid, 0.667% w/v 4-methylaminophenol 
sulphate, 0.4% anhydrous sodium sulfite, 10% v/v concentrated sulphuric 
acid) are added to the assay solution. The blue colour is left to develop 
over 2 h at room temperature before measuring the absorbance at λ = 810 
nm. For the total amount of silicon, 10 µl of NaOH 5M were added to the 
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sample 10 min before adding solution A to allow the complete dissolution 
of silica shell. 
Raman Spectroscopy 
Raman analysis was performed on Thermo Scientific DXR Raman 
microscope with point and shoot Raman microscopy equipped with 532 
nm, 633 nm, and 780 nm laser. The 632.8 nm radiation from a 17 mW air 
–cooled He/Ne laser was used as excitation source. The acquisition time 
was 90 s. Experiments were performed by placing drops of sample on 
aluminum foil and drying them at room temperature. The spectra were 
recorded in range of 0÷3500 cm-1, within 3-5 min. 
Cell culture 
Immortalized mouse cerebral endothelial bEnd.3 cells (American Type 
Culture Collection, Manassas, VA) were grown in DMEM with 4.5 g/l 
glucose, 10 % Fetal Bovine Serum (FBS), 3.7 g/l sodium bicarbonate, and 
4 mM glutamine, 1% non-essential amino acids, 100 U/ml penicillin and 
0.1 mg/ml streptomycin. Human cervix adenocarcinoma HeLa cells 
(American Type Culture Collection, Manassas, VA) were cultured in 
DMEM with 4.5 g/l glucose, 10 % FBS, and 4 mM glutamine, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin. Human glioma U87-MG cell line 
(American Type Culture Collection, Manassas, VA) was grown in Eagle's 
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Minimum Essential Medium (EMEM), 10 % FBS, and 4 mM glutamine, 
100 U/ml penicillin and 0.1 mg/ml streptomycin. All cell lines were 
cultured in 100 mm diameter cell culture dish, in a humidified atmosphere 
at 37 °C and 5% CO2. 
Confocal microscopy for nanoparticle uptake 
Cells were incubated with FITC-doped nanocapsules with and without 
PEG at the final concentration of 14.2 µg/ml for 2, 4 and 24 h at 37 °C in 
5% CO2. After each time, samples were washed two times with PBS to 
remove non internalized NPs and fixed with 4% paraformaldehyde for 20 
min. Then, cell nuclei were stained with DAPI (Sigma-Aldrich). Samples 
were observed by confocal and multiphoton microscope system (Leica 
TCS SP5 MP) equipped with oil-immersion 40× and 63× objective. 
Images were acquired with a resolution of 1024×1024 pixels. 
Cytotoxicity tests 
Cells were seeded in 96-well microplates (Costar) at a density of 8 × 103 
cells/well at a final volume of 100 µl and incubated for 24 and 48 h in a 
humidified atmosphere at 37 °C and 5% CO2 to obtain a subconfluent 
monolayer. Cells were treated with nanocapsules at concentrations of 14.2, 
2.8 and 1.4 µg/ml in a final volume of 150 µl for each well. The metabolic 
activity of all cell cultures was determined after 24 h of exposure by using 
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standard Alamar Blue assay (Invitrogen). Briefly, after incubation time, 
cells were washed with PBS and 150 µl of Dulbecco’s modified Eagle’s 
medium without phenol red (Gibco), containing 10% Alamar Blue reagent, 
were added to each well and samples were incubated for 4 h at 37 °C. The 
solution was subsequently collected from the wells and analyzed with a 
spectrophotometer (Perkin Elmer) at wavelengths of 570 and 600 nm. 
Statistical analyses of significance were performed by using ANOVA test. 
p values equal or less than 0.05 were considered statistically significant. 
Experiments were repeated three times in triplicates. 
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4.5 Supplementary Section 
Realization of silica nanocapsules with reduced size 
As mentioned in the Chapter 1, one of the main advantages of the LbL 
technique is the high versatility and, in particular, the possibility to obtain 
a final nanosystem with the desired size by starting from a template with 
appropriate dimensions.36 In this case, by reducing the size of the starting 
O/W nanoemulsion it is hypothetically possible to realize a nanocapsules 
with a final size further reduced. Indeed, the O/W nanoemulsion used in 
the typical procedure had a starting size of 175 nm (PDI < 0.1), but we 
realized O/W nanoemulsion with smaller droplet dimensions, up to 80 
nm.38 However, the transition of the whole synthetic procedure to a system 
with reduced size is not so obvious. The main difficulty is related to the 
realization of the polymeric bilayer (chitosan and heparin) with the same 
concentration, in order to maintain the relative quantities of the reactants 
unchanged. In addition, it is important that the system remain stable during 
the synthesis steps, in particular when i-propanol is added and pH is raised 
to 10.  
Starting from these considerations, a bilayer was built up using the LbL 
technique and a silica shell was realized starting from it. Dimensional and 
Z-Potential data are reported in Table 4.2. DLS analysis confirms that, 
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even starting from a bilayer system with sizes and PDIs not exactly 
suitable, it is possible to obtain a final silica-nanocapsules with good 
monodispersity. Moreover, as also suggested from the reduction of the size 
in the beginning of the seeded growth, it is possible that during this 
synthesis step a disaggregation of droplets.    
Table 4.2. Size, PDI and Z-Potential data related to the realization of the bilayer and 
Silica-NCs at different reaction time.  
 Size PDI Z-Potential 
O/W nanoemulsion 114.8 0.107 - 24.8  
Monolayer 118.3 0.169 + 16.0 
Bilayer 145.4 0.190 - 16.9 
Silica NCs (15 min) 114.7 0.044 - 35.8 
Silica NCs (60 min) 126.8 0.057 - 32.5 
Silica NCs (120 min) 129.8 0.088 - 32.3 
Silica NCs (180 min) 129.4 0.068 - 32.5 
Silica NCs (over night) 228.5 0.099 - 31.6 
 
Focusing on the seeded growth, by comparing the seeded growth time for 
the systems with different initial O/W nanoemulsion (Figure 4.21), it is 
appreciable that the reduction of the size effects on the kinetic: seeded 
growth results slowed if the starting size is smaller, even if NCs keep on 
growing till to double the size if reaction go on overnight (Table 4.2). 
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Figure 4.21. Comparison of the seeded growth time of the system realized on bigger sized 
O/W nanoemulsion (blue line) and on the smaller one (red line).  
These smaller nanoparticles were further characterized using Electron 
Microscopy (samples have been stained with OsO4 vapors, Figure 4.23) 
and NanoSight (NTA, Nanoparticle Tracking Analysis) measurements, 
whose results are summarized as follow (see also Figure 4.23): 
Concentration (particle/ml) 6.07 E+08 ± 3.82 E+07 
Mean size 134.5 ± 1.2 nm 
Mode 127.7 ± 1.7 nm 
SD 31.6 ± 5.5 nm 
D10  68.3 ± 1.1 nm 
D50  100.7 ± 0.5 nm 
D90  142.8 ± 3.1 nm 
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Figure 4.22. TEM micrograph of silica nanocapsules after 1 h of seeded growth time. 
Sample has been stained with OsO4 vapors. 
 
 
Figure 4.23. NTA plot of Silica-NCs (averaged concentration versus sizes).  
NTA utilizes the properties of both light scattering and Brownian motion 
in order to obtain the particle size distribution of samples in liquid 
suspension.57 In contrast to Dynamic Light Scattering, NTA approach 
makes possible to visualize and track individual particles and therefore 
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makes possible to determine the exact concentration of particles in the 
sample (and the distribution of concentrations, Figure 4.23) and to detect 
and quantify any aggregation. In particular, the possibility to determine the 
concentration of silica nanocapsules could be very important for further 
modification of the system, for example adding molecules for active 
targeting, since the procedure used does not allow to verify the final 
concentration of nanocapsules – due to the purification via dialysis and 
rotavapor that can increase or decrease the volume of the sample without 
any control.  
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5 Chapter 5 
 
Conclusions 
 
The field of Nanomedicine, and the related nanotechnologies and drug 
delivery systems (DDSs), is facing a critical juncture in both academic and 
industrial research centers.1 It has been over 40 years since the advent of 
use of nanoparticles as site specific drug delivery systems. During the last 
decades there have been some notable successes, namely the reformulation 
of doxorubicin, amphotericin B and paclitaxel into the lower toxicity 
versions of their more traditional formulations. This improvement, 
considering the current economic climate, the improvements of the 
therapeutic benefit (e.g. reduced toxicity) without a real pharmaco-
economic demonstration of medical benefit is insufficient to ensure the 
product utilization.1  Moreover, the choice of an appropriate nanocarrier is 
not obvious. It must be taken into account that an ideal DDS should possess 
several characteristics to positively affect the biodistribution and targeting, 
the possibility to screen the nanocarriers and the need to avoid body 
clearance. It is still not clear to what extent this is possible without 
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substantially increase the complexity of the nanocarrier and without 
influencing commercial scale-up.2  
The research conducted during these three years was oriented in this 
direction. The DDSs developed are all derived from natural materials and, 
despite the difficulties found to modify natural polymers compared to the 
synthetic ones, the former result to be biocompatible, biodegradable and 
economically more appealing than the latter. In addition, it was shown that 
the possibility to selectively add desired characteristics to the final nano-
vector can drastically change its fate. Taken altogether, the research works 
showed how adding functionality can lead to systems more appealing from 
a pharmacological point of view but less appealing from a business point 
of view.  In addition, it was shown how a target design make possible to 
obtain DDSs resulting powerful but, at the same time, less prone to the 
realization at the industrial scale-up. This issue, together with the necessity 
to develop suitable and standardized screening methodology for 
determining optimal DDSs’ characteristics, is the focus to whom 
researcher must convey their efforts.  
Although nanotechnology has the potential to revolutionize medicine,2 
only in the next years it will be understood if it will represent a revolution 
or just an important contribution. My personal hope is that this research 
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project has added a small but important contribution to answer this 
important question. 
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